?3193009 Summary - Canadian Patents Database (2024)

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
METHODS AND COMPOSITIONS FOR TREATING GLIOBLASTOMA
[0001] This application claims the benefit of priority of U.S. Provisional
Application No.
63/070,550, filed August 26, 2020, U.S. Provisional Application No.
63/171,187, filed April
6, 2021, and U.S. Provisional Application No. 63/218,761, filed July 6, 2021,
each of which is
hereby incorporated by reference in their entirety.
BACKGROUND
[0002] This invention was made with government support under Grant Number
0D012133,
awarded by the National Institutes of Health and Grant Number 1553767, awarded
by the
National Science Foundation. The government has certain rights in the
invention.
II. Field of the Invention
[0003] This invention relates generally to the fields of molecular biology
and
immunotherapy.
III. Background
[0004] Glioblastoma multiforme (GBM) is the most common type of primary brain
tumors
in adults, and the median survival period has remained at 12-16 months from
the time of
diagnosis over the past few decades. Conventional therapies such as surgery,
chemotherapy,
and radiation almost invariably fail to eradicate tumor, resulting in relapse
within weeks or
months. Consequently, GBM has been an active area of research for new
treatment options
such as adoptive T-cell therapy. Two major challenges have limited the
efficacy of T-cell
therapy for GBM thus far. First, the GBM tumor microenvironment is strongly
immunosuppressive, characterized by a high level of transforming growth factor
beta (TGF-f3),
which simultaneously promote tumor growth and potently suppress the function
of T cells.
Second, GBM tumors are highly heterogeneous in antigen expression, thus T
cells engineered
to target a single antigen are generally unable to recognize and eradicate all
tumor cells present.
Therefore, there is a need in the art for improved GBM therapies.
SUMMARY OF THE DISCLOSURE
[0005] The current disclosure provides a need in the art by providing for
novel multi-
specific CAR molecules for the treatment of glioblastoma (also called GBM or
glioblastoma
multiforme). Accordingly, aspects of the disclosure relate to a polypeptide
comprising a multi-
specific chimeric antigen receptor comprising an IL13Ra binding region, a
glioblastoma
antigen binding region, a peptide spacer, a transmembrane domain, and a
cytoplasmic region
1

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
comprising a co-stimulatory region and a primary intracellular signaling
domain; wherein the
glioblastoma antigen binding region comprises a GD2 or EGFRvIII binding
region.
[0006] A further aspect relates to a polypeptide comprising a multi-
specific chimeric
antigen receptor comprising a IL13 polypeptide of SEQ ID NO:4 or 20, a
glioblastoma antigen
binding region, a peptide spacer, a transmembrane domain, and a cytoplasmic
region
comprising a co-stimulatory region and a primary intracellular signaling
domain; wherein the
glioblastoma antigen binding region comprises a GD2 or EGFRvIII binding
region.
[0007] A further aspect relates to a polypeptide comprising a multi-
specific chimeric
antigen receptor (CAR) comprising an IL13 polypeptide of SEQ ID NO:4 or 20, a
TGF-f3
binding region, a peptide spacer, a transmembrane domain, and a cytoplasmic
region
comprising a co-stimulatory region and a primary intracellular signaling
domain.
[0008] A further aspect relates to a polypeptide comprising a multi-
specific chimeric
antigen receptor (CAR) comprising an IL13 polypeptide, a TGF-f3 binding
region, a peptide
spacer, a transmembrane domain, and a cytoplasmic region comprising a co-
stimulatory region
and a primary intracellular signaling domain.
[0009] Yet further aspects relate to a polypeptide comprising a multi-
specific chimeric
antigen receptor (CAR) comprising a glioblastoma antigen binding region, a TGF-
f3 binding
region, a peptide spacer, a transmembrane domain, and a cytoplasmic region
comprising a co-
stimulatory region and a primary intracellular signaling domain; wherein the
glioblastoma
antigen binding region comprises an anti-GD2 scFv having a variable heavy (VH)
and variable
light (VL) region, wherein the VH region comprises SEQ ID NO:48 (HCDR1), SEQ
ID NO:49
(HCDR2); and SEQ ID NO:50 (HCDR3) and the VL region comprises SEQ ID NO:51
(LCDR1), SEQ ID NO:52 (LCDR2); and SEQ ID NO:53 (LCDR3). Further aspects
relate to
a polypeptide comprising a multi-specific chimeric antigen receptor (CAR)
comprising a
glioblastoma antigen binding region, a TGF-f3 binding region, a peptide
spacer, a
transmembrane domain, and a cytoplasmic region comprising a co-stimulatory
region and a
primary intracellular signaling domain; wherein the glioblastoma antigen
binding region
comprises an anti-GD2 scFv having a variable heavy (VH) and variable light
(VL) region,
wherein the VH region comprises the HCDR1, HCDR2; and HCDR3 from the VH of SEQ
ID
NO:46 and the VL region comprises LCDR1, LCDR2; and LCDR3 from the VL of SEQ
ID
NO:47.
[0010] Also provided is a polypeptide comprising a multi-specific chimeric
antigen receptor
(CAR) comprising a glioblastoma antigen binding region, a TGF-f3 binding
region, a peptide
spacer, a transmembrane domain, and a cytoplasmic region comprising a co-
stimulatory region
2

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
and a primary intracellular signaling domain; wherein the glioblastoma antigen
binding region
comprises an EGFRvIII binding region.
[0011] This disclosure also describes nucleic acids encoding for the
polypeptides of the
disclosure, expression vectors comprising the nucleic acids of the disclosure,
cells and/or
populations of cells expressing the polypeptides of the disclosure and/or
comprising the nucleic
acids or expression vectors of the disclosure, and compositions comprising the
polypeptides,
nucleic acids, or cells of the disclosure. The compositions may be in the form
of a
pharmaceutically acceptable formulation.
[0012] Aspects of the disclosure also relate to a method of making a cell
that expresses a
polypeptide comprising introducing into a cell a nucleic acid of the
disclosure. Further method
aspects relate to a method for stimulating an immune response or for treating
glioblastoma in
a subject, the method comprising administering to the subject an effective
amount of a
composition, cell, or polypeptide of the disclosure. Also provided is a method
for expanding
therapeutic T cells in vitro, the method comprising contacting an in vitro T
cell of the disclosure
with a composition comprising TGF-P.
[0013] Aspects of the disclosure relate to polypeptides comprising one or
more
glioblastoma antigen binding regions. In some aspects, the glioblastoma
antigen binding
region comprises a GD2 binding region. The structure of GD2 is known in the
art. GD2 is a
disialoganglioside belonging to b-series ganglioside. It comprises five
monosaccharides linked
to ceramide, with the carbohydrate sequence of GalNAcf31-4(NeuAca2-8NeuAca2-
3)Galf31-4G1cf31-1. GD2 binding regions, such as anti-GD2 antibody binding
regions are known in the
art. In some aspects, the GD2 binding region comprises an anti-GD2 scFv having
a variable
heavy (VH) and variable light (VL) region, wherein the VH region comprises SEQ
ID NO:48
(HCDR1), SEQ ID NO:49 (HCDR2); and SEQ ID NO:50 (HCDR3) and the VL region
comprises SEQ ID NO:51 (LCDR1), SEQ ID NO:52 (LCDR2); and SEQ ID NO:53
(LCDR3).
[0014] In some aspects, the glioblastoma antigen binding region comprises a
EGFRvIII
antigen binding region. EGFRvIII is a variant of EGFR that lacks amino acids 6-
273, and
deletion of those 268 amino acids creates a junction site with a new glycine
residue between
amino acids 5 and 274. In some aspects, the EGFRvIII binding region comprises
an anti-
EGFRvIII scFv having a variable heavy (VH) and variable light (VL) region,
wherein the VH
region comprises SEQ ID NO:40 (HCDR1), SEQ ID NO:41 (HCDR2); and SEQ ID NO:42
(HCDR3) and the VL region comprises SEQ ID NO:43 (LCDR1), SEQ ID NO:44
(LCDR2);
and SEQ ID NO:45 (LCDR3).
3

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
[0015] In some aspects, the polypeptides comprise a TGF-f3 binding region.
In some
aspects, the TGF-f3 binding region comprises a scFv having a variable heavy
(VH) and variable
light (VL) region, wherein the VH region comprises SEQ ID NO:31 (HCDR1), SEQ
ID NO:32
(HCDR2); and SEQ ID NO:33 (HCDR3) and the VL region comprises SEQ ID NO:34
(LCDR1), SEQ ID NO:35 (LCDR2); and SEQ ID NO:36 (LCDR3).
[0016] In some aspects, LCDR1 of a GD2, EGRvIII, or TGF-f3 binding region
comprises
an amino acid sequence with, with at least, with at most, or with about 60,
61, 62, 63, 64, 65,
66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84,
85, 86, 87, 88, 89, 90,
91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% (or any derivable range therein)
sequence identity
to SEQ ID NO:51, 43, or 34, respectively. In some aspects, LCDR2 of a GD2,
EGRvIII, or
TGF-f3 binding region comprises an amino acid sequence with, with at least,
with at most, or
about 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77,
78, 79, 80, 81, 82,
83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100%
(or any derivable
range therein) sequence identity to SEQ ID NO:52, 44, or 35, respectively. In
some aspects,
LCDR3 of a GD2, EGRvIII, or TGF-f3 binding region comprises an amino acid
sequence with,
with at least, with at most, or about 60, 61, 62, 63, 64, 65, 66, 67, 68, 69,
70, 71, 72, 73, 74,
75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93,
94, 95, 96, 97, 98, 99,
or 100% (or any derivable range therein) sequence identity to SEQ ID NO:53,
45, or 36,
respectively. In some aspects, HCDR1 of a GD2, EGRvIII, or TGF-f3 binding
region comprises
an amino acid sequence with, with at least, with at most, or with about 60,
61, 62, 63, 64, 65,
66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84,
85, 86, 87, 88, 89, 90,
91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% (or any derivable range therein)
sequence identity
to SEQ ID NO:48, 40, or 31, respectively. In some aspects, HCDR2 of a GD2,
EGRvIII, or
TGF-f3 binding region comprises an amino acid sequence with, with at least,
with at most, or
about 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77,
78, 79, 80, 81, 82,
83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100%
(or any derivable
range therein) sequence identity to SEQ ID NO:49, 41, or 32, respectively. In
some aspects,
HCDR3 of a GD2, EGRvIII, or TGF-f3 binding region comprises an amino acid
sequence with,
with at least, with at most, or about 60, 61, 62, 63, 64, 65, 66, 67, 68, 69,
70, 71, 72, 73, 74, 75,
76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94,
95, 96, 97, 98, 99, or
100% (or any derivable range therein) sequence identity to SEQ ID NO:50, 42,
or 33,
respectively.
[0017] In some aspects, the GD2 binding region comprises a VH with an amino
acid
sequence having at least 80% sequence identity to SEQ ID NO:46 and/or a VL
with an amino
4

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
acid sequence having at least 80% sequence identity to SEQ ID NO:47. In some
aspects, the
GD2 binding region comprises a VH with the amino acid sequence of SEQ ID NO:46
and/or a
VL with the amino acid sequence of SEQ ID NO:47. In some aspects, the GD2
binding region
comprises a VH with an amino acid sequence having or having at least 60, 61,
62, 63, 64, 65,
66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84,
85, 86, 87, 88, 89, 90,
91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% (or any derivable range therein)
sequence identity
to SEQ ID NO:46 and/or a VL with an amino acid sequence having or having at
least 60, 61,
62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80,
81, 82, 83, 84, 85, 86,
87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% (or any derivable
range therein)
sequence identity to SEQ ID NO:47. The GD2 binding region may also be one that
comprises
an anti-GD2 scFv having an amino acid sequence with at least 80% sequence
identity to SEQ
ID NO:26. In some aspects, the GD2 binding region comprises an anti-GD2 scFv
having the
amino acid sequence of SEQ ID NO:26. Other aspects include GD2 binding regions
that
comprise an anti-GD2 scFv having an amino acid sequence having or having at
least 60, 61,
62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80,
81, 82, 83, 84, 85, 86,
87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% (or any derivable
range therein)
sequence identity to SEQ ID NO:26. In some aspects, the GD2 binding region
comprises a
binding region that binds to membrane-bound GD2 antigen. In some aspects, the
GD2 binding
region comprises a binding region that binds to soluble GD2 antigen. In some
aspects, the
GD2 binding region comprises a binding region that binds to membrane-bound and
soluble
GD2 antigen.
[0018] In some aspects, the polypeptides comprise a TGF-f3 binding region.
In some
aspects, the TGF-f3 binding region comprises a scFv having a variable heavy
(VH) and variable
light (VL) region, wherein the VH region comprises SEQ ID NO:56 (HCDR1), SEQ
ID NO:57
(HCDR2); and SEQ ID NO:58 (HCDR3) and the VL region comprises SEQ ID NO:59
(LCDR1), SEQ ID NO:60 (LCDR2); and SEQ ID NO:61 (LCDR3). In some aspects, the
polypeptides comprise a TGF-f3 binding region. In some aspects, the TGF-f3
binding region
comprises a scFv having a variable heavy (VH) and variable light (VL) region,
wherein the
VH region comprises SEQ ID NO:64 (HCDR1), SEQ ID NO:65 (HCDR2); and SEQ ID
NO:66
(HCDR3) and the VL region comprises SEQ ID NO:67 (LCDR1), SEQ ID NO:68
(LCDR2);
and SEQ ID NO:69 (LCDR3).
[0019] In some aspects, LCDR1 of a TGF-f3 binding region comprises an amino
acid
sequence with, with at least, with at most, or with about 60, 61, 62, 63, 64,
65, 66, 67, 68, 69,
70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88,
89, 90, 91, 92, 93, 94,

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
95, 96, 97, 98, 99, or 100% (or any derivable range therein) sequence identity
to SEQ ID NO:59
or 67. In some aspects, LCDR2 of a TGF-f3 binding region comprises an amino
acid sequence
with, with at least, with at most, or with about 60, 61, 62, 63, 64, 65, 66,
67, 68, 69, 70, 71, 72,
73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91,
92, 93, 94, 95, 96, 97,
98, 99, or 100% (or any derivable range therein) sequence identity to SEQ ID
NO:60 or 68. In
some aspects, LCDR3 of a TGF-f3 binding region comprises an amino acid
sequence with, with
at least, with at most, or with about 60, 61, 62, 63, 64, 65, 66, 67, 68, 69,
70, 71, 72, 73, 74, 75,
76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94,
95, 96, 97, 98, 99, or
100% (or any derivable range therein) sequence identity to SEQ ID NO:61 or 69.
In some
aspects, HCDR1 of a TGF-f3 binding region comprises an amino acid sequence
with, with at
least, with at most, or with about 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70,
71, 72, 73, 74, 75,
76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94,
95, 96, 97, 98, 99, or
100% (or any derivable range therein) sequence identity to SEQ ID NO:56 or 64.
In some
aspects, HCDR2 of a TGF-f3 binding region comprises an amino acid sequence
with, with at
least, with at most, or with about 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70,
71, 72, 73, 74, 75,
76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94,
95, 96, 97, 98, 99, or
100% (or any derivable range therein) sequence identity to SEQ ID NO:57 or 65.
In some
aspects, HCDR3 of a TGF-f3 binding region comprises an amino acid sequence
with, with at
least, with at most, or with about 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70,
71, 72, 73, 74, 75,
76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94,
95, 96, 97, 98, 99, or
100% (or any derivable range therein) sequence identity to SEQ ID NO:58 or 66.
In some
aspects, the TGF-f3 binding region comprises a VH with an amino acid sequence
having at least
80% sequence identity to SEQ ID NO:54 and/or a VL with an amino acid sequence
having at
least 80% sequence identity to SEQ ID NO:55. In some aspects, the TGF-f3
binding region
comprises a VH with the amino acid sequence of SEQ ID NO:54 and/or a VL with
the amino
acid sequence of SEQ ID NO:55. In some aspects, the TGF-f3 binding region
comprises a VH
with an amino acid sequence having or having at least 60, 61, 62, 63, 64, 65,
66, 67, 68, 69,
70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88,
89, 90, 91, 92, 93, 94,
95, 96, 97, 98, 99, or 100% (or any derivable range therein) sequence identity
to SEQ ID NO:54
and/or a VL with an amino acid sequence having or having at least 60, 61, 62,
63, 64, 65, 66,
67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85,
86, 87, 88, 89, 90, 91,
92, 93, 94, 95, 96, 97, 98, 99, or 100% (or any derivable range therein)
sequence identity to
SEQ ID NO:55. In some aspects, the TGF-f3 binding region comprises a VH with
an amino
acid sequence having at least 80% sequence identity to SEQ ID NO:62 and/or a
VL with an
6

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
amino acid sequence having at least 80% sequence identity to SEQ ID NO:63. In
some aspects,
the TGF-f3 binding region comprises a VH with the amino acid sequence of SEQ
ID NO:62
and/or a VL with the amino acid sequence of SEQ ID NO:63. In some aspects, the
TGF-f3
binding region comprises a VH with an amino acid sequence having or having at
least 60, 61,
62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80,
81, 82, 83, 84, 85, 86,
87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% (or any derivable
range therein)
sequence identity to SEQ ID NO:62 and/or a VL with an amino acid sequence
having or having
at least 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76,
77, 78, 79, 80, 81, 82,
83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100%
(or any derivable
range therein) sequence identity to SEQ ID NO:63. In some aspects, LCDR1 of a
TGF-f3
binding region comprises an amino acid sequence with, with at least, with at
most, or with
about 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77,
78, 79, 80, 81, 82,
83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100%
(or any derivable
range therein) sequence identity to SEQ ID NO:34. In some aspects, LCDR2 of a
TGF-f3
binding region comprises an amino acid sequence with, with at least, with at
most, or with
about 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77,
78, 79, 80, 81, 82,
83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100%
(or any derivable
range therein) sequence identity to SEQ ID NO:35. In some aspects, LCDR3 of a
TGF-f3
binding region comprises an amino acid sequence with, with at least, with at
most, or with
about 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77,
78, 79, 80, 81, 82,
83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100%
(or any derivable
range therein) sequence identity to SEQ ID NO:36. In some aspects, HCDR1 of a
TGF-f3
binding region comprises an amino acid sequence with, with at least, with at
most, or with
about 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77,
78, 79, 80, 81, 82,
83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100%
(or any derivable
range therein) sequence identity to SEQ ID NO:31. In some aspects, HCDR2 of a
TGF-f3
binding region comprises an amino acid sequence with, with at least, with at
most, or with
about 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77,
78, 79, 80, 81, 82,
83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100%
(or any derivable
range therein) sequence identity to SEQ ID NO:32. In some aspects, HCDR3 of a
TGF-f3
binding region comprises an amino acid sequence with, with at least, with at
most, or with
about 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77,
78, 79, 80, 81, 82,
83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100%
(or any derivable
range therein) sequence identity to SEQ ID NO:33. In some aspects, the TGF-f3
binding region
7

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
comprises a VH with an amino acid sequence having at least 80% sequence
identity to SEQ ID
NO:29 and/or a VL with an amino acid sequence having at least 80% sequence
identity to SEQ
ID NO:30. In some aspects, the TGF-f3 binding region comprises a VH with the
amino acid
sequence of SEQ ID NO:29 and/or a VL with the amino acid sequence of SEQ ID
NO:30. In
some aspects, the TGF-f3 binding region comprises a VH with an amino acid
sequence having
or having at least 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74,
75, 76, 77, 78, 79,
80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98,
99, or 100% (or any
derivable range therein) sequence identity to SEQ ID NO:29 and/or a VL with an
amino acid
sequence having or having at least 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70,
71, 72, 73, 74, 75,
76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94,
95, 96, 97, 98, 99, or
100% (or any derivable range therein) sequence identity to SEQ ID NO:30.
[0020] In some aspects, the EGFRvIII binding region comprises a VH with an
amino acid
sequence having or having at least 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70,
71, 72, 73, 74, 75,
76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94,
95, 96, 97, 98, 99, or
100% (or any derivable range therein) sequence identity to SEQ ID NO:38 and/or
a VL with
an amino acid sequence having or having at least 60, 61, 62, 63, 64, 65, 66,
67, 68, 69, 70, 71,
72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90,
91, 92, 93, 94, 95, 96,
97, 98, 99, or 100% (or any derivable range therein) sequence identity to SEQ
ID NO:39. In
some aspectsõ the EGFRvIII binding region comprises a VH with an amino acid
sequence
having at least 80% sequence identity to SEQ ID NO:38 and/or a VL with an
amino acid
sequence having at least 80% sequence identity to SEQ ID NO:39. In some
aspects, the
EGFRvIII binding region comprises a VH with the amino acid sequence of SEQ ID
NO:38
and/or a VL with the amino acid sequence of SEQ ID NO:39. In some aspects, the
EGFRvIII
binding region comprises a VH with the amino acid sequence of SEQ ID NO:38
and/or a VL
with the amino acid sequence of SEQ ID NO:39. In some aspects, the EGFRvIII
binding region
comprises an anti-EGFRvIII scFv having an amino acid sequence with at least
80% sequence
identity to SEQ ID NO:27. In some aspects, the EGFRvIII binding region
comprises an anti-
EGFRvIII scFv having an amino acid sequence having or having at least 60, 61,
62, 63, 64, 65,
66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84,
85, 86, 87, 88, 89, 90,
91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% (or any derivable range therein)
sequence identity
to SEQ ID NO:27. In some aspects, the EGFRvIII binding region comprises an
anti-EGFRvIII
scFv having the amino acid sequence of SEQ ID NO:27. In some aspects, the
EGFRvIII
binding region comprises a binding region that binds to membrane-bound
EGFRvIII antigen.
In some aspects, the EGFRvIII binding region comprises a binding region that
binds to soluble
8

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
EGFRvIII antigen. In some aspects, the EGFRvIII binding region comprises a
binding region
that binds to membrane-bound and soluble EGFRvIII antigen.
[0021] Aspects of the disclosure include polypeptides and CARs comprising a
TGF-f3
binding region. In some aspects, the TGF-f3 binding region comprises a VH with
an amino
acid sequence having at least 80% sequence identity to SEQ ID NO:29 and/or a
VL with an
amino acid sequence having at least 80% sequence identity to SEQ ID NO:30. In
some aspects,
the TGF-f3 binding region comprises a VH with an amino acid sequence having or
having at
least 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77,
78, 79, 80, 81, 82, 83,
84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% (or
any derivable range
therein) sequence identity to SEQ ID NO:29 and/or a VL with an amino acid
sequence having
at least 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76,
77, 78, 79, 80, 81, 82,
83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100%
(or any derivable
range therein) sequence identity to SEQ ID NO:30. In some aspects, the TGF-f3
binding region
comprises a VH with the amino acid sequence of SEQ ID NO:29 and/or a VL with
the amino
acid sequence of SEQ ID NO:30. In some aspects, the TGF-f3 binding region
comprises an
anti-TGF-f3 scFv having an amino acid sequence with at least 80% sequence
identity to SEQ
ID NO:11. In some aspects, the TGF-f3 binding region comprises an anti-TGF-f3
scFv having
an amino acid sequence having or having at least 60, 61, 62, 63, 64, 65, 66,
67, 68, 69, 70, 71,
72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90,
91, 92, 93, 94, 95, 96,
97, 98, 99, or 100% (or any derivable range therein) sequence identity to SEQ
ID NO:11. In
some aspects, the TGF-f3 binding region comprises an anti-TGF-f3 scFv having
the amino acid
sequence of SEQ ID NO:11.
[0022] The GD2 binding region may comprise an anti-GD2 scFv having a variable
heavy
(VH) and variable light (VL) region, wherein the VH region comprises the
HCDR1, HCDR2;
and HCDR3 from the VH of SEQ ID NO:46 and the VL region comprises LCDR1,
LCDR2;
and LCDR3 from the VL of SEQ ID NO:47. Tthe EGFRvIII binding region may
comprise an
anti- EGFRvIII scFv having a variable heavy (VH) and variable light (VL)
region, wherein the
VH region comprises the HCDR1, HCDR2; and HCDR3 from the VH of SEQ ID NO:38
and
the VL region comprises LCDR1, LCDR2; and LCDR3 from the VL of SEQ ID NO:39.
The
TGF-f3 binding region may comprise a scFv having a variable heavy (VH) and
variable light
(VL) region, wherein the VH region comprises the HCDR1, HCDR2; and HCDR3 from
the
VH of SEQ ID NO:29 and the VL region comprises LCDR1, LCDR2; and LCDR3 from
the
VL of SEQ ID NO:30. The TGF-f3 binding region may comprise a scFv having a
variable
heavy (VH) and variable light (VL) region, wherein the VH region comprises the
HCDR1,
9

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
HCDR2; and HCDR3 from the VH of SEQ ID NO:54 and the VL region comprises
LCDR1,
LCDR2; and LCDR3 from the VL of SEQ ID NO:55. The TGF-f3 binding region may
comprise
a scFv having a variable heavy (VH) and variable light (VL) region, wherein
the VH region
comprises the HCDR1, HCDR2; and HCDR3 from the VH of SEQ ID NO:62 and the VL
region comprises LCDR1, LCDR2; and LCDR3 from the VL of SEQ ID NO:63. In some
aspects, the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 is determined by the
Kabat method. In some aspects, the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and
LCDR3
is determined by the IMGT method. In some aspects, the HCDR1, HCDR2, HCDR3,
LCDR1,
LCDR2, and LCDR3 is determined by the Chothia method. In some aspects, the
HCDR1,
HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 is determined by the paratome method.
[0023] "Single-chain Fv" or "scFv" antibody fragments comprise at least a
portion of the
VH and VL domains of an antibody, such as the CDRs of each, wherein these
domains are
present in a single polypeptide chain. It is contemplated that an scFv
includes a CDR1, CDR2,
and/or CDR3 of a heavy chain variable region and a CDR1, CDR2, and/or CDR3 of
a light
chain variable region in some aspects. It is further contemplated that a CDR1,
CDR2, or CDR3
may comprise or consist of a sequence set forth in a SEQ ID NO provided herein
as CDR1,
CDR2, or CDR3, respectively. A CDR may also comprise 1, 2, 3, 4, 5, 6,7, 8, 9,
10, 11, 12,
13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or more contiguous amino acid
residues (or any range
derivable therein) flanking one or both sides of a particular CDR sequence;
therefore, there
may be one or more additional amino acids at the N-terminal or C-terminal end
of a particular
CDR sequence, such as those shown in SEQ ID NOS:31-36, 40-45, 48-53, 56-61, or
64-69.
[0024] Aspects of the disclosure also relate to multi-specific polypeptides
comprising an
IL13Ra binding region and a glioblastoma antigen binding region. In some
aspects, the
polypeptide comprises a chimeric antigen receptor (CAR), wherein the CAR
comprises in order
from amino-proximal end to carboxy-proximal end: an IL13Ra binding region, a
glioblastoma
antigen binding region, a peptide spacer, a transmembrane domain, and a
cytoplasmic region
comprising a co-stimulatory region and a primary intracellular signaling
domain.
[0025] Aspects of the disclosure also relate to multi-specific polypeptides
comprising an
IL13 polypeptide and a glioblastoma antigen binding region. In some aspects,
the polypeptide
comprises a chimeric antigen receptor (CAR), wherein the CAR comprises in
order from
amino-proximal end to carboxy-proximal end: an IL13 polypeptide, a
glioblastoma antigen
binding region, a peptide spacer, a transmembrane domain, and a cytoplasmic
region
comprising a co-stimulatory region and a primary intracellular signaling
domain.

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
[0026] It is contemplated that the IL13Ra binding region or IL13
polypeptide may be amino
proximal to the glioblastoma antigen binding region. In other aspects, the
IL13Ra binding
region or IL13 polypeptide may be carboxy proximal to the glioblastoma antigen
binding
region. The TGF-f3 binding region may be amino proximal to the glioblastoma
antigen binding
region or the TGF-f3 binding region may be carboxy proximal to the
glioblastoma antigen
binding region. The IL13Ra binding region or IL13 polypeptide may be amino
proximal to
the TGF-f3 binding region or the IL13Ra binding region or IL13 polypeptide may
be carboxy
proximal to the TGF-f3 binding region. It is contemplated that the TGF-f3
binding region may
be adjacent to the IL13Ra binding region or IL13 polypeptide, meaning that
there are no
intervening binding regions, although any two binding regions that are
adjacent may be
separated by a linker region. The IL13Ra binding region or IL13 polypeptide
may be adjacent
to the glioblastoma antigen binding region, or the glioblastoma antigen
binding region may be
adjacent to the TGF-f3 binding region.
[0027] The polypeptide may comprise or further comprise one or more linkers
separating
regions. For example, the polypeptide may comprise a linker between two
binding regions,
such as a linker between the IL13Ra binding region or IL13 polypeptide and the
glioblastoma
antigen binding region. The polypeptide may comprise a linker between the TGF-
f3 binding
region and the glioblastoma antigen binding region, and/or between the IL13Ra
binding region
or IL13 polypeptide and the TGF-f3 binding region. In certain aspects, the
polypeptide
comprises a tri-specific CAR comprising TGF-f3 binding region. The tri-
specific CAR may
comprise a TGF-f3 binding region, an IL13Ra binding region or IL13
polypeptide, and a
glioblastoma antigen binding region.
[0028] In some aspects, the IL13Ra binding region is a IL13Ra2 binding
region. In some
aspects, the IL13 polypeptide excludes an IL13 polypeptide consisting of amino
acids 3-114 of
SEQ ID NO:4. In some aspects, the IL13 polypeptide excludes an IL13
polypeptide consisting
of amino acids 11-122 of SEQ ID NO:4. In some aspects, the IL13 polypeptide
comprises the
C-terminal 112 amino acids of SEQ ID NO:4 or 20 and at least one additional
amino acid at
the N terminus. In some aspects, the IL13 polypeptide comprises the C-terminal
112 amino
acids of SEQ ID NO:4 or 20 and at least, at most, or exactly 1, 2, 3, 4, 5, 6,
7, 8, 9, or 10
additional amino acids at the N-terminus. Additionally or alternatively, in
some aspects, the
IL13 polypeptide comprises the C-terminal 112 amino acids of SEQ ID NO:4 or 20
and at least,
at most, or exactly 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 additional amino acids at
the C-terminus.
[0029] In further aspects, a CAR molecule also comprises a tag that can be
used to sort
and/or identify the CAR molecule in a host cell. In some aspects, the tag is
further defined as
11

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
a therapeutic control. In some aspects, the tag or therapeutic control is less
than a full-length
polypeptide and is truncated. For instance, to remove one or more functional
domains from the
tag. In certain aspects, the truncated protein is EGFR (EGFRt), which can be
used to detect
expression of the CAR. In another embodiment, the truncated protein is
truncated low-affinity
nerve growth factor receptor or (dNGFR). In other aspects, the tag is
colorimetric or
fluorescent. In some aspects, the tag may be separated from the CAR by a
cleavage site.
[0030] In some aspects, the VH is amino proximal to the VL. In some
aspects, the VH is
carboxy proximal to the VL. A first region is carboxy proximal to a second
region when the
first region is attached to the carboxy terminus of the second region. There
may be further
intervening amino acid residues between the first and second regions. Thus,
the regions need
not be immediately adjacent, unless specifically specified as not having
intervening amino acid
residues. The term "amino-proximal" is similarly defined in that a first
region is amino-
proximal to a second region when the first region is attached to the amino
terminus of the
second region. Similarly, there may be further intervening amino acid residues
between the
first and second regions unless stated otherwise.
[0031] In a particular embodiment, the CAR comprises in order from amino-
proximal end
to carboxy-proximal end: an IL13Ra binding region or IL13 polypeptide, a
glioblastoma
antigen binding region, a TGF-f3 binding region, a peptide spacer, a
transmembrane domain,
and a cytoplasmic region comprising a co-stimulatory region and a primary
intracellular
signaling domain.
[0032] The linker between two regions of the polypeptide, such as between
two binding
regions or between a VH and VL of the same binding region, may be a linker
that comprises
glycine and serine amino acids. In some aspects, the linker comprises or
consists of a
polypeptide with the amino acid sequence of SEQ ID NO:10 or 28. In some
aspects, the linker
is 4-40 amino acids in length. In some aspects, the linker is, is at least, is
at most, or is about
4, 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,
25, 26, 27, 28, 29, 30,
31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or
50 (or any derivable
range therein) amino acid residues in length. In some aspects, the linker
comprises at least 4
glycine and/or serine residues. In some aspects, the linker comprises at least
4, 5, 6, 7, 8, 9,
10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28,
29, 30, 31, 32, 33, 34,
35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 (or any
derivable range therein)
glycine and/or serine residues. In some aspects, the linker comprises
(GGGGS)., wherein n is
1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 (or any derivable range therein). In some
aspects, the linker
12

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
comprises, or consists of, the amino acid sequence: (EAAAK)., wherein n is 1,
2, 3, 4, 5, 6, 7,
8, 9, or 10 (or any derivable range therein).
[0033] In some aspects, the IL13Ra binding region comprises an IL13Ra2-
specific binding
region. In some aspects, the IL13Ra binding region comprises an IL13
polypeptide. The IL13
polypeptide may be a fragment of the IL13 protein that is capable of binding
to IL13Ra. In
some aspects, the IL13 polypeptide is a polypeptide from the IL13 protein that
activates the
intracellular signaling domain upon binding with IL13Ra. In aspects of the
disclosure, the
IL13Ra comprises membrane-bound IL13Ra. In certain aspects of the disclosure,
the IL13
polypeptide comprises an IL13 mutein. In some aspects, the IL13 polypeptide
comprises an
E13Y substitution of the IL13 protein. The E13Y substitution is a substitution
of a tyrosine for
glutamic acid at a position in IL13 that corresponds to position 11 of the
IL13 polypeptide of
SEQ ID NO:147, position 13 of the IL13 polypeptide of SEQ ID NO:4, or position
21 of SEQ
ID NO:20. In some aspects, the IL13 polypeptide comprises or consists of SEQ
ID NO:4. In
some aspects, the IL13 polypeptide comprises or consists of SEQ ID NO:20. In
some aspects,
the IL13 polypeptide comprises or consists of SEQ ID NO:147. In aspects of the
disclosure,
the IL13Ra binding region can comprise or consist of a polypeptide of SEQ ID
NO:147. It is
contemplated that the IL13Ra binding region of SEQ ID NO:147 may be used in
any of the
CAR aspects described herein.
[0034] The polypeptide may further comprise a second chimeric antigen
receptor (CAR)
comprising at least one antigen binding region, a second peptide spacer, a
second
transmembrane domain, and a second cytoplasmic region comprising a second co-
stimulatory
region and a second primary intracellular signaling domain. The second CAR may
be a mono-
specific or multi-specific CAR, such as a bi-specific or tri-specific CAR. In
certain aspects,
the second CAR comprises an antigen binding region to TGF- 0. The first CAR
and the second
CAR may be separated by one or more peptide cleavage site(s). The peptide
cleavage site may
be a peptide cleavage site known in the art, such as a Furin cleavage site or
a 2A cleavage site.
The 2A cleavage site may comprise one or more of a P2A, F2A, E2A, or T2A
cleavage site.
In some aspects, the peptide cleavage site comprises a T2A cleavage site. The
T2A cleavage
site may comprise an amino acid sequence of SEQ ID NO:24. Aspects in which the
cleavage
site has at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94,
95, 96, 97, 98, 99, or
100% (or any derivable range therein) sequence identity to SEQ ID NO:24 are
also
contemplated.
[0035] The CAR of the disclosure may comprise or further comprise a
torsional linker
between the transmembrane domain and the cytoplasmic region. In some aspects,
the torsional
13

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
linker comprises or consists of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid
residues (or any derivable
range therein). In some aspects, the amino acid residues comprise or consist
of alanine
residues. In some aspects, the torsional linker comprises at least, at most,
or exactly 1, 2, 3, 4,
5, 6, 7, 8, 9, or 10 (or any derivable range therein) alanine residues. In
some aspects, the
torsional linker comprises at least, at most, or exactly 1, 2, 3, 4, 5, 6, 7,
8, 9, or 10 (or any
derivable range therein) contiguous alanine residues. In some aspects, the
torsional linker
consists of 2 or 4 alanine residues. In some aspects, the torsional linker
comprises at least, at
most, or exactly 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 (or any derivable range
therein) contiguous alanine
residues. In some aspects, the torsional linker consists of 2 alanine
residues.
[0036] The CAR of the disclosure may include a peptide spacer between the
antigen binding
domains and the transmembrane domain. Similarly, the second CAR of the
disclosure may
include a peptide spacer is between the antigen binding domains and the second
transmembrane
domain of the second CAR. The peptide spacer or second peptide spacer may
comprise an
IgG4 hinge region. In some aspects, the IgG4 hinge region comprises a
polypeptide having an
amino acid sequence with at least 80% sequence identity to SEQ ID NO:12. In
some aspects,
the IgG4 hinge region comprises a polypeptide having an amino acid sequence
having or
having at least 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74,
75, 76, 77, 78, 79, 80,
81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or
100% (or any
derivable range therein) sequence identity to SEQ ID NO:12. In some aspects,
the IgG4 hinge
region comprises a polypeptide having the amino acid sequence of SEQ ID NO:12.
In some
aspects, the IgG4 hinge region comprises a polypeptide having an amino acid
sequence with at
least 80% sequence identity to SEQ ID NO:5. In some aspects, the IgG4 hinge
region
comprises a polypeptide having an amino acid sequence having or having at
least 60, 61, 62,
63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81,
82, 83, 84, 85, 86, 87,
88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% (or any derivable
range therein) sequence
identity to SEQ ID NO:5. In some aspects, the IgG4 hinge region comprises a
polypeptide
having the amino acid sequence of SEQ ID NO:5. In some aspects, the peptide
spacer or
second peptide spacer comprises or further comprises an IgG4 CH2 and CH3
region. In some
aspects, the peptide spacer or second peptide spacer comprises or further
comprises an IgG4
CH2 and CH3 region. In some aspects, the IgG4 CH2 and CH3 region comprises a
polypeptide
having an amino acid sequence with at least 80% sequence identity to SEQ ID
NO:37. In some
aspects, the IgG4 CH2 and CH3 region comprises a polypeptide having an amino
acid sequence
with at least 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75,
76, 77, 78, 79, 80, 81,
82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or
100% (or any derivable
14

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
range therein) sequence identity to SEQ ID NO:37. In some aspects, the IgG4
CH2 and CH3
region comprises a polypeptide having the amino acid sequence of SEQ ID NO:37.
In some
aspects, the CH2 region comprises L235E and/or N297Q substitutions. The
peptide spacer
may be between 8 and 1000 amino acids in length. In some aspects, the peptide
spacer is
between 8 and 500 amino acids in length. In some aspects, the peptide spacer
is between 100-
300 amino acids in length. In some aspects, the peptide spacer has fewer than
100 amino acids.
In some aspects, the peptide spacer is at least, at most, or exactly, 8, 9,
10, 11, 12, 13, 14, 15,
16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34,
35, 36, 37, 38, 39, 40,
41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59,
60, 61, 62, 63, 64, 65,
66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84,
85, 86, 87, 88, 89, 90,
91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107,
108, 109, 110, 111,
112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126,
127, 128, 129, 130,
131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145,
146, 147, 148, 149,
150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164,
165, 166, 167, 168,
169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183,
184, 185, 186, 187,
188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202,
203, 204, 205, 206,
207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221,
222, 223, 224, 225,
226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240,
241, 242, 243, 244,
245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259,
260, 261, 262, 263,
264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278,
279, 280, 281, 282,
283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297,
298, 299, 300, 301,
302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316,
317, 318, 319, 320,
321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335,
336, 337, 338, 339,
340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354,
355, 356, 357, 358,
359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373,
374, 375, 376, 377,
378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392,
393, 394, 395, 396,
397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411,
412, 413, 414, 415,
416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430,
431, 432, 433, 434,
435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449,
450, 451, 452, 453,
454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468,
469, 470, 471, 472,
473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487,
488, 489, 490, 491,
492, 493, 494, 495, 496, 497, 498, 499, or 500 amino acids (or any derivable
range therein).
[0037] The transmembrane domain or second transmembrane domain may comprise
the
transmembrane domain from the CD28 protein. In some aspects, the transmembrane
domain

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
or second transmembrane domain comprises a transmembrane domain having an
amino acid
sequence with at least 80% sequence identity to SEQ ID NO:6. In some aspects,
the
transmembrane domain or second transmembrane domain comprises a transmembrane
domain
having an amino acid sequence with at least 60, 61, 62, 63, 64, 65, 66, 67,
68, 69, 70, 71, 72,
73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91,
92, 93, 94, 95, 96, 97,
98, 99, or 100% (or any derivable range therein) sequence identity to SEQ ID
NO:6. In some
aspects, the transmembrane domain or second transmembrane domain comprises a
transmembrane domain having the amino acid sequence of SEQ ID NO:6. In some
aspects,
the transmembrane domain is an alpha or beta chain of the T cell receptor,
CD28, CD3c
(epsilon), CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86,
CD123, CD134, CD137 or CD154 transmembrane domain.
[0038] The co-stimulatory region or second co-stimulatory region in the
peptides and CARs
described herein may comprise the co-stimulatory region from the 4-1BB protein
or from the
CD28 protein. In some aspects, the co-stimulatory region or second co-
stimulatory region
comprises a co-stimulatory region having an amino acid sequence with at least
80% sequence
identity to SEQ ID NO:7, 14 or 18. In some aspects, the co-stimulatory region
or second co-
stimulatory region comprises a co-stimulatory region having an amino acid
sequence having
or having at least 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74,
75, 76, 77, 78, 79,
80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98,
99, or 100% (or any
derivable range therein) sequence identity to SEQ ID NO:7, 14, or 18. In some
aspects, the co-
stimulatory region or second co-stimulatory region comprises a co-stimulatory
region having
the amino acid sequence of SEQ ID NO:7, 14, or 18. In some aspects, the
cytoplasmic region
comprises two costimulatory domains. In some aspects, the one or more
costimulatory
domain(s) comprise a costimulatory domain from one or more of 4-1BB (CD137),
CD28, IL-
15Ra, 0X40, CD2, CD27, CDS, ICAM-1, LFA-1 (CD1 la/CD18), and/or ICOS (CD278).
In
some aspects, the one or more costimulatory domains comprise a costimulatory
domain from
CD28 or a costimulatory domain derived from CD28.
[0039] The primary intracellular signaling domain or second primary
intracellular signaling
domain of the polypeptides and CARs described herein may comprise an
intracellular signaling
domain from the CD3t protein. In some aspects, the primary intracellular
signaling domain or
second primary intracellular signaling domain comprises an intracellular
signaling domain
having an amino acid sequence with at least 80% sequence identity to SEQ ID
NO:8 or 15. In
some aspects, the primary intracellular signaling domain or second primary
intracellular
16

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
signaling domain comprises an intracellular signaling domain having an amino
acid sequence
having or at least 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74,
75, 76, 77, 78, 79,
80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98,
99, or 100% (or any
derivable range therein) sequence identity to SEQ ID NO:8 or 15. In some
aspects, the primary
intracellular signaling domain or second primary intracellular signaling
domain comprises an
intracellular signaling domain having the amino acid sequence of SEQ ID NO:8
or 15.
[0040] The polypeptides may comprise an amino acid sequence of one of SEQ ID
NOS:136-145, 159, or 160 or an amino acid sequence having at least 80%
sequence identity to
one of SEQ ID NOS:136-145, 159, or 160. The polypeptides may comprise an amino
acid
sequence having or having at least 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70,
71, 72, 73, 74, 75,
76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94,
95, 96, 97, 98, 99, or
100% (or any derivable range therein) sequence identity to one of SEQ ID
NOS:136-145, 159,
or 160. The polypeptides may comprise an amino acid sequence of one of SEQ ID
NOS:1, 9,
13, 16, 17, 19, 21-23, and 25 or an amino acid sequence having at least 80%
sequence identity
to one of SEQ ID NOS:1, 9, 13, 16, 17, 19, 21-23, and 25. The polypeptides may
comprise an
amino acid sequence having or having at least 60, 61, 62, 63, 64, 65, 66, 67,
68, 69, 70, 71, 72,
73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91,
92, 93, 94, 95, 96, 97,
98, 99, or 100% (or any derivable range therein) sequence identity to one of
SEQ ID NOS:1,
9, 13, 16, 17, 19, 21-23, and 25. The polypeptides may comprise an amino acid
sequence of
one of SEQ ID NOS:146, 148-158, and 161-172 or an amino acid sequence having
at least 80%
sequence identity to one of SEQ ID NOS:146, 148-158, and 161-172. The
polypeptides may
comprise an amino acid sequence having or having at least 60, 61, 62, 63, 64,
65, 66, 67, 68,
69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87,
88, 89, 90, 91, 92, 93,
94, 95, 96, 97, 98, 99, or 100% (or any derivable range therein) sequence
identity to one of
SEQ ID NOS:146, 148-158, and 161-172.
[0041] The polypeptides of the disclosure may comprise or further comprise
one or more
molecular tag(s). In some aspects, the one or more molecular tags comprise
FLAG and/or HA
tag. The polypeptides of the disclosure may comprise or further comprise one
or more signal
sequence(s). In some aspects, the signal sequence(s) comprise an amino acid
sequence with at
least 80% sequence identity to SEQ ID NO:2. In some aspects, the signal
sequence(s) comprise
an amino acid sequence having or having at least 60, 61, 62, 63, 64, 65, 66,
67, 68, 69, 70, 71,
72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90,
91, 92, 93, 94, 95, 96,
97, 98, 99, or 100% (or any derivable range therein) sequence identity to SEQ
ID NO:2. In
17

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
some aspects, the signal sequence(s) comprise the amino acid sequence of SEQ
ID NO:2. The
polypeptides may also exclude a FLAG tag in the CARs of the disclosure.
[0042] Aspects of the disclosure also describe nucleic acids encoding the
polypeptides and
expression vectors comprising the nucleic acid. The expression construct may
be a viral vector,
such as a retroviral vector or a vector derived from a retrovirus. In some
aspects, the viral
vector is a lentiviral vector or a vector derived from a lentivirus. Aspects
relate to a lentivirus
vector comprising a sequence encoding a polypeptide of the disclosure. Aspects
also relate to
viral particles comprising nucleic acids of the disclosure. In some aspects,
the expression
vector, such as the viral vector has integrated into the host cell's genome.
The cell may be ex
vivo. It is also contemplated that the cell is in vivo. Aspects of the
disclosure also relate to
cells expressing a polypeptide of the disclosure and/or comprising a nucleic
acid of the
disclosure. Cells of the disclosure may comprise or further comprise a nucleic
acid encoding
a second CAR. Cells of the disclosure may comprise or further comprise or
express a
polypeptide comprising a second CAR.
[0043] The cells of the disclosure may comprise a a nucleic acid that
encodes for or
comprise an expressed first polypeptide with a bi-specific CAR comprising an
IL13Ra binding
region and a TGF-beta binding region and a second polypeptide having a CAR
comprising a
GD2 binding region. The cells of the disclosure may comprise a a nucleic acid
that encodes
for or comprise an expressed first polypeptide with a bi-specific CAR
comprising an IL13Ra
binding region and a TGF-beta binding region and a second polypeptide having a
CAR
comprising a EGFRvIII binding region. The cells of the disclosure may comprise
a a nucleic
acid that encodes for or comprise an expressed first polypeptide with a bi-
specific CAR
comprising an IL13Ra binding region and a GD2 binding region and a second
polypeptide
having a CAR comprising a TGF-beta binding region. The cells of the disclosure
may comprise
a a nucleic acid that encodes for or comprise an expressed first polypeptide
with a bi-specific
CAR comprising an IL13Ra binding region and a EGFRvIII binding region and a
second
polypeptide having a CAR comprising a TGF-beta binding region. The cells of
the disclosure
may comprise a a nucleic acid that encodes for or comprise an expressed first
polypeptide with
a bi-specific CAR comprising a TGF-beta binding region and a EGFRvIII binding
region and
a second polypeptide having a CAR comprising an IL13Ra binding region. The
cells of the
disclosure may comprise a a nucleic acid that encodes for or comprise an
expressed first
polypeptide with a bi-specific CAR comprising a TGF-beta binding region and a
GD2 binding
region and a second polypeptide having a CAR comprising an IL13Ra binding
region. The
cells of the disclosure may comprise a a nucleic acid that encodes for or
comprise an expressed
18

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
first polypeptide with a bi-specific CAR comprising a TGF-beta binding region
and a GD2
binding region and a second polypeptide having a bi-specific CAR comprising an
IL13Ra
binding region and a EGFRvIII binding region. The cells of the disclosure may
comprise a a
nucleic acid that encodes for or comprise an expressed first polypeptide with
a bi-specific CAR
comprising a TGF-beta binding region and a EGFRvIII binding region and a
second
polypeptide having a bi-specific CAR comprising an IL13Ra binding region and a
GD2
binding region. The cells of the disclosure may comprise a a nucleic acid that
encodes for or
comprise an expressed first polypeptide with a bi-specific CAR comprising an
IL13Ra binding
region and a TGFbeta binding region and a second polypeptide having a bi-
specific CAR
comprising a EGFRvIII binding region and a GD2 binding region.
[0044] Nucleic acids comprising a sequence that encodes the polypeptides
disclosed herein,
and portions thereof, are provided in aspects. A nucleic acid may comprise RNA
or DNA. In
certain aspects, the nucleic acid is an expression construct. In some aspects,
the expression
construct is a vector. In certain aspects, the vector is a viral vector. The
viral vector is a
retroviral vector or derived from a retrovirus in particular aspects. In some
aspects, the
retroviral vector comprises a lentiviral vector or is derived from a
lentivirus. It is noted that a
viral vector is an integrating nucleic acid in certain aspects. Additionally,
a nucleic acid may
be a molecule involved in gene editing such that a nucleic acid (such as a
guide RNA) encoding
a CAR is used to incorporate a CAR-coding sequence into a particular locus of
the genome,
such as the TRAC gene. This may involve a gene editing system such as
CRISPR/Cas9. A
nucleic acid, polynucleotide, or polynucleotide region (or a polypeptide or
polypeptide region)
has a certain percentage (for example, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%,
98% or
99%--or any range derivable therein) of "sequence identity" or "hom*ology" to
another
sequence means that, when aligned, that percentage of bases (or amino acids)
are the same in
comparing the two sequences. This alignment and the percent hom*ology or
sequence identity
can be determined using software programs known in the art, for example those
described in
Ausubel et al. eds. (2007) Current Protocols in Molecular Biology. It is
contemplated that a
nucleic acid may have such sequence identity or hom*ology to any nucleic acid
SEQ ID NO
provided herein.
[0045] In other aspects, there is a cell or a population of cells
comprising a nucleic acid that
encodes all or part of any polypeptide discussed herein. In certain aspects, a
cell or population
of cells contains within its genome a sequence encoding any of the
polypeptides described
herein. This includes, but is not limited to, a lentivirus or retrovirus that
has integrated into the
cell's genome. In some aspects, a cell or population of cells expresses all or
part of any CAR
19

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
discussed herein, including, but not limited to those with the amino acid
sequence of any of
and/or comprising the amino acid sequence of any of SEQ ID NOS:1-159. Progeny
(F1, F2,
and beyond) of cells in which a nucleic acid encoding a polypeptide was
introduced are
included in the cells or populations of cells disclosed herein. In some
aspects, a cell or
population of cells is a T cell, a natural killer (NK) cell, a natural killer
T cell (NKT), an
invariant natural killer T cell (iNKT), stem cell, lymphoid progenitor cell,
peripheral blood
mononuclear cell (PBMC), hematopoietic stem and progenitor cell (HSPC),
hematopoietic
stem cell (HSC), CD34+ cell, peripheral blood stem cell (PBSC), bone marrow
cell, fetal liver
cell, embryonic stem cell, cord blood cell, induced pluripotent stem cell (iPS
cell). Some
aspects concern a cell that is a T cell or an NK cell. In some aspects, T cell
comprises a naïve
memory T cell. In some aspects, the naïve memory T cell comprises a CD4+ or
CD8+ T cell.
In some aspects, the cells are a population of cells comprising both CD4+ and
CD8+ T cells.
In some aspects, the cells are a population of cells comprising naïve memory T
cells comprising
CD4+ and CD8+ T cells. In some aspects, the T cell comprises a T cell from a
population of
CD14 depeleted, CD25 depleted, and/or CD62L enriched PBMCs.
[0046] In some aspects, the disclosure relates to a cell comprising one or
more polypeptides
described herein. In some aspects, the cell is an immune cell. In some
aspects, the cell is a
progenitor cell or stem cell. In some aspects, the progenitor or stem cell is
in vitro differentiated
into an immune cell. In some aspects, the cell is a T cell. In some aspects,
the cell is a CD4+
or CD8+ T cell. In some aspects, the cell is a natural killer cell. In some
aspects, the cell is ex
vivo. The term immune cells includes cells of the immune system that are
involved in
defending the body against both infectious disease and foreign materials.
Immune cells may
include, for example, neutrophils, eosinophils, basophils, natural killer
cells, lymphocytes such
as B cells and T cells, and monocytes. T cells may include, for example, CD4+,
CD8+, T
helper cells, cytotoxic T cells, y6 T cells, regulatory T cells, suppressor T
cells, and natural
killer T cells. In a specific aspect, the T cell is a regulatory T cell.
[0047] In some aspects, the population of cells comprise 103-108 cells. In
some aspects, the
the population is about, is at least about, or is at most about 102, 103, 104,
105, 106, 107, 108,
109, 1010, 1011, vo2
v cells (or any range derivable therein). In certain aspects, cells are
autologous with respect to a patient who will receive them. In other aspects,
cells are not
autologous and may be allogenic.
[0048] In some aspects of the disclosure, method aspects relate to wherein
the cell is
infected with a virus encoding a polypeptide of the disclosure. Further
aspects relate to a virus
comprising a polypeptide and/or nucleic acid of the disclosure. In some
aspects, the virus

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
comprises lentivirus or a lentiviral-derived virus or vector. In some aspects,
the cell is a T cell,
a natural killer (NK) cell, a natural killer T cell (NKT), an invariant
natural killer T cell (iNKT),
stem cell, lymphoid progenitor cell, peripheral blood mononuclear cell (PBMC),
bone marrow
cell, fetal liver cell, embryonic stem cell, cord blood cell, induced
pluripotent stem cell (iPS
cell). In some aspects, the cell is a T cell or an NK cell. In some aspects,
the T cell comprises
a naïve memory T cell. In some aspects, the naïve memory T cell comprises a
CD4+ or CD8+
T cell. In some aspects, the cell is not yet a T cell or NK cell, the method
further comprising
culturing the cell under conditions that promote the differentiation of the
cell into a T cell or
an NK cell. In some aspects, the methods further comprise culturing the cell
under conditions
to expand the cell before and or after introducing the nucleic acid into the
cell. In some aspects,
the cell is cultured with serum-free medium.
[0049]
Additional methods concern treating a patient with glioblastoma comprising
administering to the patient an effective amount of the composition comprising
a cell
population expressing a polypeptide of the disclosure. In some aspects, a
patient has relapsed
or recurrent cancer. Further aspects include a step of administering an
additional therapy to the
patient. The patient may be one that has been diagnosed with glioblastoma
and/or a
glioblastoma that has GD+ or EGFRvIII+ cells, as described herein. The patient
may be one
that has been determined to have glioblastoma and/or a glioblastoma that has
GD+ or
EGFRvIII+ cells, as described herein. In some aspects, the subject is one that
is at risk of
having glioblastoma and/or GD2+ or EGFRvIII+ glioblastoma. In some aspects,
the patient
has been previously treated to the cancer. In some aspects, the patient has
been determined to
be resistant to the previous treatment. The previous treatment may be a cancer
therapeutic
described herein, such as those described as additional therapies. Further
aspects include a step
of administering chemotherapy and/or radiation to the patient. In some
aspects, the additional
therapy comprises an immunotherapy. In some aspects, the additional therapy
comprises an
additional therapy described herein. In some aspects, the immunotherapy
comprises immune
checkpoint inhibitor therapy. In
some aspects, the immunotherapy comprises an
immunotherapy described herein. In some aspects, the immune checkpoint
inhibitor therapy
comprises a PD-1 inhibitor and/or CTLA-4 inhibitor. In some aspects, the
immune checkpoint
inhibitor therapy comprises one or more inhibitors of one or more immune
checkpoint proteins
described herein.
[0050] In
some aspects, the cancer comprises a GD2+ cancer, wherein a GD2+ cancer is
one that comprises GD2+ cells or comprises at least 0.5, 1, 2, 3, 4, 5, 6, 7,
8, 9, 10, 11, 12, 13,
21

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80,
85, or 90% GD2+ cancer
cells in a population of tumor cells.
[0051] In some aspects, the cancer comprises a EGFRvIII+ cancer, wherein a
EGFRvIII+
cancer is one that comprises EGFRvIII+ cells or comprises at least 0.5, 1, 2,
3, 4, 5, 6, 7, 8, 9,
10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60,
65, 70, 75, 80, 85, or
90% EGFRvIII+ cancer cells in a population of tumor cells.
[0052] The CAR polypeptides of the current disclosure may have a region,
domain, linker,
spacer, or other portion thereof that comprises or consists of an amino acid
sequence that is at
least, at most, or exactly 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62,
63, 64, 65, 66, 67,
68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86,
87, 88, 89, 90, 91, 92,
93, 94, 95, 96, 97, 98, 99, or 100% identical (or any range derivable therein)
to all or a portion
of the amino acid sequences described herein. In certain aspects, a CAR
polypeptide comprises
or consists of an amino acid sequence that is, is at least, is at most, or
exactly 50, 51, 52, 53,
54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72,
73, 74, 75, 76, 77, 78,
79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,
98, 99, 100% identical
(or any range derivable therein) to any one of SEQ ID NOS:1-172.
[0053] In aspects of the disclosure the method may comprise stimulating an
immune
response, wherein stimulating an immune response comprises increasing
expression and/or
secretion of immune stimulating cytokines and/or molecules. In some aspects,
the immune
stimulating cytokines and/or molecules are one or more of TNF-a, IFN-f3, IFN-
y, IL-1, IL-2,
IL-4, IL-6, IL-8, IL-10, IL-12, IL-18 and granulocyte-macrophage colony
stimulating factor.
In some aspects, stimulating an immune response comprises increasing
proliferation of
immune cells. The immune cells may be T cells. In some aspects, the cells are
ex vivo. The
cell may also be in vivo in a subject in need of immune stimulation. The
subject may be one
that produces endogenous TGF-f3 and/or an excess of endogenous TGF-f3. An
increase in
expression or proliferation as described herein may be at least, at most, or
exactly 1, 2, 3, 4, 5,
6, 7, 8, 9, 10, 50, 100, 200, 300, 500, or 1000 fold increase over a base-line
expression level
such as a control (non-disease, non-TGF-f3 or non-antigen binding polypeptide
control). In
some aspects, the methods are for treating a person with an indication,
wherein the indication
is characterized by a pathogenic level of expression of TGF- 0.
[0054] The subject may be a mammal, such as a human, rat, mouse, or non-human
primate.
In a particular aspect, the subject is a human. The subject may also be a
goat, pig, horse, cat,
or dog. The route of administration of the compositions, polypeptides, cells,
and nucleic acids
of the disclosure may be a route of administration described herein. In some
aspects, the
22

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
compositions are administered intraventricularly, intracerebroventricularly,
intratumorally,
intravenously, or into a tumor resection cavity. In some aspects, the
compositions are
formulated for intraventricular, intracerebroventricular, intratumoral, or
intravenous
administration or for administration into a tumor resection cavity.
[0055] In some aspects, the method further comprises administering TGF-f3
to the subject.
In compositions of the disclosure, the composition may comprise 1-50 ng/mL of
TGF-f3. In
some aspects, the composition comprises at least, at most, or about 0.5, 1,
1.5, 2, 2.5, 3, 3.5, 4,
4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
19, 20, 21, 22, 23, 24, 25,
30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 ng/mL of TGF-f3
(or any range
derivable therein).
[0056] In some aspects, the composition further comprises IL-2. In some
aspects, the
composition comprises 20-400 U/mL of IL-2. In some aspects, the composition
comprises at
least, at most, or about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65,
70, 75, 80, 85, 90, 95,
100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170,
175, 180, 185, 190,
195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265,
270, 275, 280, 285,
290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360,
365, 370, 375, 380,
385, 390, 395, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455,
460, 465, 470, 475,
480, 485, 490, 495, 500, 505, 510, 515, 520, 525, 530, 535, 540, 545, 550,
555, 560, 565, 570,
575, 580, 585, 590, 595, 600 U/mL of IL-2 (or any range derivable therein). In
some aspects,
the composition further comprises IL-15. In some aspects, the composition
comprises 0.1-10
ng/mL of IL-15. In some aspects, the composition comprises at least, at most,
or about 0.05,
0.06, 0.07, 0.08, 0.09,0.10, 0.15, 0.20, 0.25, 0.30, 0.35, 0.40, 0.45, 0.50,
0.55, 0.60, 0.65, 0.70,
0.75, 0.80, 0.85, 0.90, 0.95, 1.00, 1.05, 1.10, 1.15, 1.20, 1.25, 1.30, 1.35,
1.40, 1.45, 1.50, 1.55,
1.60, 1.65, 1.70, 1.75, 1.80, 1.85, 1.90, 1.95, 2.00, 2.05, 2.10, 2.15, 2.20,
2.25, 2.30, 2.35, 2.40,
2.45, 2.50, 2.55, 2.60, 2.65, 2.70, 2.75, 2.80, 2.85, 2.90, 2.95, 3.00, 3.05,
3.10, 3.15, 3.20, 3.25,
3.30, 3.35, 3.40, 3.45, 3.50, 3.55, 3.60, 3.65, 3.70, 3.75, 3.80, 3.85, 3.90,
3.95, 4.00, 4.05, 4.10,
4.15, 4.20, 4.25, 4.30, 4.35, 4.40, 4.45, 4.50, 4.55, 4.60, 4.65, 4.70, 4.75,
4.80, 4.85, 490, 495,
5.00, 5.05, 5.10, 5.15, 5.20, 5.25, 5.30, 5.35, 5.40, 5.45, 5.50, 5.55, 5.60,
5.65, 5.70, 5.75, 580,
5.85, 5.90, 5.95, 6.00, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 11, 12, 13, 14, 15,
16, 17, 18, 19, 20, 30,
40, or 50 ng/mL of IL-15 (or any range derivable therein). In some aspects,
the composition
comprises or further comprises IL-7, IL-12, and/or IL-21. In some aspects, the
composition
comprises at least, at most, or about 0.05, 0.06, 0.07, 0.08, 0.09, 0.10,
0.15, 0.20, 0.25, 0.30,
0.35, 0.40, 0.45, 0.50, 0.55, 0.60, 0.65, 0.70, 0.75, 0.80, 0.85, 0.90, 0.95,
1.00, 1.05, 1.10, 1.15,
1.20, 1.25, 1.30, 1.35, 1.40, 1.45, 1.50, 1.55, 1.60, 1.65, 1.70, 1.75, 1.80,
1.85, 1.90, 1.95, 2.00,
23

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
2.05, 2.10, 2.15, 2.20,2.25, 2.30, 2.35, 2.40, 2.45, 2.50, 2.55, 2.60, 2.65,
2.70, 2.75, 2.80, 2.85,
2.90, 2.95, 3.00, 3.05, 3.10, 3.15, 3.20, 3.25, 3.30, 3.35, 3.40, 3.45, 3.50,
3.55, 3.60, 3.65, 3.70,
3.75, 3.80, 3.85, 3.90, 3.95, 4.00, 4.05, 4.10, 4.15, 4.20, 4.25, 4.30, 4.35,
4.40, 4.45, 4.50, 4.55,
4.60, 4.65, 4.70, 4.75, 4.80, 4.85, 490, 495, 5.00, 5.05, 5.10, 5.15, 5.20,
5.25, 5.30, 5.35, 5.40,
5.45, 5.50, 5.55, 5.60, 5.65, 5.70, 5.75, 580, 5.85, 5.90, 5.95, 6.00, 6.5, 7,
7.5, 8, 8.5, 9, 9.5, 10,
11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 55, 60, 65, 70, 75, 80,
85, 90, 95, 100, 105,
110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180,
185, 190, 195, 200,
205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275,
280, 285, 290, 295,
300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365, 370,
375, 380, 385, 390,
395, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465,
470, 475, 480, 485,
490, 495, 500, 505, 510, 515, 520, 525, 530, 535, 540, 545, 550, 555, 560,
565, 570, 575, 580,
585, 590, 595, 600 pg/mL, ng/mL, i.t.g/mL, or mg/ml of IL-7, IL-12, and/or IL-
21 (or any range
derivable therein).
[0057] In
some aspects, the method further comprises contacting the cells with feeder
cells.
In some aspects, the feeder cells are irradiated. Feeder cells or support
cells can include, for
example, fibroblasts, mouse embryonic fibroblasts, JK1 cells, SNL 76/7 cells,
human fetal skin
cells, human fibroblasts, and human foreskin fibroblasts.
[0058] In
some aspects, the method excludes contacting T cells with feeder cells. In
some
cases, the excluded feeder cells are from a different animal species as the T
cells.
[0059] In
certain aspects, polypeptides described throughout this disclosure are
isolated,
meaning they are not found in the cellular milieu. In some cases, they are
purified, which means
it is mostly if not completely separated from polypeptides having a different
amino acid
sequence and/or chemical formula.
[0060] The
present disclosure provides, in some aspects, a method for treating a subject
with cancer comprising administering to the subject an effective amount of a
population of
cells or pharmaceutical composition comprising a chimeric polypeptide or
nucleic acid
encoding a chimeric polypeptide.
[0061]
"Treatment" or "Treating" may refer to any treatment of a disease in a mammal,
including: (i) suppressing the disease, that is, causing the clinical symptoms
of the disease not
to develop by administration of a protective composition after the inductive
event but prior to
the clinical appearance or reappearance of the disease; (ii) inhibiting the
disease, that is,
arresting the development of clinical symptoms by administration of a
protective composition
after their initial appearance; and/or (iii) relieving the disease, that is,
causing the regression of
24

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
clinical symptoms by administration of a protective composition after their
initial appearance.
In some aspects, the treatment may exclude prevention of the disease.
[0062] Use of the one or more sequences or compositions may be employed based
on any
of the methods described herein. Other aspects are discussed throughout this
application. Any
embodiment or aspect discussed with respect to one aspect of the disclosure
applies to other
aspects of the disclosure as well and vice versa. For example, any step in a
method described
herein can apply to any other method. Moreover, any method described herein
may have an
exclusion of any step or combination of steps. The embodiments in the Example
section are
understood to be embodiments that are applicable to all aspects of the
technology described
herein.
[0063] It is specifically contemplated that any method, composition, cell,
polypeptide, or
nucleic acid embodiment or aspect described herein may be used interchangeably
and in
combination with each other. Furthermore, it is contemplated that aspects and
embodiments
of the disclosure may specifically exclude an aspect or embodiment described
herein.
[0064] Where a range of values is provided, it is understood that each
intervening value, to
the tenth of the unit of the lower limit unless the context clearly dictates
otherwise, between
the upper and lower limit of that range and any other stated or intervening
value in that stated
range, is encompassed within the invention. The upper and lower limits of
these smaller ranges
may independently be included in the smaller ranges, and are also encompassed
within the
invention, subject to any specifically excluded limit in the stated range.
Where the stated range
includes one or both of the limits, ranges excluding either or both of those
included limits are
also included in the invention.
[0065] Throughout this application, the term "about" is used according to
its plain and
ordinary meaning in the area of cell and molecular biology to indicate that a
value includes the
standard deviation of error for the device or method being employed to
determine the value.
[0066] The use of the word "a" or "an" when used in conjunction with the
term
"comprising" may mean "one," but it is also consistent with the meaning of
"one or more," "at
least one," and "one or more than one."
[0067] As used herein, the terms "or" and "and/or" are utilized to describe
multiple
components in combination or exclusive of one another. For example, "x, y,
and/or z" can refer
to "x" alone, "y" alone, "z" alone, "x, y, and z," "(x and y) or z," "x or (y
and z)," or "x or y or
z." It is specifically contemplated that x, y, or z may be specifically
excluded from an
embodiment or aspect.

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
[0068] The words "comprising" (and any form of comprising, such as
"comprise" and
"comprises"), "having" (and any form of having, such as "have" and "has"),
"including" (and
any form of including, such as "includes" and "include"), "characterized by"
(and any form of
including, such as "characterized as"), or "containing" (and any form of
containing, such as
"contains" and "contain") are inclusive or open-ended and do not exclude
additional, unrecited
elements or method steps.
[0069] The compositions and methods for their use can "comprise," "consist
essentially of,"
or "consist of' any of the ingredients or steps disclosed throughout the
specification. The
phrase "consisting of' excludes any element, step, or ingredient not
specified. The phrase
"consisting essentially of' limits the scope of described subject matter to
the specified materials
or steps and those that do not materially affect its basic and novel
characteristics. It is
contemplated that aspects or embodiments described in the context of the term
"comprising"
may also be implemented in the context of the term "consisting of' or
"consisting essentially
of."
[0070] It is specifically contemplated that any limitation discussed with
respect to one
embodiment or aspect of the invention may apply to any other embodiment or
aspect of the
invention. Furthermore, any composition of the invention may be used in any
method of the
invention, and any method of the invention may be used to produce or to
utilize any
composition of the invention. Aspects of an embodiment set forth in the
Examples are also
embodiments that may be implemented in the context of embodiments or aspects
discussed
elsewhere in a different Example or elsewhere in the application, such as in
the Summary of
Invention, Detailed Description, Claims, and description of Figure Legends.
[0071] Other objects, features and advantages of the present invention will
become apparent
from the following detailed description. It should be understood, however,
that the detailed
description and the specific examples, while indicating specific embodiments
and aspects of
the invention, are given by way of illustration only, since various changes
and modifications
within the spirit and scope of the invention will become apparent to those
skilled in the art from
this detailed description.
BRIEF DESCRIPTION OF THE DRAWINGS
[0072] The following drawings form part of the present specification and
are included to
further demonstrate certain aspects of the present invention. The invention
may be better
understood by reference to one or more of these drawings in combination with
the detailed
description of specific embodiments presented herein.
26

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
[0073] FIG. 1A-B: (1A) Panel of CAR constructs used in the aspects of the
disclosure.
(1B) Expression of the single-input and bispecific CARs on the surface of T
cells.
[0074] FIG. 2: Stimulation of CAR-T cells with 5 ng/ml or 10 ng/ml of
exogenous TGF-f3.
Each set of three bars represents, from left to right, data for: 0, 5, and 10
ng/mL TGF-P.
[0075] FIG. 3A-C: CAR-T cells were labeled with CellTrace Violet (CTV) dye
and then
co-incubated with patient-derived PBT106 GBM neurosphere cells at a 1:8
effector-to-target
ratio for 94 hours, in the presence or absence of metalloprotease 9 (MMP-9).
The number of
surviving tumor cells (3A), number of FLAG+ CAR-T cells (3B), as well as CTV
dye intensity
among FLAG+ CAR-T cells (3C) were quantified by flow cytometry. Each set of
four bars
represents, from left to right, data for: IL13Ra2BBz (CD4tm); IL13Ra2BBz
(CD28tm);
IL13Ra2-(G45)3-TGFP.BBz (CD28tm); and IL13Ra2-(G45)4-TGFP.BBz (CD28tm).
[0076] FIG. 4: Additional contemplated CAR aspects.
[0077] FIG. 5: TGF-f3 Activates Bispecific IL-13Ra2/TGF-f3 CAR-T Cells.
Primary human
T cells were transduced with the indicated constructs and seeded at 7.5 x 104
CAR+ T cells in
100 [IL per well of a 96-well plate, with the indicated concentration of TGF-
f3. Cells were
harvested after 21 hours for surface staining with anti-CD69 and anti-CD25
antibodies
followed by flow cytometry analysis. The mean value of technical triplicates
are shown with
error bars indicating 1 standard deviation (s.d.). Each set of three bars
represents, from left
to right, data for: 0, 5, and 10 ng/mL TGF-P.
[0078] FIG. 6: IL-13Ra2/TGF-f3 CAR-T Cells Exhibit Increased Proliferation
Upon Tumor
Challenge. Patient-derived PBT-106 glioblastoma neurosphere cells that stably
express EGFP-
firefly luciferase fusion protein were sorted for IL-13Ra2 expression and
seeded at 4 x 104 per
well in 96-well plate. Primary human T cells were transduced with the
indicated constructs and
stained with CellTrace Violet (CTV) dye. CTV-stained T cells were co-incubated
with seeded
PBT-106 cells at 1:8 effector-to-target ratio for 94 hours. Flow cytometry was
performed to
quantify the number of viable EGFP+ tumor cells, viable CTV+ T cells, and CTV
dye intensity
in T cells. The mean value of technical triplicates are shown with error bars
indicating 1 s.d.
[0079] FIG. 7A-B: IL-13Ra2/TGF-f3 CAR-T Cells Exhibit Superior In Vivo Tumor
Control. Patient-derived PBT-106 glioblastoma neurosphere cells that stably
express EGFP-
firefly luciferase fusion protein were sorted for IL-13Ra2 expression. NSG
mice were
engrafted with 2 x 105 sorted PBT-106 cells via intracranial injection (1.5mm
lateral, 0.5mm
posterior of bregma, 2.5 mm into dura). Seven days later, tumor-bearing mice
were treated with
either 5 x 105 T cells expressing the indicated construct or PBS alone (7A,
left side). Tumor
27

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
progression was quantified by bioluminescence imaging; each line in the
radiance plots
indicate an individual mouse (7A, right). Survival data are displayed as
Kaplan-Meier curve
(7B); two deaths in the bispecific CAR group were censored based on
determination that the
deaths unrelated to tumor burden (e.g., exhibiting clear signs of graft-versus-
host disease while
showing no tumor signal by luciferase imaging and no sign of tumor upon brain
dissection).
[0080] FIG. 8: IL-13Ra2/TGF-f3 CAR-T Cells Exhibit Superior In Vivo Tumor
Control.
Patient-derived PBT-106 glioblastoma neurosphere cells that stably express
EGFP-firefly
luciferase fusion protein were sorted for IL-13Ra2 expression. NSG mice were
engrafted with
2 x 105 sorted PBT-106 cells via intracranial injection (1.5mm lateral, 0.5mm
posterior of
bregma, 2.5 mm into dura). Seven days later, tumor-bearing mice were treated
with either 5 x
105 T cells expressing the indicated construct or PBS alone. Tumor progression
was quantified
by bioluminescence imaging; each line in the radiance plots indicate an
individual mouse.
Survival data are displayed as Kaplan-Meier curve.
[0081] FIG. 9: TGF-f3 CAR Shows No In Vivo Toxicity Despite Cross-
reactivity with
Murine TGF-f3. Primary human T cells expressing a TGF-f3 CAR with CD28
costimulatory
domain was incubated with 0.5, 1.5, 5, 15, 50, 150, and 500 ng/mL of human or
mouse TGF-
f31, in triplicate, at lx105 cells/100 uL media per well in a 96-well plate.
All wells were treated
with 1X Brefeldin A (diluted from 1000X stock from BioLegend). The following
day,
intracellular staining was performed on the cells for IFN-y, TNF-a, and IL-2.
[0082] FIG. 10: No Systemic Toxicity with Murine TGF-f3 CAR-T Cells in
C57BL/6 Mice.
C57BL/6 mice were administered 4 x 106 T cells expressing the indicated
construct via tail-
vein injection (n = 3 per treatment group). Animal weight was measured at the
indicated time
point. On Day 31 post T-cell injection, all animals were sacrificed, and their
liver, spleen, and
kidneys were collected for histopathology analysis. No significant difference
was observed
between animals treated with mock-transduced vs. TGF-f3 CAR-T cells in either
weight or
histopathology results.
[0083] FIG. 11: FLAG (CAR) Surface Expression (No Antigen Stimulation).
Averages of
triplicates are shown, with error bars representing 1 standard deviation.
Each set of two bars
represents data, from left to right, of the SP and Full IL13R construct.
[0084] FIG. 12A-D: (12A) CD69 Activation Marker Expression after 21-hr
Stimulation.
(12B) CD25 Activation Marker Expression after 21-hr Stimulation. (12C) FLAG
(CAR)
Surface Expression after 21-hr Stimulation. (12D) FLAG (CAR) Surface
Expression after 21-
hr Stimulation. PBT106 NS is a tumor line that expresses IL-13Ra2. Averages of
triplicates
are shown, with error bars representing 1 standard deviation. Each set of
three bars represents
28

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
the data, from left to right, of 1) media only; 2) 5 ng/mL TGF-f3; and 3) 100%
IL13Ra2 +PBT
106 NS.
[0085] FIG. 13A-F: (13A-13B) Viable Tumor Count after 92-hr Coincubation.
(13C-13D)
Viable T-cell Count after 92-hr Coincubation (13E-13F) CTV Dilution among T
Cells after
92-hr Coincubation. T cells were stained with CellTrace Violet (CTV) dye,
which dilutes with
each T-cell division. Therefore, the lower the CTV MFI, the more times the T
cells have
divided. Averages of triplicates are shown, with error bars representing 1
standard deviation.
Each set of 16 bars represents the data, from left to right, of 1) SP-
IL13Ra2.BBz; 2) Full-
IL13Ra2.BBz; 3) SP-IL13Ra2/TGF-f3.BBz; 4) Full-IL13Ra2/TGF-f3.BBz; 5) SP-
IL13Ra2.BBz KR; 6) Full-IL13Ra2.BBz KR; 7) SP-IL13Ra2/TGF-f3.BBz KR; 8) SP-
IL13Ra2.28z; 9) Full-IL13Ra2.28z; 10) SP-IL13Ra2/TGF-f3.28z; 11) Full-
IL13Ra2/TGF-
f3.28z; 12) SP-IL13Ra2/TGF-f3.BBz + GD2.AA.28z; 13) Full-IL13Ra2/TGF-f3.BBz +
GD2.AA.28z; 14) SP-IL13Ra2.BBz + TGF-f3 DNR; 15) Full-IL13Ra2.BBz + TGF-f3
DNR;
and 16) scFv-less CAR.
[0086] FIG. 14. NOD/scid/y¨/¨ (NSG) mice were intracranially engrafted with
2.5 x 10^5
PBT106 glioblastoma multiforme (GBM) neurosphere cells that stably express
firefly
luciferase. Tumor-bearing mice were treated with 0.5 x 101\6 CAR+ cells 7 days
after tumor
injection. Tumor progression was monitored by bioluminescence imaging. Each
trace
represents one mouse, with "x" marking time of sacrifice for mice that reached
the humane end
point. Survival is shown in Kaplan-Meier curve.
DETAILED DESCRIPTION
I. Definitions
[0087] The peptides of the disclosure relate to peptides comprising
chimeric antigen
receptors, or CARs. CARs are engineered receptors, which are capable of
grafting an arbitrary
specificity onto an immune effector cell. In some cases, these receptors are
used to graft the
specificity of a monoclonal antibody onto a T cell. The receptors are called
chimeric because
they are composed of parts from different sources.
[0088] The terms "protein," "polypeptide," and "peptide" are used
interchangeably herein
when referring to a gene product.
[0089] "hom*ology," or "identity" refers to sequence similarity between two
peptides or
between two nucleic acid molecules. Identity can be determined by comparing a
position in
each sequence which may be aligned for purposes of comparison. When a position
in the
compared sequence is occupied by the same base or amino acid, then the
molecules share
29

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
sequence identity at that position. A degree of identity between sequences is
a function of the
number of matching or hom*ologous positions shared by the sequences. An
"unrelated" or
"non-hom*ologous" sequence shares less than 60% identity, less than 50%
identity, less than
40% identity, less than 30% identity, or less than 25% identity, with one of
the sequences of
the current disclosure.
[0090] The terms "amino proximal," "N-terminus," "amino terminus," and the
like as used
herein are used to refer to order of the regions of the polypeptide.
Furthermore, when
something is N-terminal or amino proximal to a region it is not necessarily at
the terminus (or
end) of the entire polypeptide, but just at the N-terminus of the region or
domain. Similarly,
the terms "carboxy proximal," "C-terminus," "carboxy terminus," and the like
as used herein
is used to refer to order of the regions of the polypeptide, and when
something is C-terminal or
carboxy proximal to a region it is not necessarily at the terminus (or end) of
the entire
polypeptide, but just at the C-terminus of the region or domain.
[0091] The terms "polynucleotide," "nucleic acid," and "oligonucleotide"
are used
interchangeably and refer to a polymeric form of nucleotides of any length,
either
deoxyribonucleotides or ribonucleotides or analogs thereof. Polynucleotides
can have any
three-dimensional structure and may perform any function, known or unknown.
The following
are non-limiting examples of polynucleotides: a gene or gene fragment (for
example, a probe,
primer, EST or SAGE tag), exons, introns, messenger RNA (mRNA), transfer RNA,
ribosomal
RNA, ribozymes, cDNA, dsRNA, siRNA, miRNA, recombinant polynucleotides,
branched
polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA
of any
sequence, nucleic acid probes and primers. A polynucleotide can comprise
modified
nucleotides, such as methylated nucleotides and nucleotide analogs. If
present, modifications
to the nucleotide structure can be imparted before or after assembly of the
polynucleotide. The
sequence of nucleotides can be interrupted by non-nucleotide components. A
polynucleotide
can be further modified after polymerization, such as by conjugation with a
labeling
component. The term also refers to both double- and single-stranded molecules.
Unless
otherwise specified or required, any embodiment or aspect of this invention
that is a
polynucleotide encompasses both the double-stranded form and each of two
complementary
single-stranded forms known or predicted to make up the double-stranded form.
[0092] A "gene," "polynucleotide," "coding region," "sequence," "segment,"
"fragment,"
or "transgene" which "encodes" a particular protein, is a nucleic acid
molecule which is
transcribed and optionally also translated into a gene product, e.g., a
polypeptide, in vitro or in
vivo when placed under the control of appropriate regulatory sequences. The
coding region

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
may be present in either a cDNA, genomic DNA, or RNA form. When present in a
DNA form,
the nucleic acid molecule may be single-stranded (i.e., the sense strand) or
double-stranded.
The boundaries of a coding region are determined by a start codon at the 5'
(amino) terminus
and a translation stop codon at the 3' (carboxy) terminus. A gene can include,
but is not limited
to, cDNA from prokaryotic or eukaryotic mRNA, genomic DNA sequences from
prokaryotic
or eukaryotic DNA, and synthetic DNA sequences. A transcription termination
sequence will
usually be located 3' to the gene sequence.
[0093] The term "antibody" includes monoclonal antibodies, polyclonal
antibodies, dimers,
multimers, multispecific antibodies and antibody fragments that may be human,
mouse,
humanized, chimeric, or derived from another species. A "monoclonal antibody"
is an antibody
obtained from a population of substantially hom*ogeneous antibodies that is
being directed
against a specific antigenic site.
[0094] "Antibody or functional fragment thereof' means an immunoglobulin
molecule that
specifically binds to, or is immunologically reactive with a particular
antigen or epitope, and
includes both polyclonal and monoclonal antibodies. The term antibody includes
genetically
engineered or otherwise modified forms of immunoglobulins, such as
intrabodies, peptibodies,
chimeric antibodies, fully human antibodies, humanized antibodies, and
heteroconjugate
antibodies (e.g., bispecific antibodies, diabodies, triabodies, and
tetrabodies). The term
functional antibody fragment includes antigen binding fragments of antibodies,
including e.g.,
Fab', F(ab')2, Fab, Fv, r1gG, and scFv fragments. The term scFv refers to a
single chain Fv
antibody in which the variable domains of the heavy chain and of the light
chain of a traditional
two chain antibody have been joined to form one chain.
[0095] As used herein, the term "binding affinity" refers to the
equilibrium constant for the
reversible binding of two agents and is expressed as a dissociation constant
(Kd). Binding
affinity can be at least 1-fold greater, at least 2-fold greater, at least 3-
fold greater, at least 4-
fold greater, at least 5-fold greater, at least 6-fold greater, at least 7-
fold greater, at least 8-fold
greater, at least 9-fold greater, at least 10-fold greater, at least 20-fold
greater, at least 30-fold
greater, at least 40-fold greater, at least 50-fold greater, at least 60-fold
greater, at least 70-fold
greater, at least 80-fold greater, at least 90-fold greater, at least 100-fold
greater, or at least
1000-fold greater, or more (or any derivable range therein), than the binding
affinity of an
antibody for unrelated amino acid sequences. As used herein, the term
"avidity" refers to the
resistance of a complex of two or more agents to dissociation after dilution.
The terms
"immunoreactive" and "preferentially binds" are used interchangeably herein
with respect to
antibodies and/or antigen-binding fragments.
31

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
[0096] The term "binding" refers to a direct association between two
molecules, due to, for
example, covalent, electrostatic, hydrophobic, and ionic and/or hydrogen-bond
interactions,
including interactions such as salt bridges and water bridges.
[0097] "Individual, "subject," and "patient" are used interchangeably and
can refer to a
human or non-human.
[0098] The terms "lower," "reduced," "reduction," "decrease," or "inhibit"
are all used
herein generally to mean a decrease by a statistically significant amount.
However, for
avoidance of doubt, "lower," "reduced," "reduction, "decrease," or "inhibit"
means a decrease
by at least 10% as compared to a reference level, for example a decrease by at
least about 20%,
or at least about 30%, or at least about 40%, or at least about 50%, or at
least about 60%, or at
least about 70%, or at least about 80%, or at least about 90% or up to and
including a 100%
decrease (i.e. absent level as compared to a reference sample), or any
decrease between 10-
100% as compared to a reference level.
[0099] The terms "increased," "increase," "enhance," or "activate" are all
used herein to
generally mean an increase by a statically significant amount; for the
avoidance of any doubt,
the terms "increased," "increase," "enhance," or "activate" means an increase
of at least 10%
as compared to a reference level, for example an increase of at least about
20%, or at least
about 30%, or at least about 40%, or at least about 50%, or at least about
60%, or at least about
70%, or at least about 80%, or at least about 90% or up to and including a
100% increase or
any increase between 10-100% as compared to a reference level, or at least
about a 2-fold, or
at least about a 3-fold, or at least about a 4-fold, or at least about a 5-
fold or at least about a 10-
fold increase, or any increase between 2-fold and 10-fold or greater as
compared to a reference
level.
II. Polypeptides
A. Signal peptide
[0100] Polypeptides of the present disclosure may comprise a signal
peptide. A "signal
peptide" refers to a peptide sequence that directs the transport and
localization of the protein
within a cell, e.g., to a certain cell organelle (such as the endoplasmic
reticulum) and/or the cell
surface. In some aspects, a signal peptide directs the nascent protein into
the endoplasmic
reticulum. This is essential if a receptor is to be glycosylated and anchored
in the cell
membrane. Generally, the signal peptide natively attached to the amino-
terminal most
component is used (e.g. in an scFv with orientation light chain - linker -
heavy chain, the native
signal of the light-chain is used).
32

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
[0101] In some aspects, the signal peptide is cleaved after passage of the
endoplasmic
reticulum (ER), i.e., is a cleavable signal peptide. In some aspects, a
restriction site is at the
carboxy end of the signal peptide to facilitate cleavage.
B. Antigen binding domain
[0102] Polypeptides of the present disclosure may comprise one or more
antigen binding
domains. An "antigen binding domain" describes a region of a polypeptide
capable of binding
to an antigen under appropriate conditions. In some aspects, an antigen
binding domain is a
single-chain variable fragment (scFv) based on one or more antibodies (e.g.,
CD20 antibodies).
In some aspects, an antigen binding domain comprise a variable heavy (VH)
region and a
variable light (VL) region, with the VH and VL regions being on the same
polypeptide. In
some aspects, the antigen binding domain comprises a linker between the VH and
VL regions.
A linker may enable the antigen binding domain to form a desired structure for
antigen binding.
[0103] The variable regions of the antigen-binding domains of the
polypeptides of the
disclosure can be modified by mutating amino acid residues within the VH
and/or VL CDR 1,
CDR 2 and/or CDR 3 regions to improve one or more binding properties (e.g.,
affinity) of the
antibody. The term "CDR" refers to a complementarity-determining region that
is based on a
part of the variable chains in immunoglobulins (antibodies) and T cell
receptors, generated by
B cells and T cells respectively, where these molecules bind to their specific
antigen. Since
most sequence variation associated with immunoglobulins and T cell receptors
is found in the
CDRs, these regions are sometimes referred to as hypervariable regions.
Mutations may be
introduced by site-directed mutagenesis or PCR-mediated mutagenesis and the
effect on
antibody binding, or other functional property of interest, can be evaluated
in appropriate in
vitro or in vivo assays. Preferably conservative modifications are introduced
and typically no
more than one, two, three, four or five residues within a CDR region are
altered. The mutations
may be amino acid substitutions, additions or deletions.
[0104] Framework modifications can be made to the antibodies to decrease
immunogenicity, for example, by "backmutating" one or more framework residues
to the
corresponding germline sequence.
[0105] It is also contemplated that the antigen binding domain may be multi-
specific or
multivalent by multimerizing the antigen binding domain with VH and VL region
pairs that
bind either the same antigen (multi-valent) or a different antigen (multi-
specific).
[0106] The binding affinity of the antigen binding region, such as the
variable regions
(heavy chain and/or light chain variable region), or of the CDRs may be at
least 10-5M, 10-
33

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
6M, 10-7M, 10-8M, 10-9M, 10-10M, 10-11M, 10-12M, or 10-13M. In some aspects,
the KD
of the antigen binding region, such as the variable regions (heavy chain
and/or light chain
variable region), or of the CDRs may be at least 10-5M, 10-6M, 10-7M, 10-8M,
10-9M, 10-
10M, 10-11M, 10-12M, or 10-13M (or any derivable range therein).
[0107] Binding affinity, KA, or KD can be determined by methods known in
the art such
as by surface plasmon resonance (SRP)-based biosensors, by kinetic exclusion
assay
(KinExA), by optical scanner for microarray detection based on polarization-
modulated
oblique-incidence reflectivity difference (0I-RD), or by ELISA.
[0108] In some aspects, the polypeptide comprising the humanized binding
region has
equal, better, or at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92,
93, 94, 95, 96, 97, 98,
99, 100, 101, 102, 103, 104, 104, 106, 106, 108, 109, 110, 115, or 120%
binding affinity and/or
expression level in host cells, compared to a polypeptide comprising a non-
humanized binding
region, such as a binding region from a mouse.
[0109] In some aspects, the framework regions, such as FR1, FR2, FR3,
and/or FR4 of a
human framework can each or collectively have at least, at most, or exactly 1,
2, 3, 4, 5, 6, 7,
8,9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27,
28, 29, 30, 31, 32, 33,
34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52,
53, 54, 55, 56, 57, 58,
59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77,
78, 79, 80, 81, 82, 83,
84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102,
103, 104, 105, 106,
107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121,
122, 123, 124, 125,
126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140,
141, 142, 143, 144,
145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159,
160, 161, 162, 163,
164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178,
179, 180, 181, 182,
183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197,
198, 199, or 200 (or
any derivable range therein) amino acid substitutions, contiguous amino acid
additions, or
contiguous amino acid deletions with respect to a mouse framework.
[0110] In some aspects, the framework regions, such as FR1, FR2, FR3,
and/or FR4 of a
mouse framework can each or collectively have at least, at most, or exactly 1,
2, 3, 4, 5, 6, 7,
8,9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27,
28, 29, 30, 31, 32, 33,
34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52,
53, 54, 55, 56, 57, 58,
59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77,
78, 79, 80, 81, 82, 83,
84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102,
103, 104, 105, 106,
107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121,
122, 123, 124, 125,
126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140,
141, 142, 143, 144,
34

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159,
160, 161, 162, 163,
164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178,
179, 180, 181, 182,
183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197,
198, 199, or 200 (or
any derivable range therein) amino acid substitutions, contiguous amino acid
additions, or
contiguous amino acid deletions with respect to a human framework.
[0111] The substitution may be at position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,
11, 12, 13, 14, 15, 16,
17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35,
36, 37, 38, 39, 40, 41,
42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60,
61, 62, 63, 64, 65, 66,
67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85,
86, 87, 88, 89, 90, 91,
92, 93, 94, 95, 96, 97, 98, 99, or 100 of FR1, FR2, FR3, or FR4 of a heavy or
light chain
variable region.
C. Peptide spacer
[0112] A peptide spacer, such as an extracellular spacer may link an
antigen-binding
domain to a transmembrane domain. In some aspects, a peptide spacer is
flexible enough to
allow the antigen-binding domain to orient in different directions to
facilitate antigen binding.
In one aspect, the spacer comprises the hinge region from IgG. In some
aspects, the spacer
comprises or further comprises the CH2CH3 region of immunoglobulin and
portions of CD3.
In some aspects, the CH2CH3 region may have L235E/N297Q or L235D/N297Q
modifications, or at least 75%, at least 80%, at least 85%, at least 90%, at
least 95%, at least
98%, or 100% amino acid sequence identity of the CH2CH3 region. In some
aspects, the spacer
is from IgG4. An extracellular spacer may comprise a hinge region.
[0113] As used herein, the term "hinge" refers to a flexible polypeptide
connector region
(also referred to herein as "hinge region") providing structural flexibility
and spacing to
flanking polypeptide regions and can consist of natural or synthetic
polypeptides. A "hinge"
derived from an immunoglobulin (e.g., IgG1) is generally defined as stretching
from Glu216 to
Pro230 of human IgG1 (Burton (1985) Molec. Immunol., 22: 161- 206). Hinge
regions of other
IgG isotypes may be aligned with the IgG1 sequence by placing the first and
last cysteine
residues forming inter-heavy chain disulfide (S-S) bonds in the same
positions. The hinge
region may be of natural occurrence or non-natural occurrence, including but
not limited to an
altered hinge region as described in U.S. Pat. No. 5,677,425, incorporated by
reference herein.
The hinge region can include a complete hinge region derived from an antibody
of a different
class or subclass from that of the CH1 domain. The term "hinge" can also
include regions

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
derived from CD8 and other receptors that provide a similar function in
providing flexibility
and spacing to flanking regions.
[0114] The extracellular spacer can have a length of at least, at most, or
exactly 4, 5, 6, 7,
8,9, 10, 12, 15, 16, 17, 18, 19, 20, 20, 25, 30, 35, 40,45, 50, 75, 100, 110,
119, 120, 130, 140,
150, 160, 170, 180, 190, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209,
210, 211, 212, 213,
214, 215, 216, 217, 218, 219, 220, 225, 226, 227, 228, 229, 230, 231, 232,
233, 234, 235, 236,
237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 260,
270, 280, 290, 300,
325, 350, or 400 amino acids (or any derivable range therein). In some
aspects, the extracellular
spacer consists of or comprises a hinge region from an immunoglobulin (e.g.
IgG).
Immunoglobulin hinge region amino acid sequences are known in the art; see,
e.g., Tan et al.
(1990) Proc. Natl. Acad. Sci. USA 87: 162; and Huck et al. (1986) Nucl. Acids
Res.
[0115] The length of an extracellular spacer may have effects on the CAR' s
signaling
activity and/or the CAR-T cells' expansion properties in response to antigen-
stimulated CAR
signaling. In some aspects, a shorter spacer such as less than 50, 45, 40, 30,
35, 30, 25, 20, 15,
14, 13, 12, 11, or 10 amino acids is used. In some aspects, a longer spacer,
such as one that is
at least 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 200, 201, 202, 203,
204, 205, 206,
207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 225,
226, 227, 228, 229,
230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244,
245, 246, 247, 248,
249, 250, 260, 270, 280, or 290 amino acids may have the advantage of
increased expansion in
vivo or in vitro.
[0116] As non-limiting examples, an immunoglobulin hinge region can include
one of the
following amino acid sequences:
Table: Exemplary Hinge Regions
SEQUENCE SEQ ID NO:
DKTHT 70
CPPC 71
CPEPKSCDTPPPCPR 72
ELKTPLGDTTHT 73
KSCDKTHTCP 74
KCCVDCP 75
KYGPPCP 76
EPKSCDKTHTCPPCP 77
ELKTPLGDTTHTCPRCP 78
SPNMVPHAHHAQ 79
36

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
SEQUENCE SEQ ID NO:
ESKYGPPCPPCP 80
EPKSCDKTYTCPPCP 81
[0117] The
extracellular spacer can comprise an amino acid sequence of a human IgGl,
IgG2, IgG3, or IgG4, hinge region. The extracellular spacer may also include
one or more
amino acid substitutions and/or insertions and/or deletions compared to a wild-
type (naturally-
occurring) hinge region. For example, His229 of human IgG1 hinge can be
substituted with
Tyr, so that the hinge region comprises the sequence EPKSCDKTYTCPPCP (SEQ ID
NO:81).
[0118] The
extracellular spacer can comprise an amino acid sequence derived from human
CD8; e.g., the hinge region can comprise the amino acid sequence:
TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD (SEQ 11) NO:82), or a
variant thereof.
[0119] The
extracellular spacer may comprise or further comprise a CH2 region. An
exemplary CH2 region is
APEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS QEDPEVQFNWYVDGVEVHNA
KTKPREEQFQSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPS SIEKTISKAK (SEQ
ID NO:83). The extracellular spacer may comprise or further comprise a CH3
region. An
exemplary CH3 region is
GQPREPQVYTLPPS QEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV
LDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID
NO:84).
[0120]
When the extracellular spacer comprises multiple parts, there may be anywhere
from
0-50 amino acids in between the various parts. For example, there may be at
least, at most, or
exactly 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,
20, 21, 22, 23, 24, 25,
26, 27, 28, 29, 30, 35, 40, 45, or 50 amino acids (or any derivable range
therein) between the
hinge and the CH2 or CH3 region or between the CH2 and CH3 region when both
are present.
In some aspects, the extracellular spacer consists essentially of a hinge,
CH2, and/or CH3
region, meaning that the hinge, CH2, and/or CH3 region is the only
identifiable region present
and all other domains or regions are excluded, but further amino acids not
part of an identifiable
region may be present.
37

CA 03193009 2023-02-24
WO 2022/046935
PCT/US2021/047600
D. Transmembrane domain
[0121] Polypeptides of the present disclosure may comprise a transmembrane
domain. In
some aspects, a transmembrane domain is a hydrophobic alpha helix that spans
the membrane.
Different transmembrane domains may result in different receptor stability.
[0122] In some aspects, the transmembrane domain is interposed between the
extracellular
spacer and the cytoplasmic region. In some aspects, the transmembrane domain
is interposed
between the extracellular spacer and one or more costimulatory regions. In
some aspects, a
linker is between the transmembrane domain and the one or more costimulatory
regions.
[0123] Any transmembrane domain that provides for insertion of a
polypeptide into the cell
membrane of a eukaryotic (e.g., mammalian) cell may be suitable for use. In
some aspects, the
transmembrane domain is derived from CD28, CD8, CD4, CD3-zeta, CD134, or CD7.
[0124] Exemplary transmembrane domains useful in any of the aspects of the
disclosure
include those in the table below:
Table: Exemplary transmembrane domain sequences
Description Sequence SEQ
ID
NO:
CD28-derived FWVLVVVGGVLACYSLLVTVAFIIFWV 85
CD8 beta derived LGLLVAGVLVLLVSLGVAIHLCC 86
CD4 derived ALIVLGGVAGLLLFIGLGIFFCVRC 87
CD3 zeta derived LCYLLDGILFIYGVILTALFLRV 88
CD28 derived WVLVVVGGVLACYSLLVTVAFIIFWV 89
CD134 (0X40) derived VAAILGLGLVLGLLGPLAILLALYLL 90
CD7 derived ALPAALAVISFLLGLGLGVACVLA 91
E. Cytoplasmic region
[0125] After antigen recognition, receptors of the present disclosure may
cluster and a
signal transmitted to the cell through the cytoplasmic region. In some
aspects, the
costimulatory domains described herein are part of the cytoplasmic region. In
some aspects,
the cytoplasmic region comprises an intracellular signaling domain. An
intracellular signaling
domain may comprise a primary signaling domain and one or more costimulatory
domains.
[0126] Cytoplasmic regions and/or costimulatiory regions suitable for use
in the
polypeptides of the disclosure include any desired signaling domain that
provides a distinct and
detectable signal (e.g., increased production of one or more cytokines by the
cell; change in
transcription of a target gene; change in activity of a protein; change in
cell behavior, e.g., cell
death; cellular proliferation; cellular differentiation; cell survival;
modulation of cellular
signaling responses; etc.) in response to activation by way of binding of the
antigen to the
38

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
antigen binding domain. In some aspects, the cytoplasmic region includes at
least one (e.g.,
one, two, three, four, five, six, etc.) ITAM motif as described herein. In
some aspects, the
cytoplasmic region includes DAP10/CD28 type signaling chains.
[0127] Cytoplasmic regions suitable for use in the polypeptides of the
disclosure include
immunoreceptor tyrosine-based activation motif (ITAM)-containing intracellular
signaling
polypeptides. An ITAM motif is YX1X2(L/I), where X1 and X2 are independently
any amino
acid. In some cases, the cytoplasmic region comprises 1, 2, 3, 4, or 5 ITAM
motifs. In some
cases, an ITAM motif is repeated twice in an endodomain, where the first and
second instances
of the ITAM motif are separated from one another by 6 to 8 amino acids, e.g.,
(YX1X2(L/I))(X3)n(YX1X2(L/I)), where n is an integer from 6 to 8, and each of
the 6-8 X3
can be any amino acid.
[0128] A suitable cytoplasmic region may be an [TAM motif-containing
portion that is
derived from a polypeptide that contains an ITAM motif. For example, a
suitable cytoplasmic
region can be an ITAM motif-containing domain from any ITAM motif-containing
protein.
Thus, a suitable endodomain need not contain the entire sequence of the entire
protein from
which it is derived. Examples of suitable ITAM motif-containing polypeptides
include, but are
not limited to: DAP12, DAP10, FCER1G (Fc epsilon receptor I gamma chain); CD3D
(CD3
delta); CD3E (CD3 epsilon); CD3G (CD3 gamma); CD3-zeta; and CD79A (antigen
receptor
complex-associated protein alpha chain).
[0129] Exemplary cytoplasmic regions are known in the art. The cytoplasmic
regions
shown below also provide examples of regions that may be incorporated in a CAR
of the
disclosure:
[0130] In some aspects, a suitable cytoplasmic region can comprise an ITAM
motif-
containing portion of the full length DAP12 amino acid sequence. In some
aspects, the
cytoplasmic region is derived from FCER1G (also known as FCRG; Fc epsilon
receptor I
gamma chain; Fc receptor gamma-chain; fc-epsilon R1-gamma; fcRgamma; fceRI
gamma;
high affinity immunoglobulin epsilon receptor subunit gamma; immunoglobulin E
receptor,
high affinity, gamma chain; etc.). In some aspects, a suitable cytoplasmic
region can comprise
an ITAM motif-containing portion of the full length FCER1G amino acid
sequence.
[0131] In some aspects, the cytoplasmic region is derived from T cell
surface glycoprotein
CD3 delta chain (also known as CD3D; CD3-DELTA; T3D; CD3 antigen, delta
subunit; CD3
delta; CD38; CD3d antigen, delta polypeptide (TiT3 complex); OKT3, delta
chain; T cell
receptor T3 delta chain; T cell surface glycoprotein CD3 delta chain; etc.).
In some aspects, a
39

CA 03193009 2023-02-24
WO 2022/046935
PCT/US2021/047600
suitable cytoplasmic region can comprise an ITAM motif-containing portion of
the full length
CD3 delta amino acid sequence. In some aspects, the cytoplasmic region is
derived from T
cell surface glycoprotein CD3 epsilon chain (also known as CD3e, CD3e; T cell
surface antigen
T3/Leu-4 epsilon chain, T cell surface glycoprotein CD3 epsilon chain,
AI504783, CD3, CD3-
epsilon, T3e, etc.). In some aspects, a suitable cytoplasmic region can
comprise an ITAM
motif-containing portion of the full length CD3 epsilon amino acid sequence.
In some aspects,
the cytoplasmic region is derived from T cell surface glycoprotein CD3 gamma
chain (also
known as CD3G, CD37, T cell receptor T3 gamma chain, CD3-GAMMA, T3G, gamma
polypeptide (TiT3 complex), etc.). In some aspects, a suitable cytoplasmic
region can comprise
an ITAM motif-containing portion of the full length CD3 gamma amino acid
sequence. In
some aspects, the cytoplasmic region is derived from T cell surface
glycoprotein CD3 zeta
chain (also known as CD3Z, CD3, T cell receptor T3 zeta chain, CD247, CD3-
ZETA, CD3H,
CD3Q, T3Z, TCRZ, etc.). In some aspects, a suitable cytoplasmic region can
comprise an
ITAM motif-containing portion of the full length CD3 zeta amino acid sequence.
[0132] In some aspects, the cytoplasmic region is derived from CD79A (also
known as B-
cell antigen receptor complex-associated protein alpha chain; CD79a antigen
(immunoglobulin-associated alpha); MB-1 membrane glycoprotein; ig-alpha;
membrane-
bound immunoglobulin-associated protein; surface IgM-associated protein;
etc.). In some
aspects, a suitable cytoplasmic region can comprise an ITAM motif-containing
portion of the
full length CD79A amino acid sequence.
[0133] Specific exemplary cytoplasmic regions are known in the art and
further shown in
the table below.
Table: Cytoplasmic Regions
SEQUENCE SEQ
ID NO:
MGGLEPCSRLLLLPLLLAVSGLRPVQAQAQSDCSCSTVSPGVLAGIVMGD 92
LVLTVLIALAVYFLGRLVPRGRGAAEAATRKQRITETESPYQELQGQRSD
VYSDLNTQRPYYK
MGGLEPCSRLLLLPLLLAVSGLRPVQAQAQSDCSCSTVSPGVLAGIVMGD 93
LVLTVLIALAVYFLGRLVPRGRGAAEATRKQRITETESPYQELQGQRSDV
YSDLNTQRPYYK
MGGLEPCSRLLLLPLLLAVSDCSCSTVSPGVLAGIVMGDLVLTVLIALAV 94
YFLGRLVPRGRGAAEAATRKQRITETESPYQELQGQRSDVYSDLNTQRPY
YK

CA 03193009 2023-02-24
WO 2022/046935
PCT/US2021/047600
SEQUENCE SEQ ID
NO:
MGGLEPCSRLLLLPLLLAVSDCSCSTVSPGVLAGIVMGDLVLTVLIALAV 95
YFLGRLVPRGRGAAEATRKQRITETESPYQELQGQRSDVYSDLNTQRPYY
K
MIPAVVLLLLLLVEQAAALGEPQLCYILDAILFLYGIVLTLLYCRLKIQVR 96
KAAITSYEKSDGVYTGLSTRNQETYETLKHEKPPQ
DGVYTGLSTRNQETYETLKHE 97
MEHSTFLSGLVLATLLSQVSPFKIPIEELEDRVFVNCNTSITWVEGTVGTLL 98
SDITRLDLGKRILDPRGIYRCNGTDIYKDKESTVQVHYRMCQSCVELDPA
TVAGIIVTDVIATLLLALGVFCfa*gHETGRLSGAADTQALLRNDQVYQPL
RDRDDAQYSHLGGNWARNK
MEHSTFLSGLVLATLLSQVSPFKIPIEELEDRVFVNCNTSITWVEGTVGTLL 99
SDITRLDLGKRILDPRGIYRCNGTDIYKDKESTVQVHYRTADTQALLRND
QVYQPLRDRDDAQYSHLGGNWARNK
DQVYQPLRDRDDAQYSHLGGN 100
MQSGTHWRVLGLCLLSVGVWGQDGNEEMGGITQTPYKVSISGTTVILTC 101
PQYPGSEILWQHNDKNIGGDEDDKNIGSDEDHLSLKEFSELEQSGYYVCY
PRGSKPEDANFYLYLRARVCENCMEMDVMSVATIVIVDICITGGLLLLVY
YWSKNRKAKAKPVTRGAGAGGRQRGQNKERPPPVPNPDYEPIRKGQRD
LYSGLNQRRI
NPDYEPIRKGQRDLYSGLNQR 102
MEQGKGLAVLILAIILLQGTLAQSIKGNHLVKVYDYQEDGSVLLTCDAEA 103
KNITWFKDGKMIGFLTEDKKKWNLGSNAKDPRGMYQCKGSQNKSKPLQ
VYYRMCQNCIELNAATISGFLFAEIVSIFVLAVGVYFIAGQDGVRQSRASD
KQTLLPNDQLYQPLKDREDDQYSHLQGNQLRRN
DQLYQPLKDREDDQYSHLQGN 104
MKWKALFTAAILQAQLPITEAQSFGLLDPKLCYLLDGILFIYGVILTALFLR 105
VKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKP
RRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTAT
KDTYDALHMQALPPR
MKWKALFTAAILQAQLPITEAQSFGLLDPKLCYLLDGILFIYGVILTALFLR 106
VKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKP
QRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTA
TKDTYDALHMQALPPR
RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGK 8
PRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTA
TKDTYDALHMQALPPR
41

CA 03193009 2023-02-24
WO 2022/046935
PCT/US2021/047600
SEQUENCE SEQ
ID NO:
NQLYNELNLGRREEYDVLDKR 107
EGLYNELQKDKMAEAYSEIGMK 108
DGLYQGLSTATKDTYDALHMQ 109
MPGGPGVLQALPATIFLLFLLSAVYLGPGCQALWMHKVPASLMVSLGED 110
AHFQCPHNSSNNANVTWWRVLHGNYTWPPEFLGPGEDPNGTLIIQNVNK
SHGGIYVCRVQEGNESYQQSCGTYLRVRQPPPRPFLDMGEGTKNRIITAE
GIILLFCAVVPGTLLLFRKRWQNEKLGLDAGDEYEDENLYEGLNLDDCS
MYEDISRGLQGTYQDVGSLNIGDVQLEKP
MPGGPGVLQALPATIFLLFLLSAVYLGPGCQALWMHKVPASLMVSLGED 111
AHFQCPHNSSNNANVTWWRVLHGNYTWPPEFLGPGEDPNEPPPRPFLDM
GEGTKNRIITAEGIILLFCAVVPGTLLLFRKRWQNEKLGLDAGDEYEDENL
YEGLNLDDCSMYEDISRGLQGTYQDVGSLNIGDVQLEKP
ENLYEGLNLDDCSMYEDISRG 112
FWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGP 113
TRKHYQPYAPPRDFAAYRS
F. Costimulatory region
[0134] Non-limiting examples of suitable costimulatory regions, such as
those included in
the cytoplasmic region, include, but are not limited to, polypeptides from 4-
1BB (CD137),
CD28, ICOS, OX-40, BTLA, CD27, CD30, GITR, and HVEM.
[0135] A costimulatory region may have a length of at least, at most, or
exactly 20, 25, 30,
35, 40, 50, 60, 70, 80, 90, 100, 150, 200, or 300 amino acids or any range
derivable therein. In
some aspects, the costimulatory region is derived from an intracellular
portion of the
transmembrane protein 4-1BB (also known as TNFRSF9; CD137; CDw137; ILA; etc.).
In
some aspects, the costimulatory region is derived from an intracellular
portion of the
transmembrane protein CD28 (also known as Tp44). In some aspects, the
costimulatory region
is derived from an intracellular portion of the transmembrane protein ICOS
(also known as
AILIM, CD278, and CVID1). In some aspects, the costimulatory region is derived
from an
intracellular portion of the transmembrane protein OX-40 (also known as
TNFRSF4, RP5-
902P8.3, ACT35, CD134, 0X40, TXGP1L). In some aspects, the costimulatory
region is
derived from an intracellular portion of the transmembrane protein BTLA (also
known as
BTLA1 and CD272). In some aspects, the costimulatory region is derived from an
intracellular
portion of the transmembrane protein CD27 (also known as S 152, T14, TNFRSF7,
and Tp55).
42

CA 03193009 2023-02-24
WO 2022/046935
PCT/US2021/047600
In some aspects, the costimulatory region is derived from an intracellular
portion of the
transmembrane protein CD30 (also known as TNFRSF8, D1S 166E, and Ki-1). In
some
aspects, the costimulatory region is derived from an intracellular portion of
the transmembrane
protein GITR (also known as TNFRSF18, RP5-902P8.2, AITR, CD357, and GITR-D).
In
some aspects, the costimulatory region derived from an intracellular portion
of the
transmembrane protein HVEM (also known as TNFRSF14, RP3-395M20.6, ATAR, CD270,
HVEA, HVEM, LIGHTR, and TR2).
[0136] Specific exemplary co-stimulatory domains are represented by the
amino acid
sequences below:
Table: Co-stimulatory domains
SEQUENCE SEQ
ID NO:
KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL 7
FWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS 114
TKKKYSSSVHDPNGEYMFMRAVNTAKKSRLTDVTL 115
RRDQRLPPDAHKPPGGGSFRTPIQEEQADAHSTLAKI 116
CCLRRHQGKQNELSDTAGREINLVDAHLKSEQTEASTRQNS QVLLSETGI 117
YDNDPDLCFRMQEGSEVYSNPCLEENKPGIVYASLNHSVIGPNSRLARN
VKEAPTEYASICVRS
HQRRKYRSNKGESPVEPAEPCRYSCPREEEGS TIPIQEDYRKPEPACSP 118
RRACRKRIRQKLHLCYPVQTS QPKLELVDSRPRRS STQLRSGASVTEPVA 119
EERGLMSQPLMETCHSVGAAYLESLPLQDASPAGGPSSPRDLPEPRVSTE
HTNNKIEKIYIMKADTVIVGTVKAELPEGRGLAGPAEPELEEELEADHTP
HYPEQETEPPLGSCSDVMLSVEEEGKEDPLPTAASGK
HIWQLRS QCMWPRETQLLLEVPPSTEDARSCQFPEEERGERS AEEKGRL 120
GDLWV
CVKRRKPRGDVVKVIVS VQRKRQEAEGEATVIEALQAPPDVTTVAVEET 121
IPSFTGRSPNH
RSKRSRGGHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS 18
G. Detection peptides
[0137] In some aspects, the polypeptides described herein may further
comprise a detection
peptide. Suitable detection peptides include hemagglutinin (HA; e.g.,
YPYDVPDYA (SEQ
ID NO:122); FLAG (e.g., DYKDDDDK (SEQ ID NO:3); c-myc (e.g., EQKLISEEDL; SEQ
ID NO:123), and the like. Other suitable detection peptides are known in the
art.
H. Peptide linkers
[0138] In some aspects, the polypeptides of the disclosure include peptide
linkers
(sometimes referred to as a linker). A peptide linker may be used to separate
any of the peptide
43

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
domain/regions described herein. As an example, a linker may be between the
signal peptide
and the antigen binding domain, between the VH and VL of the antigen binding
domain,
between the antigen binding domain and the peptide spacer, between the peptide
spacer and
the transmembrane domain, flanking the costimulatory region or on the N- or C-
region of the
costimulatory region, and/or between the transmembrane domain and the
endodomain. The
peptide linker may have any of a variety of amino acid sequences. Domains and
regions can
be joined by a peptide linker that is generally of a flexible nature, although
other chemical
linkages are not excluded. A linker can be a peptide of between about 6 and
about 40 amino
acids in length, or between about 6 and about 25 amino acids in length. These
linkers can be
produced by using synthetic, linker-encoding oligonucleotides to couple the
proteins.
[0139] Peptide linkers with a degree of flexibility can be used. The
peptide linkers may have
virtually any amino acid sequence, bearing in mind that suitable peptide
linkers will have a
sequence that results in a generally flexible peptide. The use of small amino
acids, such as
glycine and alanine, are of use in creating a flexible peptide. The creation
of such sequences
is routine to those of skill in the art.
[0140] Suitable linkers can be readily selected and can be of any suitable
length, such as
from 1 amino acid (e.g., Gly) to 20 amino acids, from 2 amino acids to 15
amino acids, from 3
amino acids to 12 amino acids, including 4 amino acids to 10 amino acids, 5
amino acids to 9
amino acids, 6 amino acids to 8 amino acids, or 7 amino acids to 8 amino
acids, and may be 1,
2, 3, 4, 5, 6, or 7 amino acids.
[0141] Suitable linkers can be readily selected and can be of any of a
suitable of different
lengths, such as from 1 amino acid (e.g., Gly) to 20 amino acids, from 2 amino
acids to 15
amino acids, from 3 amino acids to 12 amino acids, including 4 amino acids to
10 amino acids,
amino acids to 9 amino acids, 6 amino acids to 8 amino acids, or 7 amino acids
to 8 amino
acids, and may be 1, 2, 3, 4, 5, 6, or 7 amino acids.
[0142] Example flexible linkers include glycine polymers (G)n, glycine-
serine polymers
(including, for example, (GS)n, (GSGGS)n, (G45)n and (GGGS)n, where n is an
integer of at
least one. In some aspects, n is at least, at most, or exactly 1, 2, 3, 4, 5,
6, 7, 8, 9, or 10 (or any
derivable range therein). Glycine-alanine polymers, alanine-serine polymers,
and other
flexible linkers known in the art. Glycine and glycine-serine polymers can be
used; both Gly
and Ser are relatively unstructured, and therefore can serve as a neutral
tether between
components. Glycine polymers can be used; glycine accesses significantly more
phi-psi space
than even alanine, and is much less restricted than residues with longer side
chains. Exemplary
spacers can comprise amino acid sequences including, but not limited to, GGSG
(SEQ ID
44

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
NO:125), GGSGG (SEQ ID NO:126), GSGSG (SEQ ID NO:127), GSGGG (SEQ ID NO:128),
GGGSG (SEQ ID NO:129), GSSSG (SEQ ID NO:124), SEQ ID NO:10, SEQ ID NO:28, and
the like. In some aspects, the linker comprises a repeat, such as a contiguous
repeat of one or
more of SEQ ID NOS:124-129, 10, and 28, such as a linker comprising an amino
acid sequence
that corresponds to one of SEQ ID NOS: 124-129, 10, and 28 repeated at least,
at most, or
exactly 2, 3, 4, 5, 6, 7, 8, 9, or 10 times, or any range derivable therein.
[0143] In further aspects, the linker comprises (EAAAK)n (SEQ ID NO:130),
wherein n is
an integer of at least one. In some aspects, n is at least, at most, or
exactly 1, 2, 3, 4, 5, 6, 7, 8,
9, or 10 (or any derivable range therein).
I. Therapeutic Controls
[0144] In some aspects of the methods and compositions described herein,
the CAR
molecule is co-expressed with a therapeutic control.
[0145] Therapeutic controls regulate cell proliferation, facilitate cell
selection (for example
selecting cells which express the chimeric antigen receptors of the invention)
or a combination
thereof. In one aspect, regulating cell proliferation comprises up-regulating
cell proliferation
to promote cell propagation. In another aspect, regulating cell proliferation
comprises down-
regulating cell proliferation so as to reduce or inhibit cell propagation. In
some aspects, the
agents that serve as therapeutic controls may promote enrichment of cells
which express the
chimeric antigen receptors which may result in a therapeutic advantage. In
some aspects, agents
which serve as therapeutic controls may biochemically interact with additional
compositions
so as to regulate the functioning of the therapeutic controls. For example,
EGFRt (a therapeutic
control) may biochemically interact with cetuximab so as to regulate the
function of EGFRt in
selection, tracking, cell ablation or a combination thereof.
[0146] Exemplary therapeutic controls include truncated epidermal growth
factor receptor
(EGFRt), chimeric cytokine receptors (CCR) and/or dihydroxyfolate receptor
(DHFR) (e.g.,
mutant DHFR). The polynucleotides encoding the CAR and the therapeutic
control(s) may be
linked via IRES sequences or via polynucleotide sequences encoding cleavable
linkers. The
CARs of the invention are constructed so that they may be expressed in cells,
which in turn
proliferate in response to the presence of at least one molecule that
interacts with at least one
antigen-specific targeting region, for instance, an antigen. In further
aspects, the therapeutic
control comprises a cell-surface protein wherein the protein lacks
intracellular signaling
domains. It is contemplated that any cell surface protein lacking
intracellular signaling or
modified (e.g. by truncation) to lack intracellular signaling may be used.
Further examples of

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
a therapeutic control include truncated LNGFR, truncated CD19, etc., wherein
the truncated
proteins lack intracellular signaling domains.
[0147] "Co-express" as used herein refers to simultaneous expression of two
or more genes.
Genes may be nucleic acids encoding, for example, a single protein or a
chimeric protein as a
single polypeptide chain. For example, the CARs of the disclosure may be co-
expressed with
a therapeutic control (for example truncated epidermal growth factor (EGFRt)),
wherein the
CAR is encoded by a first polynucleotide chain and the therapeutic control is
encoded by a
second polynucleotide chain. In one aspect, the first and second
polynucleotide chains are
linked by a nucleic acid sequence that encodes a cleavable linker The
polynucleotides encoding
the CAR and the therapeutic control system may be linked by IRES sequences.
Alternately, the
CAR and the therapeutic control are encoded by two different polynucleotides
that are not
linked via a linker but are instead encoded by, for example, two different
vectors. Further, the
CARs of the disclosure may be co-expressed with a therapeutic control and CCR,
a therapeutic
control and DHFR (for example mutant DHFR) or a therapeutic control and CCR
and DHFR
(for example mutant DHFR). The CAR, therapeutic control and CCR may be co-
expressed and
encoded by first, second and third polynucleotide sequences, respectively,
wherein the first,
second and third polynucleotide sequences are linked via IRES sequences or
sequences
encoding cleavable linkers (e.g., T2A). Alternately, these sequences are not
linked via linkers
but instead are encoded via, for example, separate vectors. The CAR,
therapeutic control and
DHFR (for example mutant DHFR) may be co-expressed and encoded by first,
second and
fourth polynucleotide sequences, respectively, wherein the first, second and
fourth
polynucleotide sequences are linked via IRES sequences or via sequences
encoding cleavable
linkers. Alternately, these sequences are not linked via linkers but instead
encoded via, for
example, separate vectors. The CAR, therapeutic control, CCR and DHFR (for
example mutant
DHFR) may be co-expressed and encoded by first, second, third and fourth
polynucleotide
sequences, respectively, wherein the first, second, third and fourth
polynucleotide sequences
are linked via IRES sequences or sequences encoding cleavable linkers.
Alternately, these
sequences are not linked via linkers but instead are encoded via, for example,
separate vectors.
If the aforementioned sequences are encoded by separate vectors, these vectors
may be
simultaneously or sequentially transfected.
[0148] Further aspects of the therapeutic controls, CAR molecules, and
methods of use for
the compositions of the disclosure can be found in U.S. Patent No.: 9447194,
which is herein
incorporated by reference for all purposes.
46

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
J. Additional modifications and polypeptide enhancements
[0149] Additionally, the polypeptides of the disclosure may be chemically
modified.
Glycosylation of the polypeptides can be altered, for example, by modifying
one or more sites
of glycosylation within the polypeptide sequence to increase the affinity of
the polypeptide for
antigen (U.S. Pat. Nos. 5,714,350 and 6,350,861).
[0150] It is contemplated that a region or fragment of a polypeptide of the
disclosure may
have an amino acid sequence that has, has at least or has at most 1, 2, 3, 4,
5, 6, 7, 8, 9, 10, 11,
12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30,
31, 32, 33, 34, 35, 36,
37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55,
56, 57, 58, 59, 60, 61,
62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80,
81, 82, 83, 84, 85, 86,
87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104,
105, 106, 107, 108,
109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123,
124, 125, 126, 127,
128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142,
143, 144, 145, 146,
147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161,
162, 163, 164, 165,
166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180,
181, 182, 183, 184,
185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200
or more amino
acid substitutions, contiguous amino acid additions, or contiguous amino acid
deletions with
respect to any of SEQ ID NOS:1-172. Alternatively, a region or fragment of a
polypeptide of
the disclosure may have an amino acid sequence that comprises or consists of
an amino acid
sequence that is, is at least, or is at most 50, 51, 52, 53, 54, 55, 56, 57,
58, 59, 60, 61, 62, 63,
64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82,
83, 84, 85, 86, 87, 88,
89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% (or any range derivable
therein) identical to any
of SEQ ID NOS:1-172. Moreover, in some aspects, a region or fragment comprises
an amino
acid region of 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20,
21, 22, 23, 24, 25, 26,
27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45,
46, 47, 48, 49, 50, 51,
52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70,
71, 72, 73, 74, 75, 76,
77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95,
96, 97, 98, 99, 100, 101,
102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116,
117, 118, 119, 120,
121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135,
136, 137, 138, 139,
140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154,
155, 156, 157, 158,
159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173,
174, 175, 176, 177,
178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192,
193, 194, 195, 196,
197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211,
212, 213, 214, 215,
216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230,
231, 232, 233, 234,
47

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249,
250, 251, 252, 253,
254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268,
269, 270, 271, 272,
273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287,
288, 289, 290, 291,
292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306,
307, 308, 309, 310,
311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325,
326, 327, 328, 329,
330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344,
345, 346, 347, 348,
349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363,
364, 365, 366, 367,
368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382,
383, 384, 385, 386,
387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401,
402, 403, 404, 405,
406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420,
421, 422, 423, 424,
425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439,
440, 441, 442, 443,
444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458,
459, 460, 461, 462,
463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477,
478, 479, 480, 481,
482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496,
497, 498, 499, 500
or more contiguous amino acids starting at position 1, 2, 3, 4, 5, 6, 7, 8, 9,
10, 11, 12, 13, 14,
15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33,
34, 35, 36, 37, 38, 39,
40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58,
59, 60, 61, 62, 63, 64,
65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83,
84, 85, 86, 87, 88, 89,
90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106,
107, 108, 109, 110,
111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125,
126, 127, 128, 129,
130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144,
145, 146, 147, 148,
149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163,
164, 165, 166, 167,
168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182,
183, 184, 185, 186,
187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201,
202, 203, 204, 205,
206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220,
221, 222, 223, 224,
225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239,
240, 241, 242, 243,
244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258,
259, 260, 261, 262,
263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277,
278, 279, 280, 281,
282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296,
297, 298, 299, 300,
301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315,
316, 317, 318, 319,
320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334,
335, 336, 337, 338,
339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353,
354, 355, 356, 357,
358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372,
373, 374, 375, 376,
377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391,
392, 393, 394, 395,
48

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410,
411, 412, 413, 414,
415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429,
430, 431, 432, 433,
434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448,
449, 450, 451, 452,
453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467,
468, 469, 470, 471,
472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486,
487, 488, 489, 490,
491, 492, 493, 494, 495, 496, 497, 498, 499, 500 in any of SEQ ID NOS:1-172
(where position
1 is at the N-terminus of the SEQ ID NO). The polypeptides of the disclosure
may include 1,
2, 3, 4, 5, 6, 7, 8,9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23,
24, 25, 26, 27, 28, 29,
30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48,
49, or 50 or more variant
amino acids or be at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%,
70%, 71%,
72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%,
87%,
88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% similar,
identical, or hom*ologous with at least, or at most 3, 4, 5, 6, 7, 8, 9, 10,
11, 12, 13, 14, 15, 16,
17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35,
36, 37, 38, 39, 40, 41,
42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60,
61, 62, 63, 64, 65, 66,
67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85,
86, 87, 88, 89, 90, 91,
92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108,
109, 110, 111, 112,
113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127,
128, 129, 130, 131,
132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146,
147, 148, 149, 150,
151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165,
166, 167, 168, 169,
170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184,
185, 186, 187, 188,
189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203,
204, 205, 206, 207,
208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222,
223, 224, 225, 226,
227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241,
242, 243, 244, 245,
246, 247, 248, 249, 250, 300, 400, 500, 550, 600, or more contiguous amino
acids, or any range
derivable therein, of any of SEQ ID NOS:1-172.
[0151] The polypeptides of the disclosure may include at least, at most, or
exactly 1, 2, 3,
4, 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,
25, 26, 27, 28, 29, 30,
31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49,
50, 51, 52, 53, 54, 55,
56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74,
75, 76, 77, 78, 79, 80,
81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99,
100, 101, 102, 103, 104,
105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119,
120, 121, 122, 123,
124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138,
139, 140, 141, 142,
143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157,
158, 159, 160, 161,
49

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176,
177, 178, 179, 180,
181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195,
196, 197, 198, 199,
200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214,
215, 216, 217, 218,
219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233,
234, 235, 236, 237,
238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252,
253, 254, 255, 256,
257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271,
272, 273, 274, 275,
276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290,
291, 292, 293, 294,
295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309,
310, 311, 312, 313,
314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328,
329, 330, 331, 332,
333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347,
348, 349, 350, 351,
352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366,
367, 368, 369, 370,
371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385,
386, 387, 388, 389,
390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404,
405, 406, 407, 408,
409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423,
424, 425, 426, 427,
428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442,
443, 444, 445, 446,
447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461,
462, 463, 464, 465,
466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480,
481, 482, 483, 484,
485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499,
500, 501, 502, 503,
504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518,
519, 520, 521, 522,
523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537,
538, 539, 540, 541,
542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556,
557, 558, 559, 560,
561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575,
576, 577, 578, 579,
580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594,
595, 596, 597, 598,
599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613,
614, or 615
substitutions (or any range derivable therein).
[0152] The substitution may be at amino acid position 1, 2, 3, 4, 5, 6, 7,
8, 9, 10, 11, 12, 13,
14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32,
33, 34, 35, 36, 37, 38,
39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57,
58, 59, 60, 61, 62, 63,
64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82,
83, 84, 85, 86, 87, 88,
89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106,
107, 108, 109, 110,
111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125,
126, 127, 128, 129,
130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144,
145, 146, 147, 148,
149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163,
164, 165, 166, 167,
168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182,
183, 184, 185, 186,

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201,
202, 203, 204, 205,
206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220,
221, 222, 223, 224,
225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239,
240, 241, 242, 243,
244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258,
259, 260, 261, 262,
263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277,
278, 279, 280, 281,
282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296,
297, 298, 299, 300,
301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315,
316, 317, 318, 319,
320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334,
335, 336, 337, 338,
339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353,
354, 355, 356, 357,
358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372,
373, 374, 375, 376,
377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391,
392, 393, 394, 395,
396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410,
411, 412, 413, 414,
415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429,
430, 431, 432, 433,
434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448,
449, 450, 451, 452,
453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467,
468, 469, 470, 471,
472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486,
487, 488, 489, 490,
491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505,
506, 507, 508, 509,
510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524,
525, 526, 527, 528,
529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543,
544, 545, 546, 547,
548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562,
563, 564, 565, 566,
567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581,
582, 583, 584, 585,
586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600,
601, 602, 603, 604,
605, 606, 607, 608, 609, 610, 611, 612, 613, 614, or 650 of any of SEQ ID
NOS:1-172 (or any
derivable range therein) and may be a substitution with any amino acid or may
be a substitution
with a alanine, arginine, asparagine, aspartic acid, cysteine, glutamine,
glutamic acid, glycine,
histidine, isoleucine, leusine, lysine, methionine, phenylalanine, proline,
serine, threonine,
tryptophan, tyrosine, or valine.
[0153] The polypeptides described herein may be of a fixed length of at
least, at most, or
exactly 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23,
24, 25, 26, 27, 28, 29,
30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48,
49, 50, 51, 52, 53, 54,
55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73,
74, 75, 76, 77, 78, 79,
80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98,
99, 100, 101, 102, 103,
104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118,
119, 120, 121, 122,
123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137,
138, 139, 140, 141,
51

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156,
157, 158, 159, 160,
161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175,
176, 177, 178, 179,
180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194,
195, 196, 197, 198,
199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213,
214, 215, 216, 217,
218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232,
233, 234, 235, 236,
237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 300,
400, 500, 550, 1000
or more amino acids (or any derivable range therein).
[0154] Substitutional variants typically contain the exchange of one amino
acid for another
at one or more sites within the protein, and may be designed to modulate one
or more properties
of the polypeptide, with or without the loss of other functions or properties.
Substitutions may
be conservative, that is, one amino acid is replaced with one of similar shape
and charge.
Conservative substitutions are well known in the art and include, for example,
the changes of:
alanine to serine; arginine to lysine; asparagine to glutamine or histidine;
aspartate to
glutamate; cysteine to serine; glutamine to asparagine; glutamate to
aspartate; glycine to
proline; histidine to asparagine or glutamine; isoleucine to leucine or
valine; leucine to valine
or isoleucine; lysine to arginine; methionine to leucine or isoleucine;
phenylalanine to tyrosine,
leucine or methionine; serine to threonine; threonine to serine; tryptophan to
tyrosine; tyrosine
to tryptophan or phenylalanine; and valine to isoleucine or leucine.
Alternatively, substitutions
may be non-conservative such that a function or activity of the polypeptide is
affected. Non-
conservative changes typically involve substituting a residue with one that is
chemically
dissimilar, such as a polar or charged amino acid for a nonpolar or uncharged
amino acid, and
vice versa.
[0155] Proteins may be recombinant, or synthesized in vitro. Alternatively,
a non-
recombinant or recombinant protein may be isolated from bacteria. It is also
contemplated that
bacteria containing such a variant may be implemented in compositions and
methods.
Consequently, a protein need not be isolated.
[0156] The term "functionally equivalent codon" is used herein to refer to
codons that
encode the same amino acid, such as the six codons for arginine or serine, and
also refers to
codons that encode biologically equivalent amino acids.
[0157] It also will be understood that amino acid and nucleic acid
sequences may include
additional residues, such as additional N- or C-terminal amino acids, or 5' or
3' sequences,
respectively, and yet still be essentially as set forth in one of the
sequences disclosed herein, so
long as the sequence meets the criteria set forth above, including the
maintenance of biological
protein activity where protein expression is concerned. The addition of
terminal sequences
52

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
particularly applies to nucleic acid sequences that may, for example, include
various non-
coding sequences flanking either of the 5' or 3' portions of the coding
region.
[0158] The following is a discussion based upon changing of the amino acids
of a protein
to create an equivalent, or even an improved, second-generation molecule. For
example,
certain amino acids may be substituted for other amino acids in a protein
structure without
appreciable loss of interactive binding capacity. Structures such as, for
example, an enzymatic
catalytic domain or interaction components may have amino acid substituted to
maintain such
function. Since it is the interactive capacity and nature of a protein that
defines that protein's
biological functional activity, certain amino acid substitutions can be made
in a protein
sequence, and in its underlying DNA coding sequence, and nevertheless produce
a protein with
like properties. It is thus contemplated by the inventors that various changes
may be made in
the DNA sequences of genes without appreciable loss of their biological
utility or activity.
[0159] In other aspects, alteration of the function of a polypeptide is
intended by introducing
one or more substitutions. For example, certain amino acids may be substituted
for other amino
acids in a protein structure with the intent to modify the interactive binding
capacity of
interaction components. Structures such as, for example, protein interaction
domains, nucleic
acid interaction domains, and catalytic sites may have amino acids substituted
to alter such
function. Since it is the interactive capacity and nature of a protein that
defines that protein's
biological functional activity, certain amino acid substitutions can be made
in a protein
sequence, and in its underlying DNA coding sequence, and nevertheless produce
a protein with
different properties. It is thus contemplated by the inventors that various
changes may be made
in the DNA sequences of genes with appreciable alteration of their biological
utility or activity.
[0160] In making such changes, the hydropathic index of amino acids may be
considered.
The importance of the hydropathic amino acid index in conferring interactive
biologic function
on a protein is generally understood in the art (Kyte and Doolittle, 1982). It
is accepted that
the relative hydropathic character of the amino acid contributes to the
secondary structure of
the resultant protein, which in turn defines the interaction of the protein
with other molecules,
for example, enzymes, substrates, receptors, DNA, antibodies, antigens, and
the like.
[0161] It also is understood in the art that the substitution of like amino
acids can be made
effectively on the basis of hydrophilicity. U.S. Patent 4,554,101,
incorporated herein by
reference, states that the greatest local average hydrophilicity of a protein,
as governed by the
hydrophilicity of its adjacent amino acids, correlates with a biological
property of the protein.
It is understood that an amino acid can be substituted for another having a
similar hydrophilicity
value and still produce a biologically equivalent and immunologically
equivalent protein.
53

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
[0162] As outlined above, amino acid substitutions generally are based on
the relative
similarity of the amino acid side-chain substituents, for example, their
hydrophobicity,
hydrophilicity, charge, size, and the like. Exemplary substitutions that take
into consideration
the various foregoing characteristics are well known and include: arginine and
lysine;
glutamate and aspartate; serine and threonine; glutamine and asparagine; and
valine, leucine
and isoleucine.
[0163] In specific aspects, all or part of proteins described herein can
also be synthesized in
solution or on a solid support in accordance with conventional techniques.
Various automatic
synthesizers are commercially available and can be used in accordance with
known protocols.
See, for example, Stewart and Young, (1984); Tam et al., (1983); Merrifield,
(1986); and
Barany and Merrifield (1979), each incorporated herein by reference.
Alternatively,
recombinant DNA technology may be employed wherein a nucleotide sequence that
encodes
a peptide or polypeptide is inserted into an expression vector, transformed or
transfected into
an appropriate host cell and cultivated under conditions suitable for
expression.
[0164] One aspect includes the use of gene transfer to cells, including
microorganisms, for
the production and/or presentation of proteins. The gene for the protein of
interest may be
transferred into appropriate host cells followed by culture of cells under the
appropriate
conditions. A nucleic acid encoding virtually any polypeptide may be employed.
The
generation of recombinant expression vectors, and the elements included
therein, are discussed
herein. Alternatively, the protein to be produced may be an endogenous protein
normally
synthesized by the cell used for protein production.
III. Cells
[0165] Certain aspects relate to cells comprising polypeptides or nucleic
acids of the
disclosure. In some aspects the cell is an immune cell or a T cell. "T cell"
includes all types
of immune cells expressing CD3 including T-helper cells, invariant natural
killer T (iNKT)
cells, cytotoxic T cells, T-regulatory cells (Treg) gamma-delta T cells,
natural-killer (NK) cells,
and neutrophils. The T cell may refer to a CD4+ or CD8+ T cell.
[0166] Suitable mammalian cells include primary cells and immortalized cell
lines.
Suitable mammalian cell lines include human cell lines, non-human primate cell
lines, rodent
(e.g., mouse, rat) cell lines, and the like. Suitable mammalian cell lines
include, but are not
limited to, HeLa cells (e.g., American Type Culture Collection (ATCC) No. CCL-
2), CHO
cells (e.g., ATCC Nos. CRL9618, CCL61, CRL9096), human embryonic kidney (HEK)
293
cells (e.g., ATCC No. CRL-1573), Vero cells, NIH 3T3 cells (e.g., ATCC No. CRL-
1658),
54

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
Huh-7 cells, BHK cells (e.g., ATCC No. CCL10), PC12 cells (ATCC No. CRL1721),
COS
cells, COS-7 cells (ATCC No. CRL1651), RATI cells, mouse L cells (ATCC No.
CCLI.3),
HLHepG2 cells, Hut-78, Jurkat, HL-60, NK cell lines (e.g., NKL, NK92, and
YTS), and the
like.
[0167] In some instances, the cell is not an immortalized cell line, but is
instead a cell (e.g.,
a primary cell) obtained from an individual. For example, in some cases, the
cell is an immune
cell obtained from an individual. As an example, the cell is a T lymphocyte
obtained from an
individual. As another example, the cell is a cytotoxic cell obtained from an
individual. As
another example, the cell is a stem cell (e.g., peripheral blood stem cell) or
progenitor cell
obtained from an individual.
IV. Methods for modifying genomic DNA
[0168] In certain aspects, the genomic DNA is modified either to include
additional
mutations, insertions, or deletions, or to integrate certain molecular
constructs of the disclosure
so that the constructs are expressed from the genomic DNA. In some aspects, a
nucleic acid
encoding a polypeptide of the disclosure is integrated into the genomic DNA of
a cell. In some
aspects, a nucleic acid is integrated into a cell via viral transduction, such
as gene transfer by
lentiviral or retroviral transduction. In some aspects, genomic DNA is
modified by integration
of nucleic acid encoding a polypeptide of the present disclosure (e.g., a CAR)
into the genome
of a host cell via a retroviral vector, a lentiviral vector, or an adeno-
associated viral vector.
[0169] In some aspects, the integration is targeted integration. In some
aspects, targeted
integration is achieved through the use of a DNA digesting
agent/polynucleotide modification
enzyme, such as a site-specific recombinase and/or a targeting endonuclease.
The term "DNA
digesting agent" refers to an agent that is capable of cleaving bonds (i.e.
phosphodiester bonds)
between the nucleotide subunits of nucleic acids. One specific target is the
TRAC (T cell
receptor alpha constant) locus. For instance, cells would first be
electroporated with a
ribonucleoprotein (RNP) complex consisting of Cas9 protein complexed with a
single-guide
RNA (sgRNA) targeting the TRAC (T cell receptor alpha constant) locus. Fifteen
minutes post
electroporation, the cells would be treated with AAV6 carrying the HDR
template that encodes
for the CAR. In another example, double stranded or single stranded DNA
comprises the HDR
template and is introduced into the cell via electroporation together with the
RNP complex.
[0170] Therefore, one aspect, the current disclosure includes targeted
integration. One way
of achieving this is through the use of an exogenous nucleic acid sequence
(i.e., a landing pad)
comprising at least one recognition sequence for at least one polynucleotide
modification

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
enzyme, such as a site-specific recombinase and/or a targeting endonuclease.
Site-specific
recombinases are well known in the art, and may be generally referred to as
invertases,
resolvases, or integrases. Non-limiting examples of site-specific recombinases
may include
lambda integrase, Cre recombinase, FLP recombinase, gamma-delta resolvase, Tn3
resolvase,
(I)C31 integrase, Bxb 1 -integrase, and R4 integrase. Site-specific
recombinases recognize
specific recognition sequences (or recognition sites) or variants thereof, all
of which are well
known in the art. For example, Cre recombinases recognize LoxP sites and FLP
recombinases
recognize FRT sites.
[0171] Contemplated targeting endonucleases include zinc finger nucleases
(ZFNs),
meganucleases, transcription activator-like effector nucleases (TALENs),
CRISPR/Cas-like
endonucleases, I-Tevl nucleases or related monomeric hybrids, or artificial
targeted DNA
double strand break inducing agents. Exemplary targeting endonucleases is
further described
below. For example, typically, a zinc finger nuclease comprises a DNA binding
domain (i.e.,
zinc finger) and a cleavage domain (i.e., nuclease), both of which are
described below. Also
included in the definition of polynucleotide modification enzymes are any
other useful fusion
proteins known to those of skill in the art, such as may comprise a DNA
binding domain and a
nuclease.
[0172] A landing pad sequence is a nucleotide sequence comprising at least
one recognition
sequence that is selectively bound and modified by a specific polynucleotide
modification
enzyme such as a site-specific recombinase and/or a targeting endonuclease. In
general, the
recognition sequence(s) in the landing pad sequence does not exist
endogenously in the genome
of the cell to be modified. For example, where the cell to be modified is a
CHO cell, the
recognition sequence in the landing pad sequence is not present in the
endogenous CHO
genome. The rate of targeted integration may be improved by selecting a
recognition sequence
for a high efficiency nucleotide modifying enzyme that does not exist
endogenously within the
genome of the targeted cell. Selection of a recognition sequence that does not
exist
endogenously also reduces potential off-target integration. In other aspects,
use of a recognition
sequence that is native in the cell to be modified may be desirable. For
example, where multiple
recognition sequences are employed in the landing pad sequence, one or more
may be
exogenous, and one or more may be native.
[0173] One of ordinary skill in the art can readily determine sequences
bound and cut by
site-specific recombinases and/or targeting endonucleases.
[0174] Another example of a targeting endonuclease that can be used is an
RNA-guided
endonuclease comprising at least one nuclear localization signal, which
permits entry of the
56

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
endonuclease into the nuclei of eukaryotic cells. The RNA-guided endonuclease
also comprises
at least one nuclease domain and at least one domain that interacts with a
guiding RNA. An
RNA-guided endonuclease is directed to a specific chromosomal sequence by a
guiding RNA
such that the RNA-guided endonuclease cleaves the specific chromosomal
sequence. Since the
guiding RNA provides the specificity for the targeted cleavage, the
endonuclease of the RNA-
guided endonuclease is universal and may be used with different guiding RNAs
to cleave
different target chromosomal sequences. Discussed in further detail below are
exemplary
RNA-guided endonuclease proteins. For example, the RNA-guided endonuclease can
be a
CRISPR/Cas protein or a CRISPR/Cas-like fusion protein, an RNA-guided
endonuclease
derived from a clustered regularly interspersed short palindromic repeats
(CRISPR)/CRISPR-
associated (Cas) system.
[0175] The targeting endonuclease can also be a meganuclease. Meganucleases
are
endodeoxyribonucleases characterized by a large recognition site, i.e., the
recognition site
generally ranges from about 12 base pairs to about 40 base pairs. As a
consequence of this
requirement, the recognition site generally occurs only once in any given
genome. Among
meganucleases, the family of homing endonucleases named "LAGLIDADG" has become
a
valuable tool for the study of genomes and genome engineering. Meganucleases
may be
targeted to specific chromosomal sequence by modifying their recognition
sequence using
techniques well known to those skilled in the art. See, for example, Epinat et
al., 2003, Nuc.
Acid Res., 31(11):2952-62 and Stoddard, 2005, Quarterly Review of Biophysics,
pp. 1-47.
[0176] Yet another example of a targeting endonuclease that can be used is
a transcription
activator-like effector (TALE) nuclease. TALEs are transcription factors from
the plant
pathogen Xanthom*onas that may be readily engineered to bind new DNA targets.
TALEs or
truncated versions thereof may be linked to the catalytic domain of
endonucleases such as FokI
to create targeting endonuclease called TALE nucleases or TALENs. See, e.g.,
Sanjana et al.,
2012, Nature Protocols 7(1):171-192; Bogdanove A J, Voytas D F., 2011,
Science,
333(6051):1843-6; Bradley P, Bogdanove A J, Stoddard B L., 2013, Curr Opin
Struct Biol.,
23(1):93-9.
V. Methods
[0177] Aspects of the current disclosure relate to methods for treating
cancer, such as
glioblastoma. In further aspects, the therapeutic receptors (e.g., CARs)
described herein may
be used for stimulating an immune response. The immune response stimulation
may be done
in vitro, in vivo, or ex vivo. In some aspects, the therapeutic receptors
described herein are for
57

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
preventing relapse. The method generally involves genetically modifying a
mammalian cell
with an expression vector, or a DNA, an RNA (e.g., in vitro transcribed RNA),
or an adeno-
associated virus (AAV) comprising nucleotide sequences encoding a polypeptide
of the
disclosure or directly transferring the polypeptide to the cell. The cell can
be an immune cell
(e.g., a T lymphocyte or NK cell), a stem cell, a progenitor cell, etc. In
some aspects, the cell
is a cell described herein.
[0178] In some aspects, the genetic modification is carried out ex vivo.
For example, a T
lymphocyte, a stem cell, or an NK cell (or cell described herein) is obtained
from an individual;
and the cell obtained from the individual is genetically modified to express a
polypeptide of
the disclosure. In some cases, the genetically modified cell is activated ex
vivo. In other cases,
the genetically modified cell is introduced into an individual (e.g., the
individual from whom
the cell was obtained); and the genetically modified cell is activated in
vivo.
[0179] In some aspects, the methods relate to administration of the cells
or peptides
described herein for the treatment of a cancer or administration to a person
with a cancer. In
some aspects, the cancer is glioblastoma.
VI. Additional Therapies
A. Immunotherapy
[0180] In some aspects, the methods comprise administration of a cancer
immunotherapy.
Cancer immunotherapy (sometimes called immuno-oncology, abbreviated 10) is the
use of the
immune system to treat cancer. Immunotherapies can be categorized as active,
passive or
hybrid (active and passive). These approaches exploit the fact that cancer
cells often have
molecules on their surface that can be detected by the immune system, known as
tumor-
associated antigens (TAAs); they are often proteins or other macromolecules
(e.g.
carbohydrates). Active immunotherapy directs the immune system to attack tumor
cells by
targeting TAAs. Passive immunotherapies enhance existing anti-tumor responses
and include
the use of monoclonal antibodies, lymphocytes and cytokines. Immunotherapies
useful in the
methods of the disclosure are described below.
1. Checkpoint Inhibitors and Combination Treatment
[0181] Aspects of the disclosure may include administration of immune
checkpoint
inhibitors (also referred to as checkpoint inhibitor therapy), which are
further described below.
The checkpoint inhibitor therapy may be a monotherapy, targeting only one
cellular checkpoint
proteins or may be combination therapy that targets at least two cellular
checkpoint proteins.
For example, the checkpoint inhibitor monotherapy may comprise one of: a PD-1,
PD-L1, or
58

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
PD-L2 inhibitor or may comprise one of a CTLA-4, B7-1, or B7-2 inhibitor. The
checkpoint
inhibitor combination therapy may comprise one of: a PD-1, PD-L1, or PD-L2
inhibitor and,
in combination, may further comprise one of a CTLA-4, B7-1, or B7-2 inhibitor.
The
combination of inhibitors in combination therapy need not be in the same
composition, but can
be administered either at the same time, at substantially the same time, or in
a dosing regimen
that includes periodic administration of both of the inihibitors, wherein the
period may be a
time period described herein.
a. PD-1, PD-L1, and PD-L2 inhibitors
[0182] PD-1 can act in the tumor microenvironment where T cells encounter
an infection
or tumor. Activated T cells upregulate PD-1 and continue to express it in the
peripheral tissues.
Cytokines such as IFN-gamma induce the expression of PD-Li on epithelial cells
and tumor
cells. PD-L2 is expressed on macrophages and dendritic cells. The main role of
PD-1 is to
limit the activity of effector T cells in the periphery and prevent excessive
damage to the tissues
during an immune response. Inhibitors of the disclosure may block one or more
functions of
PD-1 and/or PD-Li activity.
[0183] Alternative names for "PD-1" include CD279 and SLEB2. Alternative
names for
"PD-Li" include B7-H1, B7-4, CD274, and B7-H. Alternative names for "PD-L2"
include B7-
DC, Btdc, and CD273. In some aspects, PD-1, PD-L1, and PD-L2 are human PD-1,
PD-Li and
PD-L2.
[0184] In some aspects, the PD-1 inhibitor is a molecule that inhibits the
binding of PD-1
to its ligand binding partners. In a specific aspect, the PD-1 ligand binding
partners are PD-Li
and/or PD-L2. In another aspect, a PD-Li inhibitor is a molecule that inhibits
the binding of
PD-Li to its binding partners. In a specific aspect, PD-Li binding partners
are PD-1 and/or
B7-1. In another aspect, the PD-L2 inhibitor is a molecule that inhibits the
binding of PD-L2
to its binding partners. In a specific aspect, a PD-L2 binding partner is PD-
1. The inhibitor may
be an antibody, an antigen binding fragment thereof, an immunoadhesin, a
fusion protein, or
oligopeptide. Exemplary antibodies are described in U.S. Patent Nos.
8,735,553, 8,354,509,
and 8,008,449, all incorporated herein by reference. Other PD-1 inhibitors for
use in the
methods and compositions provided herein are known in the art such as
described in U.S. Patent
Application Nos. US2014/0294898, US2014/022021, and US2011/0008369, all
incorporated
herein by reference.
[0185] In some aspects, the PD-1 inhibitor is an anti-PD-1 antibody (e.g.,
a human antibody,
a humanized antibody, or a chimeric antibody). In some aspects, the anti-PD-1
antibody is
59

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
selected from the group consisting of nivolumab, pembrolizumab, and
pidilizumab. In some
aspects, the PD-1 inhibitor is an immunoadhesin (e.g., an immunoadhesin
comprising an
extracellular or PD-1 binding portion of PD-Li or PD-L2 fused to a constant
region (e.g., an
Fc region of an immunoglobulin sequence). In some aspects, the PD-Li inhibitor
comprises
AMP-224. Nivolumab, also known as MDX-1106-04, MDX-1106, ONO-4538, BMS-936558,
and OPDIVO , is an anti-PD-1 antibody described in W02006/121168.
Pembrolizumab, also
known as MK-3475, Merck 3475, lambrolizumab, KEYTRUDA , and SCH-900475, is an
anti-PD-1 antibody described in W02009/114335. Pidilizumab, also known as CT-
011, hBAT,
or hBAT-1, is an anti-PD-1 antibody described in W02009/101611. AMP-224, also
known as
B7-DCIg, is a PD-L2-Fc fusion soluble receptor described in W02010/027827 and
W02011/066342. Additional PD-1 inhibitors include MEDI0680, also known as AMP-
514,
and REGN2810.
[0186] In some aspects, the immune checkpoint inhibitor is a PD-Li
inhibitor such as
Durvalumab, also known as MEDI4736, atezolizumab, also known as MPDL3280A,
avelumab, also known as MSB00010118C, MDX-1105, BMS-936559, or combinations
thereof. In certain aspects, the immune checkpoint inhibitor is a PD-L2
inhibitor such as
rHIgM 1 2B7 .
[0187] In some aspects, the inhibitor comprises the heavy and light chain
CDRs or VRs of
nivolumab, pembrolizumab, or pidilizumab. Accordingly, in one aspect, the
inhibitor
comprises the CDR1, CDR2, and CDR3 domains of the VH region of nivolumab,
pembrolizumab, or pidilizumab, and the CDR1, CDR2 and CDR3 domains of the VL
region
of nivolumab, pembrolizumab, or pidilizumab. In another aspect, the antibody
competes for
binding with and/or binds to the same epitope on PD-1, PD-L1, or PD-L2 as the
above-
mentioned antibodies. In another aspect, the antibody has at least about 70,
75, 80, 85, 90, 95,
97, or 99% (or any derivable range therein) variable region amino acid
sequence identity with
the above-mentioned antibodies.
b. CTLA-4, B7-1, and B7-2 inhibitors
[0188] Another immune checkpoint that can be targeted in the methods
provided herein is
the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), also known as CD152.
The
complete cDNA sequence of human CTLA-4 has the Genbank accession number
L15006.
CTLA-4 is found on the surface of T cells and acts as an "off' switch when
bound to B7-1
(CD80) or B7-2 (CD86) on the surface of antigen-presenting cells. CTLA-4 is a
member of the
immunoglobulin superfamily that is expressed on the surface of Helper T cells
and transmits

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
an inhibitory signal to T cells. CTLA-4 is similar to the T-cell co-
stimulatory protein, CD28,
and both molecules bind to B7-1 and B7-2 on antigen-presenting cells. CTLA-4
transmits an
inhibitory signal to T cells, whereas CD28 transmits a stimulatory signal.
Intracellular CTLA-
4 is also found in regulatory T cells and may be important to their function.
T cell activation
through the T cell receptor and CD28 leads to increased expression of CTLA-4,
an inhibitory
receptor for B7 molecules. Inhibitors of the disclosure may block one or more
functions of
CTLA-4, B7-1, and/or B7-2 activity. In some aspects, the inhibitor blocks the
CTLA-4 and
B7-1 interaction. In some aspects, the inhibitor blocks the CTLA-4 and B7-2
interaction.
[0189] In some aspects, the immune checkpoint inhibitor is an anti-CTLA-4
antibody (e.g.,
a human antibody, a humanized antibody, or a chimeric antibody), an antigen
binding fragment
thereof, an immunoadhesin, a fusion protein, or oligopeptide.
[0190] Anti-human-CTLA-4 antibodies (or VH and/or VL domains derived
therefrom)
suitable for use in the present methods can be generated using methods well
known in the art.
Alternatively, art recognized anti-CTLA-4 antibodies can be used. For example,
the anti-
CTLA-4 antibodies disclosed in: US 8,119,129, WO 01/14424, WO 98/42752; WO
00/37504
(CP675,206, also known as tremelimumab; formerly ticilimumab), U.S. Patent No.
6,207,156;
Hurwitz et al., 1998; can be used in the methods disclosed herein. The
teachings of each of the
aforementioned publications are hereby incorporated by reference. Antibodies
that compete
with any of these art-recognized antibodies for binding to CTLA-4 also can be
used. For
example, a humanized CTLA-4 antibody is described in International Patent
Application No.
W02001/014424, W02000/037504, and U.S. Patent No. 8,017,114; all incorporated
herein by
reference.
[0191] A further anti-CTLA-4 antibody useful as a checkpoint inhibitor in
the methods and
compositions of the disclosure is ipilimumab (also known as 10D1, MDX- 010,
MDX- 101,
and Yervoy ) or antigen binding fragments and variants thereof (see, e.g., WOO
1/14424).
[0192] In some aspects, the inhibitor comprises the heavy and light chain
CDRs or VRs of
tremelimumab or ipilimumab. Accordingly, in one aspect, the inhibitor
comprises the CDR1,
CDR2, and CDR3 domains of the VH region of tremelimumab or ipilimumab, and the
CDR1,
CDR2 and CDR3 domains of the VL region of tremelimumab or ipilimumab. In
another aspect,
the antibody competes for binding with and/or binds to the same epitope on PD-
1, B7-1, or B7-
2 as the above- mentioned antibodies. In another aspect, the antibody has at
least about 70, 75,
80, 85, 90, 95, 97, or 99% (or any derivable range therein) variable region
amino acid sequence
identity with the above-mentioned antibodies.
61

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
2. Inhibition of co-stimulatory molecules
[0193] In some aspects, the immunotherapy comprises an inhibitor of a co-
stimulatory
molecule. In some aspects, the inhibitor comprises an inhibitor of B7-1
(CD80), B7-2 (CD86),
CD28, ICOS, 0X40 (TNFRSF4), 4-1BB (CD137; TNFRSF9), CD4OL (CD4OLG), GITR
(TNFRSF18), and combinations thereof. Inhibitors include inhibitory
antibodies,
polypeptides, compounds, and nucleic acids.
3. Dendritic cell therapy
[0194] Dendritic cell therapy provokes anti-tumor responses by causing
dendritic cells to
present tumor antigens to lymphocytes, which activates them, priming them to
kill other cells
that present the antigen. Dendritic cells are antigen presenting cells (APCs)
in the mammalian
immune system. In cancer treatment, they aid cancer antigen targeting. One
example of cellular
cancer therapy based on dendritic cells is sipuleucel-T.
[0195] One method of inducing dendritic cells to present tumor antigens is
by vaccination
with autologous tumor lysates or short peptides (small parts of protein that
correspond to the
protein antigens on cancer cells). These peptides are often given in
combination with adjuvants
(highly immunogenic substances) to increase the immune and anti-tumor
responses. Other
adjuvants include proteins or other chemicals that attract and/or activate
dendritic cells, such
as granulocyte macrophage colony-stimulating factor (GM-CSF).
[0196] Dendritic cells can also be activated in vivo by making tumor cells
express GM-
CSF. This can be achieved by either genetically engineering tumor cells to
produce GM-CSF
or by infecting tumor cells with an oncolytic virus that expresses GM-CSF.
[0197] Another strategy is to remove dendritic cells from the blood of a
patient and activate
them outside the body. The dendritic cells are activated in the presence of
tumor antigens,
which may be a single tumor-specific peptide/protein or a tumor cell lysate (a
solution of
broken down tumor cells). These cells (with optional adjuvants) are infused
and provoke an
immune response.
[0198] Dendritic cell therapies include the use of antibodies that bind to
receptors on the
surface of dendritic cells. Antigens can be added to the antibody and can
induce the dendritic
cells to mature and provide immunity to the tumor.
4. Cytokine therapy
[0199] Cytokines are proteins produced by many types of cells present
within a tumor. They
can modulate immune responses. The tumor often employs them to allow it to
grow and reduce
62

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
the immune response. These immune-modulating effects allow them to be used as
drugs to
provoke an immune response. Two commonly used cytokines are interferons and
interleukins.
[0200]
Interferons are produced by the immune system. They are usually involved in
anti-
viral response, but also have use for cancer. They fall in three groups: type
I (IFNa and IFN(3),
type II (IFNy) and type III (IFNX).
[0201]
Interleukins have an array of immune system effects. IL-2 is an exemplary
interleukin cytokine therapy.
5. Adoptive T-cell therapy
[0202]
Adoptive T cell therapy is a form of passive immunization by the transfusion
of T-
cells (adoptive cell transfer). They are found in blood and tissue and usually
activate when they
find foreign pathogens. Specifically, they activate when the T-cell's surface
receptors encounter
cells that display parts of foreign proteins on their surface antigens. These
can be either infected
cells, or antigen presenting cells (APCs). They are found in normal tissue and
in tumor tissue,
where they are known as tumor infiltrating lymphocytes (TILs). They are
activated by the
presence of APCs such as dendritic cells that present tumor antigens. Although
these cells can
attack the tumor, the environment within the tumor is highly
immunosuppressive, preventing
immune-mediated tumor death.
[0203]
Multiple ways of producing and obtaining tumor targeted T-cells have been
developed. T-cells specific to a tumor antigen can be removed from a tumor
sample (TILs) or
filtered from blood. Subsequent activation and culturing is performed ex vivo,
with the results
reinfused. Tumor targeted T cells can be generated through gene therapy. Tumor
targeted T
cells can be expanded by exposing the T cells to tumor antigens.
[0001] In
some aspects, therapeutic cells used in adoptive cell therapies express
chimeric
antigen receptors (CARs). CARs are fusion proteins that are commonly composed
of an
extracellular antigen-binding domain (which may be an scFv), an extracellular
spacer, a
transmembrane domain, costimulatory signaling regions (the number of which
varies
depending on the specific CAR design), and a CD3-zeta signaling
domain/endodomain.
[0002] In
some aspects, therapeutic cells used in adoptive cell therapies express
engineered
T-cell receptors (TCRs), which are heterologous TCR molecules that target
tumor antigens.
Immune cells, including T cells and natural killer (NK) cells, can be
engineered to express
CARs or TCRs by a variety of methods known in the art, including viral
transduction, DNA
nucleofection, and RNA nucleofection. Binding of the CAR or TCR to the antigen
target can
63

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
activate human T cells expressing the CAR or TCR, which may result in killing
of the cell
bearing the antigen or some other immunological response.
[0204] In some aspects, the cells comprise a cancer-specific CAR or TCR.
The term
"cancer-specific" in the context of CAR or TCR polypeptides refers to a
polypeptide that has
an antigen binding specificity for a cancer-specific molecule, such as a
cancer-specific antigen.
In some aspects, the cancer-specific CAR and another CAR are on separate
polypeptides.
B. Oncolytic virus
[0205] In some aspects, the additional therapy comprises an oncolytic
virus. An oncolytic
virus is a virus that preferentially infects and kills cancer cells. As the
infected cancer cells are
destroyed by oncolysis, they release new infectious virus particles or virions
to help destroy
the remaining tumor. Oncolytic viruses are thought not only to cause direct
destruction of the
tumor cells, but also to stimulate host anti-tumor immune responses for long-
term
immunotherapy.
C. Polysaccharides
[0206] In some aspects, the additional therapy comprises polysaccharides.
Certain
compounds found in mushrooms, primarily polysaccharides, can up-regulate the
immune
system and may have anti-cancer properties. For example, beta-glucans such as
lentinan have
been shown in laboratory studies to stimulate macrophage, NK cells, T cells
and immune
system cytokines and have been investigated in clinical trials as immunologic
adjuvants.
D. Neoantigens
[0207] In some aspects, the additional therapy comprises targeting of
neoantigen mutations.
Many tumors express mutations. These mutations potentially create new
targetable antigens
(neoantigens) for use in T cell immunotherapy. The presence of CD8+ T cells in
cancer lesions,
as identified using RNA sequencing data, is higher in tumors with a high
mutational burden.
The level of transcripts associated with cytolytic activity of natural killer
cells and T cells
positively correlates with mutational load in many human tumors.
E. Chemotherapies
[0208] In some aspects, the additional therapy comprises a chemotherapy.
Suitable classes
of chemotherapeutic agents include (a) Alkylating Agents, such as nitrogen
mustards (e.g.,
mechlorethamine, cylophosphamide, ifosfamide, melphalan, chlorambucil),
ethylenimines and
methylmelamines (e.g., hexamethylmelamine, thiotepa), alkyl sulfonates (e.g.,
busulfan),
nitrosoureas (e.g., carmustine, lomustine, chlorozoticin, streptozocin) and
triazines (e.g.,
64

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
dicarbazine), (b) Antimetabolites, such as folic acid analogs (e.g.,
methotrexate), pyrimidine
analogs (e.g., 5-fluorouracil, floxuridine, cytarabine, azauridine) and purine
analogs and related
materials (e.g., 6-mercaptopurine, 6-thioguanine, pentostatin), (c) Natural
Products, such as
vinca alkaloids (e.g., vinblastine, vincristine), epipodophylotoxins (e.g.,
etoposide, teniposide),
antibiotics (e.g., dactinomycin, daunorubicin, doxorubicin, bleomycin,
plicamycin and
mitoxanthrone), enzymes (e.g., L-asparaginase), and biological response
modifiers (e.g.,
Interferon-a), and (d) Miscellaneous Agents, such as platinum coordination
complexes (e.g.,
cisplatin, carboplatin), substituted ureas (e.g., hydroxyurea),
methylhydiazine derivatives (e.g.,
procarbazine), and adreocortical suppressants (e.g., taxol and mitotane). In
some aspects,
cisplatin is a particularly suitable chemotherapeutic agent.
[0209] Cisplatin has been widely used to treat cancers such as, for
example, metastatic
testicular or ovarian carcinoma, advanced bladder cancer, head or neck cancer,
cervical cancer,
lung cancer or other tumors. Cisplatin is not absorbed orally and must
therefore be delivered
via other routes such as, for example, intravenous, subcutaneous, intratumoral
or
intraperitoneal injection. Cisplatin can be used alone or in combination with
other agents, with
efficacious doses used in clinical applications including about 15 mg/m2 to
about 20 mg/m2
for 5 days every three weeks for a total of three courses being contemplated
in certain aspects.
In some aspects, the amount of cisplatin delivered to the cell and/or subject
in conjunction with
the construct comprising an Egr-1 promoter operatively linked to a
polynucleotide encoding
the therapeutic polypeptide is less than the amount that would be delivered
when using cisplatin
alone.
[0210] Other suitable chemotherapeutic agents include antimicrotubule
agents, e.g.,
Pacl*taxel ("Taxon and doxorubicin hydrochloride ("doxorubicin"). The
combination of an
Egr-1 promoter/TNFa construct delivered via an adenoviral vector and
doxorubicin was
determined to be effective in overcoming resistance to chemotherapy and/or TNF-
a, which
suggests that combination treatment with the construct and doxorubicin
overcomes resistance
to both doxorubicin and TNF-a.
[0211] Doxorubicin is absorbed poorly and is preferably administered
intravenously. In
certain aspects, appropriate intravenous doses for an adult include about 60
mg/m2 to about 75
mg/m2 at about 21-day intervals or about 25 mg/m2 to about 30 mg/m2 on each of
2 or 3
successive days repeated at about 3 week to about 4 week intervals or about 20
mg/m2 once a
week. The lowest dose should be used in elderly patients, when there is prior
bone-marrow
depression caused by prior chemotherapy or neoplastic marrow invasion, or when
the drug is
combined with other myelopoietic suppressant drugs.

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
[0212] Nitrogen mustards are another suitable chemotherapeutic agent useful
in the
methods of the disclosure. A nitrogen mustard may include, but is not limited
to,
mechlorethamine (HN2), cyclophosphamide and/or ifosfamide, melphalan (L-
sarcolysin), and
chlorambucil. Cyclophosphamide (CYTOXANC)) is available from Mead Johnson and
NEOSTAR is available from Adria), is another suitable chemotherapeutic agent.
Suitable
oral doses for adults include, for example, about 1 mg/kg/day to about 5
mg/kg/day,
intravenous doses include, for example, initially about 40 mg/kg to about 50
mg/kg in divided
doses over a period of about 2 days to about 5 days or about 10 mg/kg to about
15 mg/kg about
every 7 days to about 10 days or about 3 mg/kg to about 5 mg/kg twice a week
or about 1.5
mg/kg/day to about 3 mg/kg/day. Because of adverse gastrointestinal effects,
the intravenous
route is preferred. The drug also sometimes is administered intramuscularly,
by infiltration or
into body cavities.
[0213] Additional suitable chemotherapeutic agents include pyrimidine
analogs, such as
cytarabine (cytosine arabinoside), 5-fluorouracil (fluouracil; 5-FU) and
floxuridine (fluorode-
oxyuridine; FudR). 5-FU may be administered to a subject in a dosage of
anywhere between
about 7.5 to about 1000 mg/m2. Further, 5-FU dosing schedules may be for a
variety of time
periods, for example up to six weeks, or as determined by one of ordinary
skill in the art to
which this disclosure pertains.
[0214] Gemcitabine diphosphate (GEMZAR , Eli Lilly & Co., "gemcitabine"),
another
suitable chemotherapeutic agent, is recommended for treatment of advanced and
metastatic
pancreatic cancer, and will therefore be useful in the present disclosure for
these cancers as
well.
[0215] The amount of the chemotherapeutic agent delivered to the patient
may be variable.
In one suitable aspect, the chemotherapeutic agent may be administered in an
amount effective
to cause arrest or regression of the cancer in a host, when the chemotherapy
is administered
with the construct. In other aspects, the chemotherapeutic agent may be
administered in an
amount that is anywhere between 2 to 10,000 fold less than the
chemotherapeutic effective
dose of the chemotherapeutic agent. For example, the chemotherapeutic agent
may be
administered in an amount that is about 20 fold less, about 500 fold less or
even about 5000
fold less than the chemotherapeutic effective dose of the chemotherapeutic
agent. The
chemotherapeutics of the disclosure can be tested in vivo for the desired
therapeutic activity in
combination with the construct, as well as for determination of effective
dosages. For example,
such compounds can be tested in suitable animal model systems prior to testing
in humans,
66

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
including, but not limited to, rats, mice, chicken, cows, monkeys, rabbits,
etc. In vitro testing
may also be used to determine suitable combinations and dosages, as described
in the examples.
F. Radiotherapy
[0216] In some aspects, the additional therapy or prior therapy comprises
radiation, such as
ionizing radiation. As used herein, "ionizing radiation" means radiation
comprising particles
or photons that have sufficient energy or can produce sufficient energy via
nuclear interactions
to produce ionization (gain or loss of electrons). An exemplary and preferred
ionizing radiation
is an x-radiation. Means for delivering x-radiation to a target tissue or cell
are well known in
the art.
[0217] In some aspects, the amount of ionizing radiation is greater than 20
Gy and is
administered in one dose. In some aspects, the amount of ionizing radiation is
18 Gy and is
administered in three doses. In some aspects, the amount of ionizing radiation
is at least, at
most, or exactly 2, 4, 6, 8, 10, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,
26, 27, 18, 19, 30, 31,
32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 40
Gy (or any derivable
range therein). In some aspects, the ionizing radiation is administered in at
least, at most, or
exactly 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 does (or any derivable range
therein). When more than
one dose is administered, the does may be about 1, 4, 8, 12, or 24 hours or 1,
2, 3, 4, 5, 6, 7, or
8 days or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, or 16 weeks apart, or any
derivable range therein.
[0218] In some aspects, the amount of IR may be presented as a total dose
of IR, which is
then administered in fractionated doses. For example, in some aspects, the
total dose is 50 Gy
administered in 10 fractionated doses of 5 Gy each. In some aspects, the total
dose is 50-90
Gy, administered in 20-60 fractionated doses of 2-3 Gy each. In some aspects,
the total dose
of IR is at least, at most, or about 20, 21, 22, 23, 24, 25, 26, 27, 28, 29,
30, 31, 32, 33, 34, 35,
36, 37, 38, 39, 40,41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55,
56, 57, 58, 59, 60,
61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79,
80, 81, 82, 83, 84, 85,
86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103,
104, 105, 106, 107,
108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 125, 130,
135, 140, or 150 (or
any derivable range therein). In some aspects, the total dose is administered
in fractionated
doses of at least, at most, or exactly 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14,
15, 20, 25, 30, 35, 40,
45, or 50 Gy (or any derivable range therein. In some aspects, at least, at
most, or exactly 2, 3,
4, 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,
25, 26, 27, 28, 29, 30,
31, 32, 33, 34, 35, 36, 37, 38, 39, 40,41, 42, 43, 44, 45, 46, 47, 48, 49, 50,
51, 52, 53, 54, 55,
56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74,
75, 76, 77, 78, 79, 80,
67

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or
100 fractionated
doses are administered (or any derivable range therein). In some aspects, at
least, at most, or
exactly 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 (or any derivable range
therein) fractionated doses
are administered per day. In some aspects, at least, at most, or exactly 1, 2,
3, 4, 5, 6, 7, 8, 9,
10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28,
29, or 30 (or any
derivable range therein) fractionated doses are administered per week.
G. Surgery
[0219] Approximately 60% of persons with cancer will undergo surgery of
some type,
which includes preventative, diagnostic or staging, curative, and palliative
surgery. Curative
surgery includes resection in which all or part of cancerous tissue is
physically removed,
excised, and/or destroyed and may be used in conjunction with other therapies,
such as the
treatment of the present aspects, chemotherapy, radiotherapy, hormonal
therapy, gene therapy,
immunotherapy, and/or alternative therapies. Tumor resection refers to
physical removal of at
least part of a tumor. In addition to tumor resection, treatment by surgery
includes laser
surgery, cryosurgery, electrosurgery, and microscopically-controlled surgery
(Mohs' surgery).
[0220] Upon excision of part or all of cancerous cells, tissue, or tumor, a
cavity may be
formed in the body. Treatment may be accomplished by perfusion, direct
injection, or local
application of the area with an additional anti-cancer therapy. Such treatment
may be repeated,
for example, every 1, 2, 3, 4, 5, 6, or 7 days, or every 1, 2, 3, 4, and 5
weeks or every 1, 2, 3,
4, 5, 6,7, 8, 9, 10, 11, or 12 months. These treatments may be of varying
dosages as well.
H. Other Agents
[0221] It is contemplated that other agents may be used in combination with
certain aspects
of the present aspects to improve the therapeutic efficacy of treatment. These
additional agents
include agents that affect the upregulation of cell surface receptors and GAP
junctions,
cytostatic and differentiation agents, inhibitors of cell adhesion, agents
that increase the
sensitivity of the hyperproliferative cells to apoptotic inducers, or other
biological agents.
Increases in intercellular signaling by elevating the number of GAP junctions
would increase
the anti-hyperproliferative effects on the neighboring hyperproliferative cell
population. In
other aspects, cytostatic or differentiation agents can be used in combination
with certain
aspects of the present aspects to improve the anti-hyperproliferative efficacy
of the treatments.
Inhibitors of cell adhesion are contemplated to improve the efficacy of the
present aspects.
Examples of cell adhesion inhibitors are focal adhesion kinase (FAKs)
inhibitors and
Lovastatin. It is further contemplated that other agents that increase the
sensitivity of a
68

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
hyperproliferative cell to apoptosis, such as the antibody c225, could be used
in combination
with certain aspects of the present aspects to improve the treatment efficacy.
[0222] It is contemplated that a cancer treatment may exclude any of the
cancer treatments
described herein. Furthermore, aspects of the disclosure include patients that
have been
previously treated for a therapy described herein, are currently being treated
for a therapy
described herein, or have not been treated for a therapy described herein. In
some aspects, the
patient is one that has been determined to be resistant to a therapy described
herein. In some
aspects, the patient is one that has been determined to be sensitive to a
therapy described herein.
VII. Pharmaceutical compositions
[0223] The present disclosure includes methods for treating disease and
modulating
immune responses in a subject in need thereof. The disclosure includes cells
that may be in
the form of a pharmaceutical composition that can be used to induce or modify
an immune
response.
[0224] Administration of the compositions according to the current
disclosure will typically
be via any common route. This includes, but is not limited to parenteral,
orthotopic,
intradermal, subcutaneous, orally, transdermally, intratumorally,
intramuscular,
intraperitoneal, intraperitoneally, intraorbitally, by implantation, by
inhalation,
intraventricularly, intracerebroventricularly, intranasally, intravenous
injection, or into a tumor
resection cavity.
[0225] Typically, compositions and therapies of the disclosure are
administered in a manner
compatible with the dosage formulation, and in such amount as will be
therapeutically effective
and immune modifying. The quantity to be administered depends on the subject
to be treated.
Precise amounts of active ingredient required to be administered depend on the
judgment of
the practitioner.
[0226] The manner of application may be varied widely. Any of the
conventional methods
for administration of pharmaceutical compositions comprising cellular
components are
applicable. The dosage of the pharmaceutical composition will depend on the
route of
administration and will vary according to the size and health of the subject.
[0227] In many instances, it will be desirable to have multiple
administrations of at most
about or at least about 3, 4, 5, 6, 7, 8, 9, 10 or more. The administrations
may range from 2-
day to 12-week intervals, more usually from one to two week intervals. The
course of the
administrations may be followed by assays for alloreactive immune responses
and T cell
activity.
69

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
[0228] The phrases "pharmaceutically acceptable" or "pharmacologically
acceptable" refer
to molecular entities and compositions that do not produce an adverse,
allergic, or other
untoward reaction when administered to an animal, or human. As used herein,
"pharmaceutically acceptable carrier" includes any and all solvents,
dispersion media, coatings,
antibacterial and antifungal agents, isotonic and absorption delaying agents,
and the like. The
use of such media and agents for pharmaceutical active substances is well
known in the art.
Except insofar as any conventional media or agent is incompatible with the
active ingredients,
its use in immunogenic and therapeutic compositions is contemplated. The
pharmaceutical
compositions of the current disclosure are pharmaceutically acceptable
compositions.
[0229] The compositions of the disclosure can be formulated for parenteral
administration,
e.g., formulated for injection via the intravenous, intramuscular, sub-
cutaneous, or even
intraperitoneal routes. Typically, such compositions can be prepared as
injectables, either as
liquid solutions or suspensions and the preparations can also be emulsified.
[0230] The pharmaceutical forms suitable for injectable use include sterile
aqueous
solutions or dispersions; formulations including sesame oil, peanut oil, or
aqueous propylene
glycol. It also should be stable under the conditions of manufacture and
storage and must be
preserved against the contaminating action of microorganisms, such as bacteria
and fungi.
[0231] Sterile injectable solutions are prepared by incorporating the
active ingredients (i.e.
cells of the disclosure) in the required amount in the appropriate solvent
with various of the
other ingredients enumerated above, as required, followed by filtered
sterilization. Generally,
dispersions are prepared by incorporating the various sterilized active
ingredients into a sterile
vehicle which contains the basic dispersion medium and the required other
ingredients from
those enumerated above.
[0232] An effective amount of a composition is determined based on the
intended goal. The
term "unit dose" or "dosage" refers to physically discrete units suitable for
use in a subject,
each unit containing a predetermined quantity of the composition calculated to
produce the
desired responses discussed herein in association with its administration,
i.e., the appropriate
route and regimen. The quantity to be administered, both according to number
of treatments
and unit dose, depends on the result and/or protection desired. Precise
amounts of the
composition also depend on the judgment of the practitioner and are peculiar
to each individual.
Factors affecting dose include physical and clinical state of the subject,
route of administration,
intended goal of treatment (alleviation of symptoms versus cure), and potency,
stability, and
toxicity of the particular composition. Upon formulation, solutions will be
administered in a
manner compatible with the dosage formulation and in such amount as is
therapeutically or

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
prophylactically effective. The formulations are easily administered in a
variety of dosage
forms, such as the type of injectable solutions described above.
[0233] The compositions and related methods of the present disclosure,
particularly
administration of a composition of the disclosure may also be used in
combination with the
administration of additional therapies such as the additional therapeutics
described herein or in
combination with other traditional therapeutics known in the art.
[0234] The therapeutic compositions and treatments disclosed herein may
precede, be co-
current with and/or follow another treatment or agent by intervals ranging
from minutes to
weeks. In aspects where agents are applied separately to a cell, tissue or
organism, one would
generally ensure that a significant period of time did not expire between the
time of each
delivery, such that the therapeutic agents would still be able to exert an
advantageously
combined effect on the cell, tissue or organism. For example, in such
instances, it is
contemplated that one may contact the cell, tissue or organism with two,
three, four or more
agents or treatments substantially simultaneously (i.e., within less than
about a minute). In
other aspects, one or more therapeutic agents or treatments may be
administered or provided
within 1 minute, 5 minutes, 10 minutes, 20 minutes, 30 minutes, 45 minutes, 60
minutes, 2
hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10
hours, 11 hours, 12
hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours,
20 hours, 21 hours,
22 hours, 22 hours, 23 hours, 24 hours, 25 hours, 26 hours, 27 hours, 28
hours, 29 hours, 30
hours, 31 hours, 32 hours, 33 hours, 34 hours, 35 hours, 36 hours, 37 hours,
38 hours, 39 hours,
40 hours, 41 hours, 42 hours, 43 hours, 44 hours, 45 hours, 46 hours, 47
hours, 48 hours, 1 day,
2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11
days, 12 days, 13
days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days,
1 week, 2 weeks,
3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, or 8 weeks or more, and any range
derivable
therein, prior to and/or after administering another therapeutic agent or
treatment.
[0235] The treatments may include various "unit doses." Unit dose is
defined as containing
a predetermined-quantity of the therapeutic composition. The quantity to be
administered, and
the particular route and formulation, is within the skill of determination of
those in the clinical
arts. A unit dose need not be administered as a single injection but may
comprise continuous
infusion over a set period of time. In some aspects, a unit dose comprises a
single administrable
dose.
[0236] The quantity to be administered, both according to number of
treatments and unit
dose, depends on the treatment effect desired. An effective dose is understood
to refer to an
amount necessary to achieve a particular effect. In the practice in certain
aspects, it is
71

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
contemplated that doses in the range from 10 mg/kg to 200 mg/kg can affect the
protective
capability of these agents. Thus, it is contemplated that doses include doses
of about 0.1, 0.5,
1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 100,
105, 110, 115, 120,
125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, and
200, 300, 400,
500, 1000 iig/kg, mg/kg, iig/day, or mg/day or any range derivable therein.
Furthermore, such
doses can be administered at multiple times during a day, and/or on multiple
days, weeks, or
months.
[0237] In some aspects, the therapeutically effective or sufficient amount
of the immune
checkpoint inhibitor, such as an antibody and/or microbial modulator, that is
administered to a
human will be in the range of about 0.01 to about 50 mg/kg of patient body
weight whether by
one or more administrations. In some aspects, the therapy used is about 0.01
to about 45 mg/kg,
about 0.01 to about 40 mg/kg, about 0.01 to about 35 mg/kg, about 0.01 to
about 30 mg/kg,
about 0.01 to about 25 mg/kg, about 0.01 to about 20 mg/kg, about 0.01 to
about 15 mg/kg,
about 0.01 to about 10 mg/kg, about 0.01 to about 5 mg/kg, or about 0.01 to
about 1 mg/kg
administered daily, for example. In one aspect, a therapy described herein is
administered to a
subject at a dose of about 100 mg, about 200 mg, about 300 mg, about 400 mg,
about 500 mg,
about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 1000 mg, about
1100 mg,
about 1200 mg, about 1300 mg or about 1400 mg on day 1 of 21-day cycles. The
dose may be
administered as a single dose or as multiple doses (e.g., 2 or 3 doses), such
as infusions. The
progress of this therapy is easily monitored by conventional techniques.
[0238] In certain aspects, the effective dose of the pharmaceutical
composition is one which
can provide a blood level of about 1 [I,M to 150 04. In another aspect, the
effective dose
provides a blood level of about 4 [I,M to 100 [M.; or about 1 [I,M to 100
[I,M; or about 1 [I,M to
50 [I,M; or about 1 [I,M to 40 [I,M; or about 1 [I,M to 30 [I,M; or about 1
[I,M to 20 [I,M; or about
1 [I,M to 10 [I,M; or about 10 [I,M to 150 [I,M; or about 10 [I,M to 100 [I,M;
or about 10 [I,M to 50
[I,M; or about 25 [I,M to 150 [I,M; or about 25 [I,M to 100 [I,M; or about 25
[I,M to 50 [I,M; or
about 50 [I,M to 150 [I,M; or about 50 [I,M to 100 [I,M (or any range
derivable therein). In other
aspects, the dose can provide the following blood level of the agent that
results from a
therapeutic agent being administered to a subject: about, at least about, or
at most about 1, 2,
3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23,
24, 25, 26, 27, 28, 29,
30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48,
49, 50, 51, 52, 53, 54,
55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73,
74, 75, 76, 77, 78, 79,
80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98,
99, or 100 1.4.M or any
72

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
range derivable therein. In certain aspects, the therapeutic agent that is
administered to a subject
is metabolized in the body to a metabolized therapeutic agent, in which case
the blood levels
may refer to the amount of that agent. Alternatively, to the extent the
therapeutic agent is not
metabolized by a subject, the blood levels discussed herein may refer to the
unmetabolized
therapeutic agent.
[0239] Precise amounts of the therapeutic composition also depend on the
judgment of the
practitioner and are peculiar to each individual. Factors affecting dose
include physical and
clinical state of the patient, the route of administration, the intended goal
of treatment
(alleviation of symptoms versus cure) and the potency, stability and toxicity
of the particular
therapeutic substance or other therapies a subject may be undergoing.
[0240] It will be understood by those skilled in the art and made aware
that dosage units of
i.t.g/kg or mg/kg of body weight can be converted and expressed in comparable
concentration
units of t.g/m1 or mM (blood levels), such as 4 [I,M to 100 04. It is also
understood that uptake
is species and organ/tissue dependent. The applicable conversion factors and
physiological
assumptions to be made concerning uptake and concentration measurement are
well-known
and would permit those of skill in the art to convert one concentration
measurement to another
and make reasonable comparisons and conclusions regarding the doses,
efficacies and results
described herein.
VIII. Therapeutic Methods
[0241] The compositions of the disclosure may be used for in vivo, in
vitro, or ex vivo
administration. The route of administration of the composition may be, for
example,
intracutaneous, subcutaneous, intravenous, local, topical, and intraperitoneal
administrations.
[0242] In some aspects, the disclosed methods are directed to methods for
treating cancer.
The cancer may be a solid tumor, metastatic cancer, or non-metastatic cancer.
In certain
aspects, the cancer is glioblastoma and may be recurrent, metastatic,
relapsed, or of a Stage I,
II, III, or IV.
IX. Sequences
[0243] The amino acid sequence of example chimeric polypeptides and CAR
molecules
useful in the methods and compositions of the present disclosure are provided
in Table 1 below.
73

CA 03193009 2023-02-24
WO 2022/046935
PCT/US2021/047600
DESCRIPTION SEQUENCE SEQ
ID NO:
IL13Ra2.BBz METDTLLLWVLLLWVPGSTGAGGSDYKDDDDKGGSG 146
(MKleader ¨ FLAG- PVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSINLTA
IL13op-IgG4 GMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQ
hinge_IgG4 CH2 CH3 FSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFNESKY
L235E N297Q peptide GPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCV
spacer-CD28 VVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFQST
transmembrane YRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTIS
domain-4-1BB Co- KAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPS
stimulatory¨CD3 Zeta) DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVD
KSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKMF
WVLVVVGGVLACYSLLVTVAFIIFWVKRGRKKLLYIFK
QPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSA
DAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPE
MGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGER
RRGKGHDGLYQGLSTATKDTYDALHMQALPPR
MKle ader METDTLLLWVLLLWVPGSTG 2
FLAG DYKDDDDK 3
IL13op GPVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSINLT 147
AGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAG
QFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFN
IgG4 hinge:IgG4 CH2 ESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPE 5
CH3 L235E N297Q VTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREE
peptide spacer QFQSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSS
IEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVK
GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSR
LTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG
K
CD28 transmembrane MFWVLVVVGGVLACYSLLVTVAFIIFWV 6
domain
4-1BB co-stimulatory KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEG 7
GCEL
CD3 Zeta RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDK 8
RRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEI
GMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALP
PR
IL13Ra2-(G4S)x3- METDTLLLWVLLLWVPGSTGAGGSDYKDDDDKGGSG 148
TGF-I3.BBz PVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSINLTA
(MKleader¨FLAG- GMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQ
IL13op¨(G4S)x3¨TGF- FS SLHVRDTKIEVAQFVKDLLLHLKKLFREGRFNGGGG
0 scFv-IgG4 hinge SGGGGSGGGGS QVQLVQSGAEVKKPGSSVKVSCKASG
peptide spacer-CD28 YTFSSNVISWVRQAPGQGLEWMGGVIPIVDIANYAQRF
transmembrane KGRVTITADESTSTTYMELSSLRSEDTAVYYCALPRAF
domain-4-1BB Co- VLDAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSETV
stimulatory¨ CD3 Zeta) LTQSPGTLSLSPGERATLSCRASQSLGSSYLAWYQQKP
GQAPRLLIYGASSRAPGIPDRFSGSGSGTDFTLTISRLEP
EDFAVYYCQQYADSPITFGQGTRLEIKESKYGPPCPPCP
MFWVLVVVGGVLACYSLLVTVAFIIFWVKRGRKKLLY
IFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSR
SADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDP
EMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGE
RRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
MKle ader METDTLLLWVLLLWVPGSTG 2
74

CA 03193009 2023-02-24
WO 2022/046935
PCT/US2021/047600
DESCRIPTION SEQUENCE SEQ
ID NO:
FLAG DYKDDDDK 3
IL13op GPVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSINLT 147
AGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAG
QFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFN
(G45)x3 GGGGSGGGGSGGGGS 28
TGF-I3 scFv QVQLVQSGAEVKKPGSSVKVSCKASGYTFSSNVISWVR 11
QAPGQGLEWMGGVIPIVDIANYAQRFKGRVTITADEST
STTYMELSSLRSEDTAVYYCALPRAFVLDAMDYWGQG
TLVTVSSGGGGSGGGGSGGGGSETVLTQSPGTLSLSPG
ERATLSCRASQSLGSSYLAWYQQKPGQAPRLLIYGASS
RAPGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYA
DSPITFGQGTRLEIK
IgG4 hinge peptide ESKYGPPCPPCP 12
spacer
CD28 transmembrane MFWVLVVVGGVLACYSLLVTVAFIIFWV 6
domain
4-1BB co-stimulatory KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEG 7
GCEL
CD3 Zeta RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDK 8
RRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEI
GMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALP
PR
IL13Ra2-(G4S)x4- METDTLLLWVLLLWVPGSTGAGGSDYKDDDDKGGSG 149
TGF-I3.BBz PVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSINLTA
(MKleader¨FLAG- GMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQ
IL13op¨(G4S)x4¨TGF- FS SLHVRDTKIEVAQFVKDLLLHLKKLFREGRFNGGGG
0 scFv-IgG4 hinge SGGGGSGGGGSGGGGSQVQLVQSGAEVKKPGSSVKVS
peptide spacer-CD28 CKASGYTFSSNVISWVRQAPGQGLEWMGGVIPIVDIAN
transmembrane YAQRFKGRVTITADESTSTTYMELSSLRSEDTAVYYCA
domain-4-1BB Co- LPRAFVLDAMDYWGQGTLVTVSSGGGGSGGGGSGGG
stimulatory¨CD3 Zeta) GSETVLTQSPGTLSLSPGERATLSCRASQSLGSSYLAWY
QQKPGQAPRLLIYGASSRAPGIPDRFSGSGSGTDFTLTIS
RLEPEDFAVYYCQQYADSPITFGQGTRLEIKESKYGPPC
PPCPMFWVLVVVGGVLACYSLLVTVAFIIFWVKRGRK
KLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRV
KFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRR
GRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIG
MKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPP
R
MKleader METDTLLLWVLLLWVPGSTG 2
FLAG DYKDDDDK 3
IL13op GPVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSINLT 147
AGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAG
QFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFN
(G45)x4 GGGGSGGGGSGGGGSGGGGS 10
TGF-I3 scFv QVQLVQSGAEVKKPGSSVKVSCKASGYTFSSNVISWVR 11
QAPGQGLEWMGGVIPIVDIANYAQRFKGRVTITADEST
STTYMELSSLRSEDTAVYYCALPRAFVLDAMDYWGQG
TLVTVSSGGGGSGGGGSGGGGSETVLTQSPGTLSLSPG
ERATLSCRASQSLGSSYLAWYQQKPGQAPRLLIYGASS
RAPGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYA
DSPITFGQGTRLEIK

CA 03193009 2023-02-24
WO 2022/046935
PCT/US2021/047600
DESCRIPTION SEQUENCE SEQ
ID NO:
IgG4 hinge peptide ESKYGPPCPPCP 12
spacer
CD28 transmembrane MFWVLVVVGGVLACYSLLVTVAFIIFWV 6
domain
4-1BB co-stimulatory KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEG 7
GCEL
CD3 Zeta RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDK 8
RRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEI
GMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALP
PR
IL13Ra2-(G4S)x4- METDTLLLWVLLLWVPGSTGAGGSDYKDDDDKGGSG 150
EGFRvIII.BB z PVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSINLTA
(MKleader¨FLAG- GMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQ
IL13op¨(G4S)x4¨ FS SLHVRDTKIEVAQFVKDLLLHLKKLFREGRFNGGGG
EGFRvIII scFv-IgG4 SGGGGSGGGGSGGGGSEIQLVQSGAEVKKPGESLRISC
hinge peptide spacer KGSGFNIEDYYIHWVRQMPGKGLEWMGRIDPENDETK
transmembrane YGPIFQGHVTISADTSINTVYLQWSSLKASDTAMYYCA
domain-4-1BB Co- FRGGVYWGQGTTVTVSSGSTSGSGKPGSGEGSTKGDV
stimulatory¨CD3 Zeta) VMTQSPDSLAVSLGERATINCKSSQSLLDSDGKTYLNW
LQQKPGQPPKRLISLVSKLDSGVPDRFSGSGSGTDFTLTI
SSLQAEDVAVYYCWQGTHFPGTFGGGTKVEIKESKYG
PPCPPCPMFWVLVVVGGVLACYSLLVTVAFIIFWVKRG
RKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL
RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDK
RRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEI
GMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALP
PR
MKle ader METDTLLLWVLLLWVPGSTG 2
FLAG DYKDDDDK 3
IL13op GPVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSINLT 147
AGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAG
QFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFN
(G45)x4 GGGGSGGGGSGGGGSGGGGS 10
EGFRvIII scFv EIQLVQSGAEVKKPGESLRISCKGSGFNIEDYYIHWVRQ 27
MPGKGLEWMGRIDPENDETKYGPIFQGHVTISADTSIN
TVYLQWSSLKASDTAMYYCAFRGGVYWGQGTTVTVS
SGS TS GSGKPGS GEGSTKGDVVMT QSPD SLAVSLGERA
TINCKSSQSLLDSDGKTYLNWLQQKPGQPPKRLISLVSK
LDSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCWQG
THFPGTFGGGTKVEIK
IgG4 hinge peptide ESKYGPPCPPCP 12
spacer
CD28 transmembrane MFWVLVVVGGVLACYSLLVTVAFIIFWV 6
domain
4-1BB co-stimulatory KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEG 7
GCEL
CD3 Zeta RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDK 8
RRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEI
GMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALP
PR
76

CA 03193009 2023-02-24
WO 2022/046935
PCT/US2021/047600
DESCRIPTION SEQUENCE SEQ
ID NO:
IL13Ra2-(G4S)x4- METDTLLLWVLLLWVPGSTGAGGSDYKDDDDKGGSG 151
EGFRvIII.BB z PVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSINLTA
(MKleader¨FLAG- GMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQ
IL13op¨(G4S)x4¨ FS SLHVRDTKIEVAQFVKDLLLHLKKLFREGRFNGGGG
EGFRvIII scFv-IgG4 SGGGGSGGGGSGGGGSEIQLVQSGAEVKKPGESLRISC
hinge:IgG4 CH2 CH3 KGSGFNIEDYYIHWVRQMPGKGLEWMGRIDPENDETK
L235E N297Q peptide YGPIFQGHVTISADTSINTVYLQWSSLKASDTAMYYCA
spacer¨CD28 FRGGVYWGQGTTVTVSSGSTSGSGKPGSGEGSTKGDV
transmembrane VMTQSPDSLAVSLGERATINCKSS QSLLDSDGKTYLNW
domain-4-1BB Co- LQQKPGQPPKRLISLVSKLDSGVPDRFSGSGSGTDFTLTI
stimulatory¨CD3 Zeta) SSLQAEDVAVYYCWQGTHFPGTFGGGTKVEIKESKYG
PPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVV
VDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFQSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISK
AKGQPREPQVYTLPPS QEEMTKNQVSLTCLVKGFYPSD
IAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDK
SRWQEGNVFS CS VMHEALHNHYT QKS LSLS LGKMFW
VLVVVGGVLACYSLLVTVAFIIFWVKRGRKKLLYIFKQ
PFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSAD
APAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEM
GGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRR
GKGHDGLYQGLSTATKDTYDALHMQALPPR
MKle ader METDTLLLWVLLLWVPGSTG 2
FLAG DYKDDDDK 3
IL13op GPVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSINLT 147
AGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAG
QFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFN
(G45)x4 GGGGSGGGGSGGGGSGGGGS 10
EGFRvIII scFv EIQLVQSGAEVKKPGESLRISCKGSGFNIEDYYIHWVRQ 27
MPGKGLEWMGRIDPENDETKYGPIFQGHVTISADTSIN
TVYLQWSSLKASDTAMYYCAFRGGVYWGQGTTVTVS
SGS TS GSGKPGS GEGSTKGDVVMT QSPD SLAVSLGERA
TINCKSS QSLLDSDGKTYLNWLQQKPGQPPKRLISLVSK
LDSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCWQG
THFPGTFGGGTKVEIK
IgG4 hinge:IgG4 CH2 ESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPE 5
CH3 L235E N297Q VTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREE
peptide spacer QFQSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSS
IEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVK
GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSR
LTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG
K
CD28 transmembrane MFWVLVVVGGVLACYSLLVTVAFIIFWV 6
domain
4-1BB co-stimulatory KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEG 7
GCEL
CD3 Zeta RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDK 8
RRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEI
GMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALP
PR
77

CA 03193009 2023-02-24
WO 2022/046935
PCT/US2021/047600
DESCRIPTION SEQUENCE SEQ
ID NO:
IL13Ra2-(G4S)x4- METDTLLLWVLLLWVPGSTGAGGSDYKDDDDKGGSG 152
GD2. BB z (MKleader¨ PVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSINLTA
FLAG-IL13op¨ GMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQ
(G45)x4¨GD2 scFv- FSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFNGGGG
IgG4 hinge peptide SGGGGSGGGGSGGGGSEVQLLQSGPELEKPGASVMISC
spacer¨CD28 KASGSSFTGYNMNWVRQNIGKSLEWIGAIDPYYGGTS
transmembrane YNQKFKGRATLTVDKSSSTAYMHLKSLTSEDSAVYYC
domain-4-1BB co- VSGMEYWGQGTSVTVSSGSTSGSGKPGSGEGSTKGDV
stimulatory¨CD3 Zeta) VMTQTPLSLPVSLGDQASISCRSSQSLVHRNGNTYLHW
YLQKPGQSPKLLIHKVSNRFSGVPDRFSGSGSGTDFTLK
ISRVEAEDLGVYFC S QS THVPPLTFGAGTKLELKRAES K
YGPPCPPCPMFWVLVVVGGVLACYSLLVTVAFIIFWVK
RGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGG
CELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDV
LDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEA
YSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM
QALPPR
MKle ader METDTLLLWVLLLWVPGSTG 2
FLAG DYKDDDDK 3
IL13op GPVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSINLT 147
AGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAG
QFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFN
(G45)x4 GGGGSGGGGSGGGGSGGGGS 10
GD2 scFv EVQLLQSGPELEKPGASVMISCKASGSSFTGYNMNWV 26
RQNIGKSLEWIGAIDPYYGGTSYNQKFKGRATLTVDKS
SSTAYMHLKSLTSEDSAVYYCVSGMEYWGQGTSVTVS
SGS TS GSGKPGS GEGSTKGDVVMT QTPLSLPVSLGD QA
SIS CRS S QSLVHRNGNTYLHWYLQKPGQSPKLLIHKVS
NRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQS
THVPPLTFGAGTKLELKRA
IgG4 hinge peptide ESKYGPPCPPCP 12
spacer
CD28 transmembrane MFWVLVVVGGVLACYSLLVTVAFIIFWV 6
domain
4-1BB co-stimulatory KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEG 7
GCEL
CD3 Zeta RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDK 8
RRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEI
GMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALP
PR
78

CA 03193009 2023-02-24
WO 2022/046935
PCT/US2021/047600
DESCRIPTION SEQUENCE SEQ
ID NO:
IL13Ra2-(G4S)x4- METDTLLLWVLLLWVPGSTGAGGSDYKDDDDKGGSG 153
GD2.BBz (MKleader¨ PVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSINLTA
FLAG-IL13op¨ GMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQ
(G45)x4¨GD2 scFv- FSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFNGGGG
IgG4 hinge :IgG4 CH2 SGGGGSGGGGSGGGGSEVQLLQSGPELEKPGASVMISC
CH3 L235E N297Q KASGSSFTGYNMNWVRQNIGKSLEWIGAIDPYYGGTS
peptide spacer¨CD28 YNQKFKGRATLTVDKSSSTAYMHLKSLTSEDSAVYYC
transmembrane VSGMEYWGQGTSVTVSSGSTSGSGKPGSGEGSTKGDV
domain-4-1BB co- VMTQTPLSLPVSLGDQASISCRSSQSLVHRNGNTYLHW
stimulatory-CD3 Zeta) YLQKPGQSPKLLIHKVSNRFSGVPDRFSGSGSGTDFTLK
ISRVEAEDLGVYFCSQSTHVPPLTFGAGTKLELKRAESK
YGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTC
VVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFQ
STYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKT
ISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFY
PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTV
DKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKMF
WVLVVVGGVLACYSLLVTVAFIIFWVKRGRKKLLYIFK
QPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSA
DAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPE
MGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGER
RRGKGHDGLYQGLSTATKDTYDALHMQALPPR
MKleader METDTLLLWVLLLWVPGSTG 2
FLAG DYKDDDDK 3
IL13op GPVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSINLT 147
AGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAG
QFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFN
(G45)x4 GGGGSGGGGSGGGGSGGGGS 10
GD2 scFv EVQLLQSGPELEKPGASVMISCKASGSSFTGYNMNWV 26
RQNIGKSLEWIGAIDPYYGGTSYNQKFKGRATLTVDKS
SSTAYMHLKSLTSEDSAVYYCVSGMEYWGQGTSVTVS
SGSTSGSGKPGSGEGSTKGDVVMTQTPLSLPVSLGDQA
SISCRSSQSLVHRNGNTYLHWYLQKPGQSPKLLIHKVS
NRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQS
THVPPLTFGAGTKLELKRA
IgG4 hinge :IgG4 CH2 ESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPE 5
CH3 L235E N297Q VTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREE
peptide spacer QFQSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSS
IEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVK
GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSR
LTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG
K
CD28 transmembrane MFWVLVVVGGVLACYSLLVTVAFIIFWV 6
domain
4-1BB co-stimulatory KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEG 7
GCEL
CD3 Zeta RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDK 8
RRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEI
GMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALP
PR
79

CA 03193009 2023-02-24
WO 2022/046935
PCT/US2021/047600
DESCRIPTION SEQUENCE SEQ
ID NO:
IL13Ra2.BBz + TGF- METDTLLLWVLLLWVPGSTGAGGSDYKDDDDKGGSG 154
I3.28z (MKleader¨ PVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSINLTA
FLAG-IL13op-IgG4 GMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQ
hinge:IgG4 CH2 CH3 FSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFNESKY
L235E N297Q peptide GPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCV
spacer-CD28 VVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFQST
transmembrane YRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTIS
domain-4-1BB co- KAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPS
stimulatory- CD3 Zeta¨ DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVD
T2A¨MKleader¨HA¨ KSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKMF
TGF-I3 scFv¨IgG4 WVLVVVGGVLACYSLLVTVAFIIFWVKRGRKKLLYIFK
hinge peptide spacer¨ QPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSA
CD28 transmembrane DAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPE
domain¨CD28cyto MGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGER
(with gg mutations)¨ RRGKGHDGLYQGLSTATKDTYDALHMQALPPRLEGG
CD3 Zeta) GEGRGSLLTCGDVEENPGPRMETDTLLLWVLLLWVPG
STGTSYPYDVPDYAGGSQVQLVQSGAEVKKPGSSVKV
SCKASGYTFSSNVISWVRQAPGQGLEWMGGVIPIVDIA
NYAQRFKGRVTITADESTSTTYMELSSLRSEDTAVYYC
ALPRAFVLDAMDYWGQGTLVTVSSGGGGSGGGGSGG
GGSETVLTQSPGTLSLSPGERATLSCRASQSLGSSYLAW
YQQKPGQAPRLLIYGASSRAPGIPDRFSGSGSGTDFTLTI
SRLEPEDFAVYYCQQYADSPITFGQGTRLEIKESKYGPP
CPPCPMFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRS
RGGHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSG
GGRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVL
DKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAY
SEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQ
ALPPR
MKleader METDTLLLWVLLLWVPGSTG 2
FLAG DYKDDDDK 3
IL13op GPVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSINLT 147
AGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAG
QFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFN
IgG4 hinge:IgG4 CH2 ESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPE 5
CH3 L235E N297Q VTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREE
peptide spacer QFQSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSS
IEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVK
GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSR
LTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG
K
CD28 transmembrane MFWVLVVVGGVLACYSLLVTVAFIIFWV 6
domain
4-1BB co-stimulatory KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEG 7
GCEL
CD3 Zeta RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDK 8
RRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEI
GMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALP
PR
T2A EGRGSLLTCGDVEENPGPR 24
MKleader METDTLLLWVLLLWVPGSTG 2
HA YPYDVPDYA 122

CA 03193009 2023-02-24
WO 2022/046935
PCT/US2021/047600
DESCRIPTION SEQUENCE SEQ
ID NO:
TGF-I3 scFv QVQLVQSGAEVKKPGSSVKVSCKASGYTFSSNVISWVR 11
QAPGQGLEWMGGVIPIVDIANYAQRFKGRVTITADEST
STTYMELSSLRSEDTAVYYCALPRAFVLDAMDYWGQG
TLVTVSSGGGGSGGGGSGGGGSETVLTQSPGTLSLSPG
ERATLSCRASQSLGSSYLAWYQQKPGQAPRLLIYGASS
RAPGIPDRFS GS GSGTDFTLTISRLEPEDFAVYYC QQYA
DSPITFGQGTRLEIK
IgG4 hinge peptide ESKYGPPCPPCP 12
spacer
CD28 transmembrane MFWVLVVVGGVLACYSLLVTVAFIIFWV 6
domain
CD28cyto (with gg RS KRSRGGHSDYMNMTPRRPGPTRKHYQPYAPPRDFA 18
mutations) AYRS
CD3 Zeta RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDK 8
RRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEI
GMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALP
PR
IL13Ra2- METDTLLLWVLLLWVPGSTGAGGSDYKDDDDKGGSG 155
EGFRvIII.BB z + TGF- PVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSINLTA
I3.28z (MKleader¨ GMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQ
FLAG- IL13op¨ FS SLHVRDTKIEVAQFVKDLLLHLKKLFREGRFNGGGG
(G45)x4¨EGFRvIII SGGGGSGGGGSGGGGSEIQLVQSGAEVKKPGESLRISC
scFv-IgG4 hinge-CD28 KGSGFNIEDYYIHWVRQMPGKGLEWMGRIDPENDETK
transmembrane YGPIFQGHVTISADTSINTVYLQWSSLKASDTAMYYCA
domain-4-1BB co- FRGGVYWGQGTTVTVSSGSTSGSGKPGSGEGSTKGDV
stimulatory¨CD3 Zeta¨ VMTQSPDSLAVSLGERATINCKSSQSLLDSDGKTYLNW
T2A¨MKleader¨HA¨ LQQKPGQPPKRLISLVSKLDSGVPDRFSGSGSGTDFTLTI
TGF-I3 scFv¨IgG4 SSLQAEDVAVYYCWQGTHFPGTFGGGTKVEIKESKYG
hinge peptide spacer¨ PPCPPCPMFWVLVVVGGVLACYSLLVTVAFIIFWVKRG
CD28 transmembrane RKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL
domain¨CD28cyto RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDK
(with gg mutations)¨ RRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEI
CD3 Zeta) GMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALP
PRLEGGGEGRGSLLTCGDVEENPGPRMETDTLLLWVLL
LWVPGSTGTSYPYDVPDYAGGSQVQLVQSGAEVKKPG
SSVKVSCKASGYTFSSNVISWVRQAPGQGLEWMGGVIP
IVDIANYAQRFKGRVTITADESTSTTYMELSSLRSEDTA
VYYCALPRAFVLDAMDYWGQGTLVTVSSGGGGSGGG
GSGGGGSETVLTQSPGTLSLSPGERATLSCRASQSLGSS
YLAWYQQKPGQAPRLLIYGAS SRAPGIPD RFSGS GS GT
DFTLTISRLEPEDFAVYYCQQYADSPITFGQGTRLEIKES
KYGPPCPPCPMFWVLVVVGGVLACYSLLVTVAFIIFWV
RS KRSRGGHSDYMNMTPRRPGPTRKHYQPYAPPRDFA
AYRSGGGRVKFSRSADAPAYQQGQNQLYNELNLGRRE
EYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDK
MAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYD
ALHMQALPPR
MKle ader METDTLLLWVLLLWVPGSTG 2
FLAG DYKDDDDK 3
IL13op GPVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSINLT 147
AGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAG
QFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFN
81

CA 03193009 2023-02-24
WO 2022/046935
PCT/US2021/047600
DESCRIPTION SEQUENCE SEQ
ID NO:
(G45)x4 GGGGSGGGGSGGGGSGGGGS 10
EGFRvIII scFv EIQLVQSGAEVKKPGESLRISCKGSGFNIEDYYIHWVRQ 27
MPGKGLEWMGRIDPENDETKYGPIFQGHVTISADTSIN
TVYLQWSSLKASDTAMYYCAFRGGVYWGQGTTVTVS
SGSTSGSGKPGSGEGSTKGDVVMTQSPDSLAVSLGERA
TINCKSSQSLLDSDGKTYLNWLQQKPGQPPKRLISLVSK
LDSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCWQG
THFPGTFGGGTKVEIK
IgG4 hinge ESKYGPPCPPCP 12
CD28 transmembrane MFWVLVVVGGVLACYSLLVTVAFIIFWV 6
domain
4-1BB co-stimulatory KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEG 7
GCEL
CD3 Zeta RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDK 8
RRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEI
GMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALP
PR
T2A EGRGSLLTCGDVEENPGPR 24
MKleader METDTLLLWVLLLWVPGSTG 2
HA YPYDVPDYA 122
TGF-I3 scFv QVQLVQSGAEVKKPGSSVKVSCKASGYTFSSNVISWVR 11
QAPGQGLEWMGGVIPIVDIANYAQRFKGRVTITADEST
STTYMELSSLRSEDTAVYYCALPRAFVLDAMDYWGQG
TLVTVSSGGGGSGGGGSGGGGSETVLTQSPGTLSLSPG
ERATLSCRASQSLGSSYLAWYQQKPGQAPRLLIYGASS
RAPGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYA
DSPITFGQGTRLEIK
IgG4 hinge peptide ESKYGPPCPPCP 12
spacer
CD28 transmembrane MFWVLVVVGGVLACYSLLVTVAFIIFWV 6
domain
CD28cyto (with gg RSKRSRGGHSDYMNMTPRRPGPTRKHYQPYAPPRDFA 18
mutations) AYRS
CD3 Zeta RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDK 8
RRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEI
GMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALP
PR
82

CA 03193009 2023-02-24
WO 2022/046935
PCT/US2021/047600
DESCRIPTION SEQUENCE SEQ
ID NO:
IL13Ra2-GD2.BB z + METDTLLLWVLLLWVPGSTGAGGSDYKDDDDKGGSG 156
TGF-I3.28z (MKleader¨ PVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSINLTA
FLAG-IL13op¨ GMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQ
(G45)x4¨GD2 scFv- FSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFNGGGG
IgG4 hinge:IgG4 CH2 SGGGGSGGGGSGGGGSEVQLLQSGPELEKPGASVMISC
CH3 L235E N297Q KASGSSFTGYNMNWVRQNIGKSLEWIGAIDPYYGGTS
peptide spacer¨CD28 YNQKFKGRATLTVDKSSSTAYMHLKSLTSEDSAVYYC
transmembrane VSGMEYWGQGTSVTVSSGSTSGSGKPGSGEGSTKGDV
domain-4-1BB co- VMTQTPLSLPVSLGDQASISCRSSQSLVHRNGNTYLHW
stimulatory-CD3 Zeta¨ YLQKPGQSPKLLIHKVSNRFSGVPDRFSGSGSGTDFTLK
T2A¨MKleader¨HA¨ ISRVEAEDLGVYFC S QS THVPPLTFGAGTKLELKRAES K
TGF-I3 scFv¨IgG4 YGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTC
hinge peptide spacer¨ VVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFQ
CD28 transmembrane STYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKT
domain¨CD28cyto ISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFY
(with gg mutations)¨ PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTV
CD3 Zeta) DKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKMF
WVLVVVGGVLACYSLLVTVAFIIFWVKRGRKKLLYIFK
QPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSA
DAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPE
MGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGER
RRGKGHDGLYQGLSTATKDTYDALHMQALPPRLEGG
GEGRGSLLTCGDVEENPGPRMETDTLLLWVLLLWVPG
STGT SYPYDVPDYAGGS QV QLVQS GAEVKKPGS SVKV
SCKASGYTFSSNVISWVRQAPGQGLEWMGGVIPIVDIA
NYAQRFKGRVTITADESTSTTYMELSSLRSEDTAVYYC
ALPRAFVLDAMDYWGQGTLVTVSSGGGGSGGGGSGG
GGSETVLTQSPGTLSLSPGERATLSCRASQSLGSSYLAW
YQQKPGQAPRLLIYGAS SRAPGIPDRFS GS GSGTDFTLTI
SRLEPEDFAVYYCQQYADSPITFGQGTRLEIKESKYGPP
CPPCPMFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRS
RGGHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSG
GGRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVL
DKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAY
SEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQ
ALPPR
MKle ader METDTLLLWVLLLWVPGSTG 2
FLAG DYKDDDDK 3
IL13op GPVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSINLT 147
AGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAG
QFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFN
(G45)x4 GGGGSGGGGSGGGGSGGGGS 10
GD2 scFv EVQLLQSGPELEKPGASVMISCKASGSSFTGYNMNWV 26
RQNIGKSLEWIGAIDPYYGGTSYNQKFKGRATLTVDKS
SSTAYMHLKSLTSEDSAVYYCVSGMEYWGQGTSVTVS
SGS TS GSGKPGS GEGSTKGDVVMT QTPLSLPVSLGD QA
SIS CRS S QSLVHRNGNTYLHWYLQKPGQSPKLLIHKVS
NRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQS
THVPPLTFGAGTKLELKRA
83

CA 03193009 2023-02-24
WO 2022/046935
PCT/US2021/047600
DESCRIPTION SEQUENCE SEQ
ID NO:
IgG4 hinge :IgG4 CH2 ESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPE 5
CH3 L235E N297Q VTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREE
peptide spacer QFQSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSS
IEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVK
GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSR
LTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG
K
CD28 transmembrane MFWVLVVVGGVLACYSLLVTVAFIIFWV 6
domain
4-1BB co-stimulatory KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEG 7
GCEL
CD3 Zeta RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDK 8
RRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEI
GMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALP
PR
T2A EGRGSLLTCGDVEENPGPR 24
MKleader METDTLLLWVLLLWVPGSTG 2
HA YPYDVPDYA 122
TGF-I3 scFv QVQLVQSGAEVKKPGSSVKVSCKASGYTFSSNVISWVR 11
QAPGQGLEWMGGVIPIVDIANYAQRFKGRVTITADEST
STTYMELSSLRSEDTAVYYCALPRAFVLDAMDYWGQG
TLVTVSSGGGGSGGGGSGGGGSETVLTQSPGTLSLSPG
ERATLSCRASQSLGSSYLAWYQQKPGQAPRLLIYGASS
RAPGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYA
DSPITFGQGTRLEIK
IgG4 hinge peptide ESKYGPPCPPCP 12
spacer
CD28 transmembrane MFWVLVVVGGVLACYSLLVTVAFIIFWV 6
domain
CD28cyto (with gg RSKRSRGGHSDYMNMTPRRPGPTRKHYQPYAPPRDFA 18
mutations) AYRS
CD3 Zeta RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDK 8
RRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEI
GMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALP
PR
84

CA 03193009 2023-02-24
WO 2022/046935
PCT/US2021/047600
DESCRIPTION SEQUENCE SEQ
ID NO:
IL13Ra2-GD2-TGF- METDTLLLWVLLLWVPGSTGAGGSDYKDDDDKGGSG 157
I3.BBz (MKleader¨ PVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSINLTA
FLAG-IL13op¨ GMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQ
(G45)x4¨GD2 scFv- FSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFNGGGG
(G45)x4¨TGF-13 scFv¨ SGGGGSGGGGSGGGGSEVQLLQSGPELEKPGASVMISC
IgG4 hinge peptide KASGSSFTGYNMNWVRQNIGKSLEWIGAIDPYYGGTS
spacer ¨CD28 YNQKFKGRATLTVDKSSSTAYMHLKSLTSEDSAVYYC
transmembrane VSGMEYWGQGTSVTVSSGSTSGSGKPGSGEGSTKGDV
domain-4-1BB co- VMTQTPLSLPVSLGDQASISCRSSQSLVHRNGNTYLHW
stimulatory-CD3 Zeta) YLQKPGQSPKLLIHKVSNRFSGVPDRFSGSGSGTDFTLK
ISRVEAEDLGVYFCSQSTHVPPLTFGAGTKLELKRAGG
GGSGGGGS GGGGS GGGGS QV QLVQS GAEVKKPGS SV K
VSCKASGYTFSSNVISWVRQAPGQGLEWMGGVIPIVDI
ANYAQRFKGRVTITADESTSTTYMELSSLRSEDTAVYY
CALPRAFVLDAMDYWGQGTLVTVSSGGGGSGGGGSG
GGGSETVLTQSPGTLSLSPGERATLSCRASQSLGSSYLA
WYQQKPGQAPRLLIYGASSRAPGIPDRFSGSGSGTDFTL
TISRLEPEDFAVYYCQQYADSPITFGQGTRLEIKESKYG
PPCPPCPMFWVLVVVGGVLACYSLLVTVAFIIFWVKRG
RKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL
RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDK
RRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEI
GMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALP
PR
MKle ader METDTLLLWVLLLWVPGSTG 2
FLAG DYKDDDDK 3
IL13op GPVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSINLT 147
AGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAG
QFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFN
(G45)x4 GGGGSGGGGSGGGGSGGGGS 10
GD2 scFv EVQLLQSGPELEKPGASVMISCKASGSSFTGYNMNWV 26
RQNIGKSLEWIGAIDPYYGGTSYNQKFKGRATLTVDKS
SSTAYMHLKSLTSEDSAVYYCVSGMEYWGQGTSVTVS
SGS TS GSGKPGS GEGSTKGDVVMT QTPLSLPVSLGD QA
SIS CRS S QSLVHRNGNTYLHWYLQKPGQSPKLLIHKVS
NRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQS
THVPPLTFGAGTKLELKRA
(G45)x4 GGGGSGGGGSGGGGSGGGGS 10
TGF-I3 scFv QVQLVQSGAEVKKPGSSVKVSCKASGYTFSSNVISWVR 11
QAPGQGLEWMGGVIPIVDIANYAQRFKGRVTITADEST
STTYMELSSLRSEDTAVYYCALPRAFVLDAMDYWGQG
TLVTVSSGGGGSGGGGSGGGGSETVLTQSPGTLSLSPG
ERATLSCRASQSLGSSYLAWYQQKPGQAPRLLIYGASS
RAPGIPDRFS GS GSGTDFTLTISRLEPEDFAVYYC QQYA
DSPITFGQGTRLEIK
IgG4 hinge peptide ESKYGPPCPPCP 12
spacer
CD28 transmembrane MFWVLVVVGGVLACYSLLVTVAFIIFWV 6
domain
4-1BB co-stimulatory KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEG 7
GCEL

CA 03193009 2023-02-24
WO 2022/046935
PCT/US2021/047600
DESCRIPTION SEQUENCE SEQ
ID NO:
CD3 Zeta RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDK 8
RRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEI
GMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALP
PR
IL13Ra2-EGFRvIII- METDTLLLWVLLLWVPGSTGAGGSDYKDDDDKGGSG 158
TGF-I3.BBz PVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSINLTA
(MKleader¨FLAG- GMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQ
IL13op¨(G4S)x4¨ FS SLHVRDTKIEVAQFVKDLLLHLKKLFREGRFNGGGG
EGFRvIII scFv- SGGGGSGGGGSGGGGSEIQLVQSGAEVKKPGESLRISC
(G45)x4¨TGF-I3 scFv¨ KGSGFNIEDYYIHWVRQMPGKGLEWMGRIDPENDETK
IgG4 hinge peptide YGPIFQGHVTISADTSINTVYLQWSSLKASDTAMYYCA
spacer¨CD28 FRGGVYWGQGTTVTVSSGSTSGSGKPGSGEGSTKGDV
transmembrane VMTQSPD SLAV SLGERATINCKS S QSLLDSDGKTYLNW
domain- 4-1BB co- LQQKPGQPPKRLISLVSKLDSGVPDRFSGSGSGTDFTLTI
stimulatory-CD3 Zeta) SSLQAEDVAVYYCWQGTHFPGTFGGGTKVEIKGGGGS
GGGGSGGGGSGGGGS QVQLV QSGAEVKKPGS SVKV SC
KASGYTFSSNVISWVRQAPGQGLEWMGGVIPIVDIANY
AQRFKGRVTITADESTSTTYMELSSLRSEDTAVYYCAL
PRAFVLDAMDYWGQGTLVTVSSGGGGSGGGGSGGGG
SETVLTQSPGTLSLSPGERATLSCRASQSLGSSYLAWYQ
QKPGQAPRLLIYGASSRAPGIPDRFSGSGSGTDFTLTISR
LEPEDFAVYYCQQYADSPITFGQGTRLEIKESKYGPPCP
PCPMFWVLVVVGGVLACYSLLVTVAFIIFWVKRGRKK
LLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVK
FSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRG
RDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGM
KGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
MKle ader METDTLLLWVLLLWVPGSTG 2
FLAG DYKDDDDK 3
IL13op GPVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSINLT 147
AGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAG
QFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFN
(G45)x4 GGGGSGGGGSGGGGSGGGGS 10
EGFRvIII scFv EIQLVQSGAEVKKPGESLRISCKGSGFNIEDYYIHWVRQ 27
MPGKGLEWMGRIDPENDETKYGPIFQGHVTISADTSIN
TVYLQWSSLKASDTAMYYCAFRGGVYWGQGTTVTVS
SGS TS GSGKPGS GEGSTKGDVVMT QSPD SLAVSLGERA
TINCKSSQSLLDSDGKTYLNWLQQKPGQPPKRLISLVSK
LDSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCWQG
THFPGTFGGGTKVEIK
(G45)x4 GGGGSGGGGSGGGGSGGGGS 10
TGF-I3 scFv QVQLVQSGAEVKKPGSSVKVSCKASGYTFSSNVISWVR 11
QAPGQGLEWMGGVIPIVDIANYAQRFKGRVTITADEST
STTYMELSSLRSEDTAVYYCALPRAFVLDAMDYWGQG
TLVTVSSGGGGSGGGGSGGGGSETVLTQSPGTLSLSPG
ERATLSCRASQSLGSSYLAWYQQKPGQAPRLLIYGASS
RAPGIPDRFS GS GSGTDFTLTISRLEPEDFAVYYC QQYA
DSPITFGQGTRLEIK
IgG4 hinge peptide ESKYGPPCPPCP 12
spacer
CD28 transmembrane MFWVLVVVGGVLACYSLLVTVAFIIFWV 6
domain
86

CA 03193009 2023-02-24
WO 2022/046935
PCT/US2021/047600
DESCRIPTION SEQUENCE SEQ
ID NO:
4-1BB co-stimulatory KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEG 7
GCEL
CD3 Zeta RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDK 8
RRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEI
GMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALP
PR
SP-IL -13Ra2.B B z METDTLLLWVLLLWVPGSTGAGGSDYKDDDDKGGSS 1
CAR; (Murine kappa PGPVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSINL
signal TAGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSA
sequence_FLAG_SP GQFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFNES
IL13 mutein_IgG4 KYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVT
(L235E, CVVVDVS QEDPEVQFNWYVDGVEVHNAKTKPREEQF
N297 Q)_CD28tm_4- QSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE
1BB_CD3zeta) KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKG
FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRL
TVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
MFWVLVVVGGVLACYSLLVTVAFIIFWVKRGRKKLLY
IFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSR
SADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDP
EMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGE
RRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
SP-IL-13Ra2.BBz METDTLLLWVLLLWVSPGSTGSPGPVPPSTALRYLIEEL 136
CAR; (Murine kappa VNITQNQKAPLCNGSMVWSINLTAGMYCAALESLINVS
signal sequence_SP GCS AIEKT QRMLS GFCPHKV SAGQFS S LHVRDTKIEVA
IL13 mutein_IgG4 QFVKDLLLHLKKLFREGRFNESKYGPPCPPCPAPEFEGG
(L235E, PSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFN
N297 Q)_CD28tm_4- WYVDGVEVHNAKTKPREEQFQSTYRVVSVLTVLHQD
1BB_CD3zeta) WLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYT
LPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE
NNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCS
VMHEALHNHYTQKSLSLSLGKMFWVLVVVGGVLACY
SLLVTVAFIIFWVKRGRKKLLYIFKQPFMRPVQTTQEED
GCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYN
ELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLY
NELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLST
ATKDTYDALHMQALPPR
MK signal sequence METDTLLLWVLLLWVPGSTG 2
FLAG DYKDDDDK 3
SP IL13 mutein SPGPVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSIN 4
LTAGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVS
AGQFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFN
IgG4 (L235E, N297Q) ESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPE 5
VTCVVVDVS QEDPEVQFNWYVDGVEVHNAKTKPREE
QFQSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSS
IEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVK
GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSR
LTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG
K
CD28 transmembrane MFWVLVVVGGVLACYSLLVTVAFIIFWV 6
domain
4-1BB co-stimulatory KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEG 7
GCEL
87

CA 03193009 2023-02-24
WO 2022/046935
PCT/US2021/047600
DESCRIPTION SEQUENCE SEQ
ID NO:
CD3 Zeta RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDK 8
RRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEI
GMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALP
PR
SP-IL-13Ra2/TGF- METDTLLLWVLLLWVPGSTGAGGSDYKDDDDKGGSS 9
I3.BBz CAR; (Murine PGPVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSINL
kappa signal TAGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSA
sequence_FLAG_SP GQFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFNGG
IL13 GGSGGGGSGGGGSGGGGSQVQLVQSGAEVKKPGSSVK
mutein_(G45)x4_TGF- VSCKASGYTFSSNVISWVRQAPGQGLEWMGGVIPIVDI
0 scFv_IgG4 ANYAQRFKGRVTITADESTSTTYMELSSLRSEDTAVYY
hinge_CD28tm_4- CALPRAFVLDAMDYWGQGTLVTVSSGGGGSGGGGSG
1BB_CD3zeta) GGGSETVLTQSPGTLSLSPGERATLSCRASQSLGSSYLA
WYQQKPGQAPRLLIYGASSRAPGIPDRFSGSGSGTDFTL
TISRLEPEDFAVYYCQQYADSPITFGQGTRLEIKESKYG
PPCPPCPMFWVLVVVGGVLACYSLLVTVAFIIFWVKRG
RKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL
RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDK
RRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEI
GMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALP
PR
SP-IL-13Ra2/TGF- METDTLLLWVLLLWVPGSTGSPGPVPPSTALRYLIEEL 137
I3.BBz CAR; (Murine VNITQNQKAPLCNGSMVWSINLTAGMYCAALESLINVS
kappa signal sequence_ GCSAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTKIEVA
SP IL13 QFVKDLLLHLKKLFREGRFNGGGGSGGGGSGGGGSGG
mutein_(G45)x4_TGF- GGSQVQLVQSGAEVKKPGSSVKVSCKASGYTFSSNVIS
0 scFv_IgG4 WVRQAPGQGLEWMGGVIPIVDIANYAQRFKGRVTITA
hinge_CD28tm_4- DESTSTTYMELSSLRSEDTAVYYCALPRAFVLDAMDY
1BB_CD3zeta) WGQGTLVTVSSGGGGSGGGGSGGGGSETVLTQSPGTL
SLSPGERATLSCRASQSLGSSYLAWYQQKPGQAPRLLI
YGASSRAPGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC
QQYADSPITFGQGTRLEIKESKYGPPCPPCPMFWVLVV
VGGVLACYSLLVTVAFIIFWVKRGRKKLLYIFKQPFMR
PVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAY
QQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKP
RRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKG
HDGLYQGLSTATKDTYDALHMQALPPR
MK signal sequence METDTLLLWVLLLWVPGSTG 2
FLAG DYKDDDDK 3
SP IL13 mutein SPGPVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSIN 4
LTAGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVS
AGQFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFN
(G45)x4 GGGGSGGGGSGGGGSGGGGS 10
TGF-I3 scFv QVQLVQSGAEVKKPGSSVKVSCKASGYTFSSNVISWVR 11
QAPGQGLEWMGGVIPIVDIANYAQRFKGRVTITADEST
STTYMELSSLRSEDTAVYYCALPRAFVLDAMDYWGQG
TLVTVSSGGGGSGGGGSGGGGSETVLTQSPGTLSLSPG
ERATLSCRASQSLGSSYLAWYQQKPGQAPRLLIYGASS
RAPGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYA
DSPITFGQGTRLEIK
IgG4 hinge ESKYGPPCPPCP 12
88

CA 03193009 2023-02-24
WO 2022/046935
PCT/US2021/047600
DESCRIPTION SEQUENCE SEQ
ID NO:
CD28 transmembrane MFWVLVVVGGVLACYSLLVTVAFIIFWV 6
domain
4-1BB co-stimulatory KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEG 7
GCEL
CD3 Zeta RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDK 8
RRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEI
GMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALP
PR
SP-IL -13Ra2.B B z METDTLLLWVLLLWVPGSTGAGGSDYKDDDDKGGSS 13
(KR) CAR; (Murine PGPVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSINL
kappa signal TAGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSA
sequence_FLAG_SP GQFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFNES
IL13 mutein_IgG4 KYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVT
(L235E, CVVVDVS QEDPEVQFNWYVDGVEVHNAKTKPREEQF
N297 Q)_CD28tm_4- QSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE
1B B (KR)_CD3zeta(KR KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKG
)) FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRL
TVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
MFWVLVVVGGVLACYSLLVTVAFIIFWVRRGRRRLLYI
FRQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVRFSRS
ADAPAYQQGQNQLYNELNLGRREEYDVLDRRRGRDPE
MGGRPRRRNPQEGLYNELQRDRMAEAYSEIGMRGERR
RGRGHDGLYQGLSTATRDTYDALHMQALPPR
SP-IL-13Ra2.BBz METDTLLLWVLLLWVPGSTGSPGPVPPSTALRYLIEEL 138
(KR) CAR; (Murine VNITQNQKAPLCNGSMVWSINLTAGMYCAALESLINVS
kappa signal sequence_ GCSAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTKIEVA
SP IL13 mutein_IgG4 QFVKDLLLHLKKLFREGRFNESKYGPPCPPCPAPEFEGG
(L235E, PSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFN
N297 Q)_CD28tm_4- WYVDGVEVHNAKTKPREEQFQSTYRVVSVLTVLHQD
1B B (KR)_CD3zeta(KR WLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYT
)) LPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE
NNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCS
VMHEALHNHYTQKSLSLSLGKMFWVLVVVGGVLACY
SLLVTVAFIIFWVRRGRRRLLYIFRQPFMRPVQTTQEED
GCSCRFPEEEEGGCELRVRFSRSADAPAYQQGQNQLYN
ELNLGRREEYDVLDRRRGRDPEMGGRPRRRNPQEGLY
NELQRDRMAEAYSEIGMRGERRRGRGHDGLYQGLSTA
TRDTYDALHMQALPPR
MK signal sequence METDTLLLWVLLLWVPGSTG 2
FLAG DYKDDDDK 3
SP IL13 mutein SPGPVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSIN 4
LTAGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVS
AGQFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFN
IgG4 (L235E, N297Q) ESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPE 5
VTCVVVDVS QEDPEVQFNWYVDGVEVHNAKTKPREE
QFQSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSS
IEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVK
GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSR
LTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG
K
CD28 transmembrane MFWVLVVVGGVLACYSLLVTVAFIIFWV 6
domain
89

CA 03193009 2023-02-24
WO 2022/046935
PCT/US2021/047600
DESCRIPTION SEQUENCE SEQ
ID NO:
4-1BB (KR) co- RRGRRRLLYIFRQPFMRPVQTTQEEDGCSCRFPEEEEGG 14
stimulatory CEL
CD3 Zeta(KR) RVRFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDR 15
RRGRDPEMGGRPRRRNPQEGLYNELQRDRMAEAYSEI
GMRGERRRGRGHDGLYQGLSTATRDTYDALHMQALP
PR
SP-IL -13Ra2/TGF- METDTLLLWVLLLWVPGSTGAGGSDYKDDDDKGGSS 16
I3.BBz (KR) CAR; PGPVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSINL
(Murine kappa signal TAGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSA
sequence_FLAG_SP GQFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFNGG
IL13 GGSGGGGS GGGGS GGGGS QV QLVQS GAEVKKPGS SV K
mutein_(G45)x4_TGF- VSCKASGYTFSSNVISWVRQAPGQGLEWMGGVIPIVDI
0 scFv_IgG4 ANYAQRFKGRVTITADESTSTTYMELSSLRSEDTAVYY
hinge_CD28tm_4- CALPRAFVLDAMDYWGQGTLVTVSSGGGGSGGGGSG
1B B (KR)_CD3zeta(KR GGGSETVLTQS PGTLS LS PGERATLS CRAS QS LGS S YLA
)) WYQQKPGQAPRLLIYGASSRAPGIPDRFSGSGSGTDFTL
TISRLEPEDFAVYYCQQYADSPITFGQGTRLEIKESKYG
PPCPPCPMFWVLVVVGGVLACYSLLVTVAFIIFWVRRG
RRRLLYIFRQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL
RVRFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDR
RRGRDPEMGGRPRRRNPQEGLYNELQRDRMAEAYSEI
GMRGERRRGRGHDGLYQGLSTATRDTYDALHMQALP
PR
SP-IL -13Ra2/TGF- METDTLLLWVLLLWVPGSTGSPGPVPPSTALRYLIEEL 139
I3.BBz (KR) CAR; VNITQNQKAPLCNGSMVWSINLTAGMYCAALESLINVS
(Murine kappa signal GCSAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTKIEVA
sequence_SP IL13 QFVKDLLLHLKKLFREGRFNGGGGSGGGGSGGGGSGG
mutein_(G45)x4_TGF- GGSQVQLVQSGAEVKKPGSSVKVSCKASGYTFSSNVIS
0 scFv_IgG4 WVRQAPGQGLEWMGGVIPIVDIANYAQRFKGRVTITA
hinge_CD28tm_4- DESTSTTYMELSSLRSEDTAVYYCALPRAFVLDAMDY
1B B (KR)_CD3zeta(KR WGQGTLVTVS SGGGGSGGGGS GGGGS ETVLT QS PGTL
)) SLSPGERATLSCRASQSLGSSYLAWYQQKPGQAPRLLI
YGASSRAPGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC
QQYADSPITFGQGTRLEIKESKYGPPCPPCPMFWVLVV
VGGVLACYSLLVTVAFIIFWVRRGRRRLLYIFRQPFMRP
VQTTQEEDGCSCRFPEEEEGGCELRVRFSRSADAPAYQ
QGQNQLYNELNLGRREEYDVLDRRRGRDPEMGGRPRR
RNPQEGLYNELQRDRMAEAYSEIGMRGERRRGRGHDG
LYQGLSTATRDTYDALHMQALPPR
MK signal sequence METDTLLLWVLLLWVPGSTG 2
FLAG DYKDDDDK 3
SP IL13 mutein SPGPVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSIN 4
LTAGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVS
AGQFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFN
(G45)x4 GGGGSGGGGSGGGGSGGGGS 10
TGF-I3 scFv QVQLVQSGAEVKKPGSSVKVSCKASGYTFSSNVISWVR 11
QAPGQGLEWMGGVIPIVDIANYAQRFKGRVTITADEST
STTYMELSSLRSEDTAVYYCALPRAFVLDAMDYWGQG
TLVTVS SGGGGS GGGGS GGGGSETVLTQS PGTLSLS PG
ERATLSCRAS QSLGSSYLAWYQQKPGQAPRLLIYGASS
RAPGIPDRFS GS GSGTDFTLTIS RLEPEDFAVYYC QQYA
DSPITFGQGTRLEIK

CA 03193009 2023-02-24
WO 2022/046935
PCT/US2021/047600
DESCRIPTION SEQUENCE SEQ
ID NO:
IgG4 hinge ESKYGPPCPPCP 12
CD28 transmembrane MFWVLVVVGGVLACYSLLVTVAFIIFWV 6
domain
4-1BB (KR) co- RRGRRRLLYIFRQPFMRPVQTTQEEDGCSCRFPEEEEGG 14
stimulatory CEL
CD3zeta(KR) RVRFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDR 15
RRGRDPEMGGRPRRRNPQEGLYNELQRDRMAEAYSEI
GMRGERRRGRGHDGLYQGLSTATRDTYDALHMQALP
PR
SP-IL -13Ra2.28z METDTLLLWVLLLWVPGSTGAGGSDYKDDDDKGGSS 17
CAR; (Murine kappa PGPVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSINL
signal TAGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSA
sequence_FLAG_SP GQFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFNES
IL13 mutein_IgG4 KYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVT
(L235E, CVVVDVS QEDPEVQFNWYVDGVEVHNAKTKPREEQF
N297 Q)_CD28tm_CD2 QSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE
8cyto_CD3zeta) KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKG
FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRL
TVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
MFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRGGH
SDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSGGGRV
KFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRR
GRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIG
MKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPP
R
SP-IL-13Ra2.28z METDTLLLWVLLLWVPGSTGSPGPVPPSTALRYLIEEL 140
CAR; (Murine kappa VNITQNQKAPLCNGSMVWSINLTAGMYCAALESLINVS
signal sequence_ SP GCSAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTKIEVA
IL13 mutein_IgG4 QFVKDLLLHLKKLFREGRFNESKYGPPCPPCPAPEFEGG
(L235E, PSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFN
N297 Q)_CD28tm_CD2 WYVDGVEVHNAKTKPREEQFQSTYRVVSVLTVLHQD
8cyto_CD3zeta) WLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYT
LPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE
NNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCS
VMHEALHNHYTQKSLSLSLGKMFWVLVVVGGVLACY
SLLVTVAFIIFWVRSKRSRGGHSDYMNMTPRRPGPTRK
HYQPYAPPRDFAAYRSGGGRVKFSRSADAPAYQQGQN
QLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQ
EGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQ
GLSTATKDTYDALHMQALPPR
MK signal sequence METDTLLLWVLLLWVPGSTG 2
FLAG DYKDDDDK 3
SP IL13 mutein SPGPVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSIN 4
LTAGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVS
AGQFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFN
IgG4 (L235E, N297Q) ESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPE 5
VTCVVVDVS QEDPEVQFNWYVDGVEVHNAKTKPREE
QFQSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSS
IEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVK
GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSR
LTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG
K
91

CA 03193009 2023-02-24
WO 2022/046935
PCT/US2021/047600
DESCRIPTION SEQUENCE SEQ
ID NO:
CD28tm MFWVLVVVGGVLACYSLLVTVAFIIFWV 6
CD28cyto RSKRSRGGHSDYMNMTPRRPGPTRKHYQPYAPPRDFA 18
AYRS
CD3zeta RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDK 8
RRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEI
GMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALP
PR
SP-IL-13Ra2/TGF- METDTLLLWVLLLWVPGSTGAGGSDYKDDDDKGGSS 25
I3.28z CAR; (Murine PGPVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSINL
kappa signal TAGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSA
sequence_FLAG_SP GQFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFNGG
IL13 GGSGGGGSGGGGSGGGGSQVQLVQSGAEVKKPGSSVK
mutein_(G45)x4_TGF- VSCKASGYTFSSNVISWVRQAPGQGLEWMGGVIPIVDI
0 scFv_IgG4 ANYAQRFKGRVTITADESTSTTYMELSSLRSEDTAVYY
hinge_CD28tm_ CALPRAFVLDAMDYWGQGTLVTVSSGGGGSGGGGSG
CD28cyto_CD3zeta) GGGSETVLTQSPGTLSLSPGERATLSCRASQSLGSSYLA
WYQQKPGQAPRLLIYGASSRAPGIPDRFSGSGSGTDFTL
TISRLEPEDFAVYYCQQYADSPITFGQGTRLEIKESKYG
PPCPPCPMFWVLVVVGGVLACYSLLVTVAFIIFWVRSK
RSRGGHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYR
SGGGRVKFSRSADAPAYQQGQNQLYNELNLGRREEYD
VLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAE
AYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALH
MQALPPR
SP-IL-13Ra2/TGF- METDTLLLWVLLLWVPGSTGSPGPVPPSTALRYLIEEL 141
I3.28z CAR; (Murine VNITQNQKAPLCNGSMVWSINLTAGMYCAALESLINVS
kappa signal sequence_ GCSAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTKIEVA
SP IL13 QFVKDLLLHLKKLFREGRFNGGGGSGGGGSGGGGSGG
mutein_(G45)x4_TGF- GGSQVQLVQSGAEVKKPGSSVKVSCKASGYTFSSNVIS
0 scFv_IgG4 WVRQAPGQGLEWMGGVIPIVDIANYAQRFKGRVTITA
hinge_CD28tm_ DESTSTTYMELSSLRSEDTAVYYCALPRAFVLDAMDY
CD28cyto_CD3zeta WGQGTLVTVSSGGGGSGGGGSGGGGSETVLTQSPGTL
SLSPGERATLSCRASQSLGSSYLAWYQQKPGQAPRLLI
YGASSRAPGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC
QQYADSPITFGQGTRLEIKESKYGPPCPPCPMFWVLVV
VGGVLACYSLLVTVAFIIFWVRSKRSRGGHSDYMNMT
PRRPGPTRKHYQPYAPPRDFAAYRSGGGRVKFSRSADA
PAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMG
GKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRG
KGHDGLYQGLSTATKDTYDALHMQALPPR
MK signal sequence METDTLLLWVLLLWVPGST 2
FLAG DYKDDDDK 3
SP IL13 mutein SPGPVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSIN 4
LTAGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVS
AGQFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFN
(G45)x4 GGGGSGGGGSGGGGSGGGGS 10
TGF-I3 scFv QVQLVQSGAEVKKPGSSVKVSCKASGYTFSSNVISWVR 11
QAPGQGLEWMGGVIPIVDIANYAQRFKGRVTITADEST
STTYMELSSLRSEDTAVYYCALPRAFVLDAMDYWGQG
TLVTVSSGGGGSGGGGSGGGGSETVLTQSPGTLSLSPG
ERATLSCRASQSLGSSYLAWYQQKPGQAPRLLIYGASS
92

CA 03193009 2023-02-24
WO 2022/046935
PCT/US2021/047600
DESCRIPTION SEQUENCE SEQ
ID NO:
RAPGIPDRFS GS GSGTDFTLTIS RLEPEDFAVYYC QQYA
DSPITFGQGTRLEIK
IgG4 hinge ESKYGPPCPPCP 12
CD28tm MFWVLVVVGGVLACYSLLVTVAFIIFWV 6
CD28cyto RS KRSRGGHSDYMNMTPRRPGPTRKHYQPYAPPRDFA 18
AYRS
CD3zeta RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDK 8
RRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEI
GMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALP
PR
Full IL-13Ra2.BBz METDTLLLWVLLLWVPGSTGAGGSDYKDDDDKGGSL 19
CAR; (Murine kappa TCLGGFASPGPVPPSTALRYLIEELVNITQNQKAPLCNG
signal SMVWSINLTAGMYCAALES LINVS GCS AIEKT QRMLS G
sequence_FLAG_Full FCPHKVSAGQFSSLHVRDTKIEVAQFVKDLLLHLKKLF
IL13 mutein_IgG4 REGRFNESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTL
(L235E, MIS RTPEVTCVVVDVS QEDPEVQFNWYVDGVEVHNAK
N297 Q)_CD28tm_4- TKPREEQFQSTYRVVSVLTVLHQDWLNGKEYKCKVSN
1BB_CD3zeta) KGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVS
LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDG
SFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQK
SLSLSLGKMFWVLVVVGGVLACYSLLVTVAFIIFWVKR
GRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGC
ELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVL
DKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAY
SEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQ
ALPPR
Full IL-13Ra2.BBz METDTLLLWVLLLWVPGSTGLTCLGGFASPGPVPPSTA 142
CAR; (Murine kappa LRYLIEELVNITQNQKAPLCNGSMVWSINLTAGMYCAA
signal sequence_Full LESLINVSGCSAIEKTQRMLSGFCPHKVSAGQFSSLHVR
IL13 mutein_IgG4 DTKIEVAQFVKDLLLHLKKLFREGRFNESKYGPPCPPCP
(L235E, APEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS QE
N297 Q)_CD28tm_4- DPEVQFNWYVDGVEVHNAKTKPREEQFQSTYRVVSVL
1BB_CD3zeta) TVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPR
EPQVYTLPPS QEEMTKNQVSLTCLVKGFYPSDIAVEWE
SNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEG
NVFSCSVMHEALHNHYTQKSLSLSLGKMFWVLVVVG
GVLACYSLLVTVAFIIFWVKRGRKKLLYIFKQPFMRPV
QTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQ
GQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRR
KNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHD
GLYQGLSTATKDTYDALHMQALPPR
MK signal sequence METDTLLLWVLLLWVPGSTG 2
FLAG DYKDDDDK 3
Full IL13 mutein LTCLGGFASPGPVPPSTALRYLIEELVNITQNQKAPLCN 20
GSMVWSINLTAGMYCAALES LINVS GCS AIEKT QRMLS
GFCPHKVSAGQFSSLHVRDTKIEVAQFVKDLLLHLKKL
FREGRFN
IgG4 (L235E, N297Q) ESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPE 5
VTCVVVDVS QEDPEVQFNWYVDGVEVHNAKTKPREE
QFQSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSS
IEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVK
GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSR
93

CA 03193009 2023-02-24
WO 2022/046935
PCT/US2021/047600
DESCRIPTION SEQUENCE SEQ
ID NO:
LTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG
K
CD28tm MFWVLVVVGGVLACYSLLVTVAFIIFWV 6
4-1BB KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEG 7
GCEL
CD3zeta RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDK 8
RRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEI
GMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALP
PR
Full-IL-13Ra2/TGF- METDTLLLWVLLLWVPGSTGAGGSDYKDDDDKGGSL 21
I3.BBz CAR; (Murine TCLGGFASPGPVPPSTALRYLIEELVNITQNQKAPLCNG
kappa signal SMVWSINLTAGMYCAALESLINVSGCSAIEKTQRMLSG
sequence_FLAG_Full FCPHKVSAGQFSSLHVRDTKIEVAQFVKDLLLHLKKLF
IL13 REGRFNGGGGSGGGGSGGGGSGGGGSQVQLVQSGAE
mutein_(G45)x4_TGF- VKKPGSSVKVSCKASGYTFSSNVISWVRQAPGQGLEW
0 scFv_IgG4 MGGVIPIVDIANYAQRFKGRVTITADESTSTTYMELSSL
hinge_CD28tm_4- RSEDTAVYYCALPRAFVLDAMDYWGQGTLVTVSSGG
1BB_CD3zeta) GGSGGGGSGGGGSETVLTQSPGTLSLSPGERATLSCRA
SQSLGSSYLAWYQQKPGQAPRLLIYGASSRAPGIPDRFS
GSGSGTDFTLTISRLEPEDFAVYYCQQYADSPITFGQGT
RLEIKESKYGPPCPPCPMFWVLVVVGGVLACYSLLVTV
AFIIFWVKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRF
PEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLG
RREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQK
DKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDT
YDALHMQALPPR
Full IL-13Ra2/TGF- METDTLLLWVLLLWVPGSTGLTCLGGFASPGPVPPSTA 143
I3.BBz CAR; (Murine LRYLIEELVNITQNQKAPLCNGSMVWSINLTAGMYCAA
kappa signal sequence_ LESLINVSGCSAIEKTQRMLSGFCPHKVSAGQFSSLHVR
Full IL13 DTKIEVAQFVKDLLLHLKKLFREGRFNGGGGSGGGGS
mutein_(G45)x4_TGF- GGGGSGGGGSQVQLVQSGAEVKKPGSSVKVSCKASGY
0 scFv_IgG4 TFSSNVISWVRQAPGQGLEWMGGVIPIVDIANYAQRFK
hinge_CD28tm_4- GRVTITADESTSTTYMELSSLRSEDTAVYYCALPRAFVL
1BB_CD3zeta) DAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSETVLT
QSPGTLSLSPGERATLSCRASQSLGSSYLAWYQQKPGQ
APRLLIYGASSRAPGIPDRFSGSGSGTDFTLTISRLEPEDF
AVYYCQQYADSPITFGQGTRLEIKESKYGPPCPPCPMF
WVLVVVGGVLACYSLLVTVAFIIFWVKRGRKKLLYIFK
QPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSA
DAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPE
MGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGER
RRGKGHDGLYQGLSTATKDTYDALHMQALPPR
MK signal sequence METDTLLLWVLLLWVPGSTG 2
FLAG DYKDDDDK 3
Full IL13 mutein LTCLGGFASPGPVPPSTALRYLIEELVNITQNQKAPLCN 20
GSMVWSINLTAGMYCAALESLINVSGCSAIEKTQRMLS
GFCPHKVSAGQFSSLHVRDTKIEVAQFVKDLLLHLKKL
FREGRFN
(G45)x4 GGGGSGGGGSGGGGSGGGGS 10
TGF-I3 scFv QVQLVQSGAEVKKPGSSVKVSCKASGYTFSSNVISWVR 11
QAPGQGLEWMGGVIPIVDIANYAQRFKGRVTITADEST
STTYMELSSLRSEDTAVYYCALPRAFVLDAMDYWGQG
94

CA 03193009 2023-02-24
WO 2022/046935
PCT/US2021/047600
DESCRIPTION SEQUENCE SEQ
ID NO:
TLVTVS SGGGGS GGGGS GGGGSETVLTQS PGTLSLS PG
ERATLSCRAS QSLGSSYLAWYQQKPGQAPRLLIYGASS
RAPGIPDRFS GS GSGTDFTLTIS RLEPEDFAVYYC QQYA
DSPITFGQGTRLEIK
IgG4 hinge ESKYGPPCPPCP 12
CD28tm MFWVLVVVGGVLACYSLLVTVAFIIFWV 6
4-1BB KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEG 7
GCEL
CD3zeta RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDK 8
RRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEI
GMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALP
PR
Full-IL-13Ra2.28z METDTLLLWVLLLWVPGSTGAGGSDYKDDDDKGGSL 22
CAR; (Murine kappa TCLGGFASPGPVPPSTALRYLIEELVNITQNQKAPLCNG
signal SMVWSINLTAGMYCAALES LINVS GCS AIEKT QRMLS G
sequence_FLAG_Full FCPHKVSAGQFSSLHVRDTKIEVAQFVKDLLLHLKKLF
IL13 mutein_IgG4 REGRFNESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTL
(L235E, MIS RTPEVTCVVVDVS QEDPEVQFNWYVDGVEVHNAK
N297 Q)_CD28tm_CD2 TKPREEQFQSTYRVVSVLTVLHQDWLNGKEYKCKVSN
8cyto_CD3zeta) KGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVS
LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDG
SFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQK
SLSLSLGKMFWVLVVVGGVLACYSLLVTVAFIIFWVRS
KRSRGGHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAY
RSGGGRVKFSRSADAPAYQQGQNQLYNELNLGRREEY
DVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMA
EAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALH
MQALPPR
Full-IL-13Ra2.28z METDTLLLWVLLLWVPGSTGLTCLGGFASPGPVPPSTA 144
CAR; (Murine kappa LRYLIEELVNITQNQKAPLCNGSMVWSINLTAGMYCAA
signal sequence_ Full LESLINVSGCSAIEKTQRMLSGFCPHKVSAGQFSSLHVR
IL13 mutein_IgG4 DTKIEVAQFVKDLLLHLKKLFREGRFNESKYGPPCPPCP
(L235E, APEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS QE
N297 Q)_CD28tm_CD2 DPEVQFNWYVDGVEVHNAKTKPREEQFQSTYRVVSVL
8cyto_CD3zeta) TVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPR
EPQVYTLPPS QEEMTKNQVSLTCLVKGFYPSDIAVEWE
SNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEG
NVFSCSVMHEALHNHYTQKSLSLSLGKMFWVLVVVG
GVLACYSLLVTVAFIIFWVRSKRSRGGHSDYMNMTPRR
PGPTRKHYQPYAPPRDFAAYRSGGGRVKFSRSADAPA
YQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGK
PRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKG
HDGLYQGLSTATKDTYDALHMQALPPR
MK signal sequence METDTLLLWVLLLWVPGSTG 2
FLAG DYKDDDDK 3
Full IL13 mutein LTCLGGFASPGPVPPSTALRYLIEELVNITQNQKAPLCN 20
GSMVWSINLTAGMYCAALES LINVS GCS AIEKT QRMLS
GFCPHKVSAGQFSSLHVRDTKIEVAQFVKDLLLHLKKL
FREGRFN
IgG4 (L235E, N297Q) ESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPE 5
VTCVVVDVS QEDPEVQFNWYVDGVEVHNAKTKPREE
QFQSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSS

CA 03193009 2023-02-24
WO 2022/046935
PCT/US2021/047600
DESCRIPTION SEQUENCE SEQ
ID NO:
IEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVK
GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSR
LTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG
K
CD28tm MFWVLVVVGGVLACYSLLVTVAFIIFWV 6
CD28cyto RSKRSRGGHSDYMNMTPRRPGPTRKHYQPYAPPRDFA 18
AYRS
CD3zeta RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDK 8
RRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEI
GMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALP
PR
Full-IL-13Ra2/TGF- METDTLLLWVLLLWVPGSTGAGGSDYKDDDDKGGSL 23
I3.28z CAR; (Murine TCLGGFASPGPVPPSTALRYLIEELVNITQNQKAPLCNG
kappa signal SMVWSINLTAGMYCAALESLINVSGCSAIEKTQRMLSG
sequence_FLAG_Full FCPHKVSAGQFSSLHVRDTKIEVAQFVKDLLLHLKKLF
IL13 REGRFNGGGGSGGGGSGGGGSGGGGSQVQLVQSGAE
mutein_(G45)x4_TGF- VKKPGSSVKVSCKASGYTFSSNVISWVRQAPGQGLEW
0 scFv_IgG4 MGGVIPIVDIANYAQRFKGRVTITADESTSTTYMELSSL
hinge_CD28tm_ RSEDTAVYYCALPRAFVLDAMDYWGQGTLVTVSSGG
CD28cyto_CD3zeta) GGSGGGGSGGGGSETVLTQSPGTLSLSPGERATLSCRA
SQSLGSSYLAWYQQKPGQAPRLLIYGASSRAPGIPDRFS
GSGSGTDFTLTISRLEPEDFAVYYCQQYADSPITFGQGT
RLEIKESKYGPPCPPCPMFWVLVVVGGVLACYSLLVTV
AFIIFWVRSKRSRGGHSDYMNMTPRRPGPTRKHYQPYA
PPRDFAAYRSGGGRVKFSRSADAPAYQQGQNQLYNEL
NLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNE
LQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTAT
KDTYDALHMQALPPR
Full-IL-13Ra2/TGF- METDTLLLWVLLLWVPGSTGLTCLGGFASPGPVPPSTA 145
I3.28z CAR; (Murine LRYLIEELVNITQNQKAPLCNGSMVWSINLTAGMYCAA
kappa signal sequence_ LESLINVSGCSAIEKTQRMLSGFCPHKVSAGQFSSLHVR
Full IL13 DTKIEVAQFVKDLLLHLKKLFREGRFNGGGGSGGGGS
mutein_(G45)x4_TGF- GGGGSGGGGSQVQLVQSGAEVKKPGSSVKVSCKASGY
0 scFv_IgG4 TFSSNVISWVRQAPGQGLEWMGGVIPIVDIANYAQRFK
hinge_CD28tm_ GRVTITADESTSTTYMELSSLRSEDTAVYYCALPRAFVL
CD28cyto_CD3zeta) DAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSETVLT
QSPGTLSLSPGERATLSCRASQSLGSSYLAWYQQKPGQ
APRLLIYGASSRAPGIPDRFSGSGSGTDFTLTISRLEPEDF
AVYYCQQYADSPITFGQGTRLEIKESKYGPPCPPCPMF
WVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRGGHSD
YMNMTPRRPGPTRKHYQPYAPPRDFAAYRSGGGRVKF
SRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGR
DPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMK
GERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
MK signal sequence METDTLLLWVLLLWVPGSTG 2
FLAG DYKDDDDK 3
Full IL13 mutein LTCLGGFASPGPVPPSTALRYLIEELVNITQNQKAPLCN 20
GSMVWSINLTAGMYCAALESLINVSGCSAIEKTQRMLS
GFCPHKVSAGQFSSLHVRDTKIEVAQFVKDLLLHLKKL
FREGRFN
(G45)x4 GGGGSGGGGSGGGGSGGGGS 10
96

CA 03193009 2023-02-24
WO 2022/046935
PCT/US2021/047600
DESCRIPTION SEQUENCE SEQ
ID NO:
TGF-I3 scFv QVQLVQSGAEVKKPGSSVKVSCKASGYTFSSNVISWVR 11
QAPGQGLEWMGGVIPIVDIANYAQRFKGRVTITADEST
STTYMELSSLRSEDTAVYYCALPRAFVLDAMDYWGQG
TLVTVSSGGGGSGGGGSGGGGSETVLTQSPGTLSLSPG
ERATLSCRASQSLGSSYLAWYQQKPGQAPRLLIYGASS
RAPGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYA
DSPITFGQGTRLEIK
IgG4 hinge ESKYGPPCPPCP 12
CD28tm MFWVLVVVGGVLACYSLLVTVAFIIFWV 6
CD28cyto RSKRSRGGHSDYMNMTPRRPGPTRKHYQPYAPPRDFA 18
AYRS
CD3zeta RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDK 8
RRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEI
GMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALP
PR
TGF-I3 scFv VH QVQLVQSGAEVKKPGSSVKVSCKASGYTFSSNVISWVR 29
QAPGQGLEWMGGVIPIVDIANYAQRFKGRVTITADEST
STTYMELSSLRSEDTAVYYCALPRAFVLDAMDYWGQG
TLVTVSS
TGF-I3 scFv VL ETVLTQSPGTLSLSPGERATLSCRASQSLGSSYLAWYQ 30
QKPGQAPRLLIYGASSRAPGIPDRFSGSGSGTDFTLTISR
LEPEDFAVYYCQQYADSPITFGQGTRLEIK
TGF-I3 scFv HCDR1 SNVIS 31
TGF-I3 scFv HCDR2 GVIPIVDIANYAQRFKG 32
TGF-I3 scFv HCDR3 PRAFVLDAMDY 33
TGF-I3 scFv LCDR1 RASQSLGSSYLA 34
TGF-I3 scFv LCDR2 GASSRAP 35
TGF-I3 scFv LCDR3 QQYADSPIT 36
IgG4 CH2 CH3 L235E APEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQE 37
N297Q peptide spacer DPEVQFNWYVDGVEVHNAKTKPREEQFQSTYRVVSVL
TVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPR
EPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWE
SNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEG
NVFSCSVMHEALHNHYTQKSLSLSLGK
EGFRvIII scFv VH EIQLVQSGAEVKKPGESLRISCKGSGFNIEDYYIHWVRQ 38
MPGKGLEWMGRIDPENDETKYGPIFQGHVTISADTSIN
TVYLQWSSLKASDTAMYYCAFRGGVYWGQGTTVTVS
S
EGFRvIII scFv VL DVVMTQSPDSLAVSLGERATINCKSSQSLLDSDGKTYL 39
NWLQQKPGQPPKRLISLVSKLDSGVPDRFSGSGSGTDF
TLTISSLQAEDVAVYYCWQGTHFPGTFGGGTKVEIK
EGFRvIII scFv DYYIH 40
HCDR1
EGFRvIII scFv RIDPENDETKYGPIFQG 41
HCDR2
EGFRvIII scFv RGGVY 42
HCDR3
EGFRvIII scFv LCDR1 KSSQSLLDSDGKTYLN 43
EGFRvIII scFv LCDR2 LVSKLDS 44
EGFRvIII scFv LCDR3 WQGTHFPGT 45
97

CA 03193009 2023-02-24
WO 2022/046935
PCT/US2021/047600
DESCRIPTION SEQUENCE SEQ
ID NO:
GD2 (14g2a scFv) VH EVQLLQSGPELEKPGASVMISCKASGSSFTGYNMNWV 46
RQNIGKSLEWIGAIDPYYGGTSYNQKFKGRATLTVDKS
SSTAYMHLKSLTSEDSAVYYCVSGMEYWGQGTSVTVS
S
GD2 (14g2a scFv) VL DVVMTQTPLSLPVSLGDQASISCRSSQSLVHRNGNTYL 47
HWYLQKPGQSPKLLIHKVSNRFSGVPDRFSGSGSGTDF
TLKISRVEAEDLGVYFCSQSTHVPPLTFGAGTKLELKRA
GD2scFv HCDR1 GYNMN 48
GD2scFv HCDR2 AIDPYYGGTSYNQKFKG 49
GD2scFv HCDR3 GMEY 50
GD2scFv LCDR1 RS S QS LVHRNGNTYLH 51
GD2scFv LCDR2 KVSNRFS 52
GD2scFv LCDR3 SQSTHVPPLT 53
TGF-I3 scFv VH #2 EVQLVESGGGLVQPGGSLRLSCAASGYAFTNYLIEWVR 54
QAPGKGLEWVGVINPGSGGSNYNEKFKGRATISADNS
KNTLYLQMNSLRAEDTAVYYCARSGGFYFDYWGQGT
LVTVSSASTKGPS
TGF-I3 scFv VL #2 DIQMTQSPSSLSASVGDRVTITCRASQSVLYSSNQKNYL 55
AWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDF
TLTISSLQPEDFATYYCHQYLSSDTFGQGTKVEIKRTVA
TGF-I3 scFv #2 GYAFTNYLIE 56
HCDR1
TGF-I3 scFv #2 VINPGSGGSNYNEKFKG 57
HCDR2
TGF-I3 scFv #2 SGGFYFDY 58
HCDR3
TGF-I3 scFv #2 LCDR1 RASQSVLYSSNQKNYLA 59
TGF-I3 scFv #2 LCDR2 WASTRES 60
TGF-I3 scFv #2 LCDR3 HQYLSSDT 61
TGF-I3 scFv VH #3
EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWV 62
RQAPGKELEWVAVISYDGSIKYYADSVKGRFTISRDNS
KNTLYLQMNSLRAEDTAVYYCARTGEYSGYDTDPQYS
WGQGTTVTVSS
TGF-I3 scFv VL #3 EIVLTQSPSSLSASVGDRVTITCRSSQGIGDDLGWYQQK 63
PGKAPILLIYGTSTLQSGVPSRFSGSGSGTDFTLTINSLQP
EDFATYYCLQDSNYPLTFGGGTRLEIK
TGF-I3 scFv #3 SYGMH 64
HCDR1
TGF-I3 scFv #3 VISYDGSIKYYADSVKG 65
HCDR2
TGF-I3 scFv #3 TGEYSGYDTDPQYS 66
HCDR3
TGF-I3 scFv #3 LCDR1 RSSQGIGDDLG 67
TGF-I3 scFv #3 LCDR2 GTSTLQS 68
TGF-I3 scFv #3 LCDR3 LQDSNYPLT 69
98

CA 03193009 2023-02-24
WO 2022/046935
PCT/US2021/047600
DESCRIPTION SEQUENCE SEQ
ID NO:
Murine kappa signal METDTLLLWVLLLWVPGSTGLTCLGGFASPGPVPPSTA 159
sequence_Full IL13 LRYLIEELVNITQNQKAPLCNGSMVWSINLTAGMYCAA
mutein_IgG4 (L235E, LESLINVSGCSAIEKTQRMLSGFCPHKVSAGQFSSLHVR
N297 Q)_CD28tm_4- DTKIEVAQFVKDLLLHLKKLFREGRFNESKYGPPCPPCP
1B B (KR)_CD3 zeta APEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS QE
(KR) DPEVQFNWYVDGVEVHNAKTKPREEQFQSTYRVVSVL
TVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPR
EPQVYTLPPS QEEMTKNQVSLTCLVKGFYPSDIAVEWE
SNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEG
NVFSCSVMHEALHNHYTQKSLSLSLGKMFWVLVVVG
GVLACYSLLVTVAFIIFWVRRGRRRLLYIFRQPFMRPVQ
TT QEEDGC SCRFPEEEEGGCELRVRFSRSADAPAYQQG
QNQLYNELNLGRREEYDVLDRRRGRDPEMGGRPRRRN
PQEGLYNELQRDRMAEAYSEIGMRGERRRGRGHDGLY
QGLSTATRDTYDALHMQALPPR
Murine kappa signal METDTLLLWVLLLWVPGSTGLTCLGGFASPGPVPPSTA 160
sequence_Full IL13 LRYLIEELVNITQNQKAPLCNGSMVWSINLTAGMYCAA
mutein_(G45)x4_TGF- LESLINVSGCSAIEKTQRMLSGFCPHKVSAGQFSSLHVR
0 scFv_IgG4 DTKIEVAQFVKDLLLHLKKLFREGRFNGGGGSGGGGS
hinge_CD28tm_4-1BB GGGGSGGGGS QV QLVQS GAEVKKPGS SVKV SCKASGY
(KR)_CD3zeta (KR) TFSSNVISWVRQAPGQGLEWMGGVIPIVDIANYAQRFK
GRVTITADESTSTTYMELSSLRSEDTAVYYCALPRAFVL
DAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSETVLT
QSPGTLS LSPGERATLSCRAS QS LGS S YLAWYQ QKPGQ
APRLLIYGASSRAPGIPDRFSGSGSGTDFTLTISRLEPEDF
AVYYCQQYADSPITFGQGTRLEIKESKYGPPCPPCPMF
WVLVVVGGVLACYSLLVTVAFIIFWVRRGRRRLLYIFR
QPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVRFSRSA
DAPAYQQGQNQLYNELNLGRREEYDVLDRRRGRDPE
MGGRPRRRNPQEGLYNELQRDRMAEAYSEIGMRGERR
RGRGHDGLYQGLSTATRDTYDALHMQALPPR
IL13Ra2.BBz METDTLLLWVLLLWVPGSTGGPVPPSTALRYLIEELVNI 161
(MKleader ¨IL13op- T QNQKAPLCNGSMVWS INLTAGMYCAALESLINVS GC
IgG4 hinge_IgG4 CH2 SAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTKIEVAQF
CH3 L235E N297Q VKDLLLHLKKLFREGRFNESKYGPPCPPCPAPEFEGGPS
peptide spacer-CD28 VFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNW
transmembrane YVDGVEVHNAKTKPREEQFQSTYRVVSVLTVLHQDWL
domain-4-1BB Co- NGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPP
stimulatory¨CD3 Zeta) SQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN
YKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVM
HEALHNHYTQKSLSLSLGKMFWVLVVVGGVLACYSLL
VTVAFIIFWVKRGRKKLLYIFKQPFMRPVQTTQEEDGC
SCRFPEEEEGGCELRV KFS RS ADAPAYQ QGQNQLYNEL
NLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNE
LQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTAT
KDTYDALHMQALPPR
99

CA 03193009 2023-02-24
WO 2022/046935
PCT/US2021/047600
DESCRIPTION SEQUENCE SEQ
ID NO:
IL13Ra2-(G4S)x3- METDTLLLWVLLLWVPGSTGGPVPPSTALRYLIEELVNI 162
TGF-I3.BBz TQNQKAPLCNGSMVWSINLTAGMYCAALESLINVSGC
(MKleader¨ IL13op¨ SAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTKIEVAQF
(G45)x3¨TGF-I3 scFv- VKDLLLHLKKLFREGRFNGGGGSGGGGSGGGGSQVQL
IgG4 hinge peptide VQSGAEVKKPGSSVKVSCKASGYTFSSNVISWVRQAPG
spacer-CD28 QGLEWMGGVIPIVDIANYAQRFKGRVTITADESTSTTY
transmembrane MELSSLRSEDTAVYYCALPRAFVLDAMDYWGQGTLVT
domain-4-1BB Co- VSSGGGGSGGGGSGGGGSETVLTQSPGTLSLSPGERAT
stimulatory¨ CD3 Zeta) LSCRASQSLGSSYLAWYQQKPGQAPRLLIYGASSRAPGI
PDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYADSPITF
GQGTRLEIKESKYGPPCPPCPMFWVLVVVGGVLACYSL
LVTVAFIIFWVKRGRKKLLYIFKQPFMRPVQTTQEEDG
CSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNE
LNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYN
ELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTAT
KDTYDALHMQALPPR
IL13Ra2-(G4S)x4- METDTLLLWVLLLWVPGSTGGPVPPSTALRYLIEELVNI 163
TGF-I3.BBz TQNQKAPLCNGSMVWSINLTAGMYCAALESLINVSGC
(MKleader¨IL13op¨ SAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTKIEVAQF
(G45)x4¨TGF-I3 scFv- VKDLLLHLKKLFREGRFNGGGGSGGGGSGGGGSGGGG
IgG4 hinge peptide SQVQLVQSGAEVKKPGSSVKVSCKASGYTFSSNVISWV
spacer-CD28 RQAPGQGLEWMGGVIPIVDIANYAQRFKGRVTITADES
transmembrane TSTTYMELSSLRSEDTAVYYCALPRAFVLDAMDYWGQ
domain-4-1BB Co- GTLVTVSSGGGGSGGGGSGGGGSETVLTQSPGTLSLSP
stimulatory¨CD3 Zeta) GERATLSCRASQSLGSSYLAWYQQKPGQAPRLLIYGAS
SRAPGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQY
ADSPITFGQGTRLEIKESKYGPPCPPCPMFWVLVVVGG
VLACYSLLVTVAFIIFWVKRGRKKLLYIFKQPFMRPVQ
TTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQG
QNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRK
NPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDG
LYQGLSTATKDTYDALHMQALPPR
IL13Ra2-(G4S)x4- METDTLLLWVLLLWVPGSTGGPVPPSTALRYLIEELVNI 164
EGFRvIII.BBz TQNQKAPLCNGSMVWSINLTAGMYCAALESLINVSGC
(MKleader¨IL13op¨ SAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTKIEVAQF
(G45)x4¨EGFRvIII VKDLLLHLKKLFREGRFNGGGGSGGGGSGGGGSGGGG
scFv-IgG4 hinge SEIQLVQSGAEVKKPGESLRISCKGSGFNIEDYYIHWVR
peptide spacer QMPGKGLEWMGRIDPENDETKYGPIFQGHVTISADTSI
transmembrane NTVYLQWSSLKASDTAMYYCAFRGGVYWGQGTTVTV
domain-4-1BB Co- SSGSTSGSGKPGSGEGSTKGDVVMTQSPDSLAVSLGER
stimulatory¨CD3 Zeta) ATINCKSSQSLLDSDGKTYLNWLQQKPGQPPKRLISLVS
KLDSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCWQ
GTHFPGTFGGGTKVEIKESKYGPPCPPCPMFWVLVVVG
GVLACYSLLVTVAFIIFWVKRGRKKLLYIFKQPFMRPV
QTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQ
GQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRR
KNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHD
GLYQGLSTATKDTYDALHMQALPPR
100

CA 03193009 2023-02-24
WO 2022/046935
PCT/US2021/047600
DESCRIPTION SEQUENCE SEQ
ID NO:
IL13Ra2-(G4S)x4- METDTLLLWVLLLWVPGSTGGPVPPSTALRYLIEELVNI 165
EGFRvIII.BBz TQNQKAPLCNGSMVWSINLTAGMYCAALESLINVSGC
(MKleader¨ IL13op¨ SAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTKIEVAQF
(G45)x4¨EGFRvIII VKDLLLHLKKLFREGRFNGGGGSGGGGSGGGGSGGGG
scFv-IgG4 hinge:IgG4 SEIQLVQSGAEVKKPGESLRISCKGSGFNIEDYYIHWVR
CH2 CH3 L235E QMPGKGLEWMGRIDPENDETKYGPIFQGHVTISADTSI
N297Q peptide spacer¨ NTVYLQWSSLKASDTAMYYCAFRGGVYWGQGTTVTV
CD28 transmembrane SSGSTSGSGKPGSGEGSTKGDVVMTQSPDSLAVSLGER
domain-4-1BB Co- ATINCKSSQSLLDSDGKTYLNWLQQKPGQPPKRLISLVS
stimulatory¨CD3 Zeta) KLDSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCWQ
GTHFPGTFGGGTKVEIKESKYGPPCPPCPAPEFEGGPSV
FLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWY
VDGVEVHNAKTKPREEQFQSTYRVVSVLTVLHQDWLN
GKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPS
QEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY
KTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMH
EALHNHYTQKSLSLSLGKMFWVLVVVGGVLACYSLLV
TVAFIIFWVKRGRKKLLYIFKQPFMRPVQTTQEEDGCSC
RFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNL
GRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQ
KDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKD
TYDALHMQALPPR
IL13Ra2-(G4S)x4- METDTLLLWVLLLWVPGSTGGPVPPSTALRYLIEELVNI 166
GD2.BBz (MKleader¨ TQNQKAPLCNGSMVWSINLTAGMYCAALESLINVSGC
IL13op¨(G4S)x4¨GD2 SAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTKIEVAQF
scFv-IgG4 hinge VKDLLLHLKKLFREGRFNGGGGSGGGGSGGGGSGGGG
peptide spacer¨CD28 SEVQLLQSGPELEKPGASVMISCKASGSSFTGYNMNWV
transmembrane RQNIGKSLEWIGAIDPYYGGTSYNQKFKGRATLTVDKS
domain-4-1BB co- SSTAYMHLKSLTSEDSAVYYCVSGMEYWGQGTSVTVS
stimulatory¨CD3 Zeta) SGSTSGSGKPGSGEGSTKGDVVMTQTPLSLPVSLGDQA
SISCRSSQSLVHRNGNTYLHWYLQKPGQSPKLLIHKVS
NRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQS
THVPPLTFGAGTKLELKRAESKYGPPCPPCPMFWVLVV
VGGVLACYSLLVTVAFIIFWVKRGRKKLLYIFKQPFMR
PVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAY
QQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKP
RRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKG
HDGLYQGLSTATKDTYDALHMQALPPR
101

CA 03193009 2023-02-24
WO 2022/046935
PCT/US2021/047600
DESCRIPTION SEQUENCE SEQ
ID NO:
IL13Ra2-(G4S)x4- METDTLLLWVLLLWVPGSTGGPVPPSTALRYLIEELVNI 167
GD2. BB z (MKleader¨ T QNQKAPLCNGSMVWSINLTAGMYCAALESLINVS GC
IL13op¨(G4S)x4¨GD2 SAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTKIEVAQF
scFv-IgG4 hinge:IgG4 VKDLLLHLKKLFREGRFNGGGGSGGGGSGGGGSGGGG
CH2 CH3 L235E SEVQLLQSGPELEKPGASVMISCKASGSSFTGYNMNWV
N297Q peptide spacer¨ RQNIGKSLEWIGAIDPYYGGTSYNQKFKGRATLTVDKS
CD28 transmembrane SSTAYMHLKSLTSEDSAVYYCVSGMEYWGQGTSVTVS
domain-4-1BB co- SGS TS GSGKPGS GEGSTKGDVVMT QTPLS LPVSLGD QA
stimulatory-CD3 Zeta) SISCRSSQSLVHRNGNTYLHWYLQKPGQSPKLLIHKVS
NRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQS
THVPPLTFGAGTKLELKRAESKYGPPCPPCPAPEFEGGP
SVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFN
WYVDGVEVHNAKTKPREEQFQSTYRVVSVLTVLHQD
WLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYT
LPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE
NNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCS
VMHEALHNHYTQKSLSLSLGKMFWVLVVVGGVLACY
SLLVTVAFIIFWVKRGRKKLLYIFKQPFMRPVQTTQEED
GCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYN
ELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLY
NELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLST
ATKDTYDALHMQALPPR
IL13Ra2.BBz + TGF- METDTLLLWVLLLWVPGSTGGPVPPSTALRYLIEELVNI 168
I3.28z (MKleader¨ T QNQKAPLCNGSMVWSINLTAGMYCAALESLINVS GC
IL13op-IgG4 SAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTKIEVAQF
hinge:IgG4 CH2 CH3 VKDLLLHLKKLFREGRFNESKYGPPCPPCPAPEFEGGPS
L235E N297Q peptide VFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNW
spacer-CD28 YVDGVEVHNAKTKPREEQFQSTYRVVSVLTVLHQDWL
transmembrane NGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPP
domain-4-1BB co- SQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN
stimulatory- CD3 Zeta¨ YKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVM
T2A¨MKleader¨HA¨ HEALHNHYTQKSLSLSLGKMFWVLVVVGGVLACYSLL
TGF-I3 scFv¨IgG4 VTVAFIIFWVKRGRKKLLYIFKQPFMRPVQTTQEEDGC
hinge peptide spacer¨ SCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNEL
CD28 transmembrane NLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNE
domain¨CD28cyto LQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTAT
(with gg mutations)¨ KDTYDALHMQALPPRLEGGGEGRGSLLTCGDVEENPG
CD3 Zeta) PRMETDTLLLWVLLLWVPGSTGTSYPYDVPDYAGGSQ
V QLV QSGAEVKKPGS SVKV SCKASGYTFS S NVISWVRQ
APGQGLEWMGGVIPIVDIANYAQRFKGRVTITADESTS
TTYMELSSLRSEDTAVYYCALPRAFVLDAMDYWGQGT
LVTVSSGGGGSGGGGSGGGGSETVLTQSPGTLSLSPGE
RATLSCRAS QSLGS SYLAWYQQKPGQAPRLLIYGAS SR
APGIPDRFSGS GS GTDFTLTISRLEPEDFAVYYC QQYAD
SPITFGQGTRLEIKESKYGPPCPPCPMFWVLVVVGGVLA
CYSLLVTVAFIIFWVRSKRSRGGHSDYMNMTPRRPGPT
RKHYQPYAPPRDFAAYRSGGGRVKFSRSADAPAYQQG
QNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRK
NPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDG
LYQGLSTATKDTYDALHMQALPPR
102

CA 03193009 2023-02-24
WO 2022/046935
PCT/US2021/047600
DESCRIPTION SEQUENCE SEQ
ID NO:
IL13Ra2- METDTLLLWVLLLWVPGSTGGPVPPSTALRYLIEELVNI 169
EGFRvIII.BB z + TGF- TQNQKAPLCNGSMVWSINLTAGMYCAALESLINVSGC
I3.28z (MKleader- SAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTKIEVAQF
IL13op¨(G4S)x4¨ VKDLLLHLKKLFREGRFNGGGGSGGGGSGGGGSGGGG
EGFRvIII scFv-IgG4 SEIQLVQSGAEVKKPGESLRISCKGSGFNIEDYYIHWVR
hinge-CD2 8 QMPGKGLEWMGRIDPENDETKYGPIFQGHVTISADTSI
transmembrane NTVYLQWSSLKASDTAMYYCAFRGGVYWGQGTTVTV
domain-4-1BB co- SSGSTSGSGKPGSGEGSTKGDVVMTQSPDSLAVSLGER
stimulatory¨CD3 Zeta¨ ATINCKSSQSLLDSDGKTYLNWLQQKPGQPPKRLISLVS
T2A¨MKleader¨HA¨ KLDSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCWQ
TGF-I3 scFv¨IgG4 GTHFPGTFGGGTKVEIKESKYGPPCPPCPMFWVLVVVG
hinge peptide spacer¨ GVLACYSLLVTVAFIIFWVKRGRKKLLYIFKQPFMRPV
CD28 transmembrane QTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQ
domain¨CD2 8 cyto GQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRR
(with gg mutations)¨ KNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHD
CD3 Zeta) GLYQGLSTATKDTYDALHMQALPPRLEGGGEGRGSLL
TCGDVEENPGPRMETDTLLLWVLLLWVPGSTGTSYPY
DVPDYAGGSQVQLVQSGAEVKKPGSSVKVSCKASGYT
FS SNVISWVRQAPGQGLEWMGGVIPIVDIANYAQRFKG
RVTITADESTSTTYMELSSLRSEDTAVYYCALPRAFVLD
AMDYWGQGTLVTVSSGGGGSGGGGSGGGGSETVLTQ
SPGTLSLSPGERATLSCRASQSLGSSYLAWYQQKPGQA
PRLLIYGASSRAPGIPDRFSGSGSGTDFTLTISRLEPEDFA
VYYCQQYADSPITFGQGTRLEIKESKYGPPCPPCPMFW
VLVVVGGVLACYSLLVTVAFIIFWVRSKRSRGGHSDY
MNMTPRRPGPTRKHYQPYAPPRDFAAYRSGGGRVKFS
RS ADAPAYQ QGQNQLYNELNLGRREEYDVLDKRRGR
DPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMK
GERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
103

CA 03193009 2023-02-24
WO 2022/046935
PCT/US2021/047600
DESCRIPTION SEQUENCE SEQ
ID NO:
IL13Ra2-GD2.BB z + METDTLLLWVLLLWVPGSTGGPVPPSTALRYLIEELVNI 170
TGF-I3.28z (MKleader¨ T QNQKAPLCNGSMVWSINLTAGMYCAALESLINVS GC
IL13op¨(G4S)x4¨GD2 SAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTKIEVAQF
scFv-IgG4 hinge:IgG4 VKDLLLHLKKLFREGRFNGGGGSGGGGSGGGGSGGGG
CH2 CH3 L235E SEVQLLQSGPELEKPGASVMISCKASGSSFTGYNMNWV
N297Q peptide spacer¨ RQNIGKSLEWIGAIDPYYGGTSYNQKFKGRATLTVDKS
CD28 transmembrane SSTAYMHLKSLTSEDSAVYYCVSGMEYWGQGTSVTVS
domain-4-1BB co- SGS TS GSGKPGS GEGSTKGDVVMT QTPLS LPVSLGD QA
stimulatory-CD3 Zeta¨ SISCRSSQSLVHRNGNTYLHWYLQKPGQSPKLLIHKVS
T2A¨MKleader¨HA¨ NRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQS
TGF-I3 scFv¨IgG4 THVPPLTFGAGTKLELKRAESKYGPPCPPCPAPEFEGGP
hinge peptide spacer¨ SVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFN
CD28 transmembrane WYVDGVEVHNAKTKPREEQFQSTYRVVSVLTVLHQD
domain¨CD28cyto WLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYT
(with gg mutations)¨ LPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE
CD3 Zeta) NNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCS
VMHEALHNHYTQKSLSLSLGKMFWVLVVVGGVLACY
SLLVTVAFIIFWVKRGRKKLLYIFKQPFMRPVQTTQEED
GCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYN
ELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLY
NELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLST
ATKDTYDALHMQALPPRLEGGGEGRGSLLTCGDVEEN
PGPRMETDTLLLWVLLLWVPGSTGTSYPYDVPDYAGG
S QV QLVQS GAEVKKPGS SVKVS CKAS GYTFS SNVISWV
RQAPGQGLEWMGGVIPIVDIANYAQRFKGRVTITADES
TSTTYMELSSLRSEDTAVYYCALPRAFVLDAMDYWGQ
GTLVTVSSGGGGSGGGGSGGGGSETVLTQSPGTLSLSP
GERATLSCRASQSLGSSYLAWYQQKPGQAPRLLIYGAS
SRAPGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQY
ADSPITFGQGTRLEIKESKYGPPCPPCPMFWVLVVVGG
VLACYSLLVTVAFIIFWVRSKRSRGGHSDYMNMTPRRP
GPTRKHYQPYAPPRDFAAYRSGGGRVKFSRSADAPAY
QQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKP
RRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKG
HDGLYQGLSTATKDTYDALHMQALPPR
IL13Ra2-GD2-TGF- METDTLLLWVLLLWVPGSTGGPVPPSTALRYLIEELVNI 171
I3.BBz (MKleader¨ T QNQKAPLCNGSMVWSINLTAGMYCAALESLINVS GC
IL13op¨(G4S)x4¨GD2 SAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTKIEVAQF
scFv-(G45)x4¨TGF-I3 VKDLLLHLKKLFREGRFNGGGGSGGGGSGGGGSGGGG
scFv¨IgG4 hinge SEVQLLQSGPELEKPGASVMISCKASGSSFTGYNMNWV
peptide spacer ¨CD28 RQNIGKSLEWIGAIDPYYGGTSYNQKFKGRATLTVDKS
transmembrane SSTAYMHLKSLTSEDSAVYYCVSGMEYWGQGTSVTVS
domain-4-1BB co- SGS TS GSGKPGS GEGSTKGDVVMT QTPLS LPVSLGD QA
stimulatory-CD3 Zeta) SISCRSSQSLVHRNGNTYLHWYLQKPGQSPKLLIHKVS
NRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQS
THVPPLTFGAGTKLELKRAGGGGSGGGGSGGGGSGGG
GSQVQLVQSGAEVKKPGSSVKVSCKASGYTFSSNVISW
VRQAPGQGLEWMGGVIPIVDIANYAQRFKGRVTITADE
ST STTYMELS SLRSEDTAVYYCALPRAFVLDAMDYWG
QGTLVTVSSGGGGSGGGGSGGGGSETVLTQSPGTLSLS
PGERATLSCRASQSLGSSYLAWYQQKPGQAPRLLIYGA
S SRAPGIPDRFS GS GSGTDFTLTISRLEPEDFAVYYC QQY
ADSPITFGQGTRLEIKESKYGPPCPPCPMFWVLVVVGG
104

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
DESCRIPTION SEQUENCE SEQ
ID NO:
VLACYSLLVTVAFIIFWVKRGRKKLLYIFKQPFMRPVQ
TTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQG
QNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRK
NPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDG
LYQGLSTATKDTYDALHMQALPPR
IL13Ra2-EGFRvIII- METDTLLLWVLLLWVPGSTGGPVPPSTALRYLIEELVNI 172
TGF-r3.BBz TQNQKAPLCNGSMVWSINLTAGMYCAALESLINVSGC
(MKleader¨IL13op¨ SAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTKIEVAQF
(G45)x4¨EGFRvIII VKDLLLHLKKLFREGRFNGGGGSGGGGSGGGGSGGGG
scFv-(G45)x4¨TGF-I3 SEIQLVQSGAEVKKPGESLRISCKGSGFNIEDYYIHWVR
scFv¨IgG4 hinge QMPGKGLEWMGRIDPENDETKYGPIFQGHVTISADTSI
peptide spacer¨CD28 NTVYLQWSSLKASDTAMYYCAFRGGVYWGQGTTVTV
transmembrane SSGSTSGSGKPGSGEGSTKGDVVMTQSPDSLAVSLGER
domain- 4-1BB co- ATINCKSSQSLLDSDGKTYLNWLQQKPGQPPKRLISLVS
stimulatory-CD3 Zeta) KLDSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCWQ
GTHFPGTFGGGTKVEIKGGGGSGGGGSGGGGSGGGGS
QVQLVQSGAEVKKPGSSVKVSCKASGYTFSSNVISWVR
QAPGQGLEWMGGVIPIVDIANYAQRFKGRVTITADEST
STTYMELSSLRSEDTAVYYCALPRAFVLDAMDYWGQG
TLVTVSSGGGGSGGGGSGGGGSETVLTQSPGTLSLSPG
ERATLSCRASQSLGSSYLAWYQQKPGQAPRLLIYGASS
RAPGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYA
DSPITFGQGTRLEIKESKYGPPCPPCPMFWVLVVVGGVL
ACYSLLVTVAFIIFWVKRGRKKLLYIFKQPFMRPVQTT
QEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQN
QLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQ
EGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQ
GLSTATKDTYDALHMQALPPR
X. Examples
[0244] The following examples are included to demonstrate preferred
embodiments of the
disclosure. It should be appreciated by those of skill in the art that the
techniques disclosed in
the examples which follow represent techniques discovered by the inventor to
function well in
the practice of the disclosure, and thus can be considered to constitute
preferred modes for its
practice. However, those of skill in the art should, in light of the present
disclosure, appreciate
that many changes can be made in the specific embodiments which are disclosed
and still obtain
a like or similar result without departing from the spirit and scope of the
disclosure. The
Examples should not be construed as limiting in any way. The contents of all
cited references
(including literature references, issued patents, published patent
applications, and GenBank
Accession numbers as cited throughout this application) are hereby expressly
incorporated by
reference. When definitions of terms in documents that are incorporated by
reference herein
conflict with those used herein, the definitions used herein govern.
105

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
Example 1: Treatment of Glioblastoma multiforme with multispecific chimeric
antigen
receptors.
[0245] Glioblastoma multiforme (GBM) is a highly aggressive disease with
poor prognosis,
and targeted immunotherapy for GBM is particularly challenging due to a highly
immunosuppressive tumor microenvironment characterized by high transforming
growth
factor beta (TGF-f3) levels. Single-chain bispecific CARs that simultaneously
target IL-13Ra2,
a clinically relevant GBM antigen, and TGF-f3 were constructed by connecting
the IL-13
mutein with a TGF-P¨specific scFv via a peptide linker, and fusing the dual-
targeting ligand-
binding domain to IgG4 hinge followed by CD28 transmembrane domain, 4-1BB co-
stimulatory domain, and CD3t signaling domain. The peptide linkers evaluated
include 3 or 4
repeats of Gly-Gly-Gly-Gly-Ser (i.e., (G45)3 or (G45)4). The bispecific CARs
were compared
against the single-input IL-13Ra2 CAR. Since the bispecific CAR contains the
CD28
transmembrane domain (CD28tm) whereas the original IL-13Ra2 CAR that had been
evaluated in the clinic contained the CD4 transmembrane domain (CD28tm; Brown
et al.,
NEJM, 2016, 375(26):2561-2569), single-input IL-13Ra2 CARs containing either
CD4tm or
CD28tm were evaluated (FIG. 1A). Both single-input and bispecific CARs were
efficiently
expressed on the surface of T cells as reflected by surface antibody staining
of a FLAG tag that
is fused to the N terminus of each CAR, together with truncated EGFR (EGFRt),
which is fused
to the C terminus of each CAR via a self-cleaving T2A peptide. CAR-T cells
were stimulated
with 5 ng/ml or 10 ng/ml of exogenous TGF-f3, and antibody staining for the
activation markers
CD69 and CD25 confirm the bispecific CARs, but not the single-input CARs,
respond to TGF-
0 by triggering T-cell activation (FIG. 2). Furthermore, CAR-T cells were
labeled with
CellTrace Violet (CTV) dye and then co-incubated with patient-derived PBT106
GBM
neurosphere cells at a 1:8 effector-to-target ratio for 94 hours, in the
presence or absence of
metalloprotease 9 (MMP-9). MMP-9 is known to activate TGF-f3 by releasing the
mature form
of TGF-f3 through proteolytic processing. The number of surviving tumor cells,
number of
FLAG+ CAR-T cells, as well as CTV dye intensity among FLAG+ CAR-T cells were
quantified by flow cytometry. Results indicate that the bispecific CAR-T cells
exhibit superior
cytotoxicity compared to single-input IL-13Ra2 CAR-T cells in the presence of
MMP-9 (FIG.
3A). Furthermore, bispecific CAR-T cells show superior antigen-stimulated T-
cell
proliferation both in the presence and in the absence of MMP-9 compared to
single-input IL-
13Ra2 CAR-T cells (FIG. 3B).
106

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
Example 2: Treatment of Glioblastoma multiforme with multispecific chimeric
antigen
receptors.
[0246] Glioblastoma multiforme (GBM) is the most common type of primary brain
tumors
in adults, and the median survival period has remained at 12-16 months from
the time of
diagnosis over the past few decades. Conventional therapies such as surgery,
chemotherapy,
and radiation almost invariably fail to eradicate tumor, resulting in relapse
within weeks or
months. Consequently, GBM has been an active area of research for new
treatment options
such as adoptive T-cell therapy. Two major challenges have limited the
efficacy of T-cell
therapy for GBM thus far. First, the GBM tumor microenvironment is strongly
immunosuppressive, characterized by a high level of transforming growth factor
beta (TGF-f3),
which simultaneously promote tumor growth and potently suppress the function
of T cells.
Second, GBM tumors are highly heterogeneous in antigen expression, thus T
cells engineered
to target a single antigen are generally unable to recognize and eradicate all
tumor cells present.
[0247] The inventors propose to overcome the two main challenges of
adoptive T-cell
therapy against GBM through the use of bispecific chimeric antigen receptor
(CAR)-T cells
that can simultaneously target a GBM-associated surface antigen and convert
TGF-f3 from an
immunosuppressive cytokine into a potent stimulant for the engineered T cells.
Importantly,
the TGF-f3 CAR can both inhibit endogenous TGF-f3 signaling (by competing
against
endogenous TGF-f3 receptors for binding to TGF-f3 ligands) and trigger T-cell
activation in the
presence of both soluble and immobilized TGF-f3. The concept is that the TGF-
f3 conversion
function of the CAR-T cells could modify the tumor microenvironment, thus
promoting the
anti-tumor function of both the engineered T cells and endogenous immune
cells.
[0248] The inventors have built a series of bispecific CARs that
simultaneously respond to
TGF-f3 plus IL-13Ra2, and antigen found on the surface of brain-tumor cells.
Specifically, they
have constructed the following bispecific CARs:
107

CA 03193009 2023-02-24
WO 2022/046935
PCT/US2021/047600
CAR SEQUENCE SEQ
ID
NO:
SP-IL- METDTLLLWVLLLWVPGSTGAGGSDYKDDDDKGGSSPGPV 1
13Ra2.BBz PPSTALRYLIEELVNITQNQKAPLCNGSMVWSINLTAGMYC
CAR; (Murine AALES LINVS GCS AIEKT QRMLS GFCPHKVS AGQFS S LHVRD
kappa signal TKIEVAQFVKDLLLHLKKLFREGRFNESKYGPPCPPCPAPEF
sequence_FLAG EGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFN
_SP IL13 WYVDGVEVHNAKTKPREEQFQSTYRVVSVLTVLHQDWLN
mutein_IgG4 GKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPS QEE
(L235E, MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL
N297 Q)_CD28t D SDGSFFLYS RLTVD KSRWQEGNVFS CS VMHEALHNHYTQ
m_4- KSLSLSLGKMFWVLVVVGGVLACYSLLVTVAFIIFWVKRGR
1B B_CD3zeta) KKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKF
SRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPE
MGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRG
KGHDGLYQGLSTATKDTYDALHMQALPPR
SP-IL- METDTLLLWVLLLWVPGSTGAGGSDYKDDDDKGGSSPGPV 9
13Ra2/TGF- PPSTALRYLIEELVNITQNQKAPLCNGSMVWSINLTAGMYC
13.BBz CAR; AALES LINVS GCS AIEKT QRMLS GFCPHKVS AGQFS S LHVRD
(Murine kappa TKIEVAQFVKDLLLHLKKLFREGRFNGGGGSGGGGSGGGGS
signal GGGGS QVQLV QSGAEVKKPGS SVKV SC KAS GYTFS SNVISW
sequence_FLAG VRQAPGQGLEWMGGVIPIVDIANYAQRFKGRVTITADESTS
_SP IL13 TTYMELSSLRSEDTAVYYCALPRAFVLDAMDYWGQGTLVT
mutein_(G45)x4 VSSGGGGSGGGGSGGGGSETVLTQSPGTLSLSPGERATLSCR
_TGF-13 AS QSLGS SYLAWYQQKPGQAPRLLIYGAS SRAPGIPDRFS GS
scFv_IgG4 GSGTDFTLTISRLEPEDFAVYYCQQYADSPITFGQGTRLEIKE
hinge_CD28tm_4 SKYGPPCPPCPMFWVLVVVGGVLACYSLLVTVAFIIFWVKR
-1B B_CD3zeta) GRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRV
KFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRD
PEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRR
GKGHDGLYQGLSTATKDTYDALHMQALPPR
SP-IL- METDTLLLWVLLLWVPGSTGAGGSDYKDDDDKGGSSPGPV 13
13Ra2.BBz (KR) PPSTALRYLIEELVNITQNQKAPLCNGSMVWSINLTAGMYC
CAR; (Murine AALES LINVS GCS AIEKT QRMLS GFCPHKVS AGQFS S LHVRD
kappa signal TKIEVAQFVKDLLLHLKKLFREGRFNESKYGPPCPPCPAPEF
sequence_FLAG EGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFN
_SP IL13 WYVDGVEVHNAKTKPREEQFQSTYRVVSVLTVLHQDWLN
mutein_IgG4 GKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPS QEE
(L235E, MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL
N297 Q)_CD28t D SDGSFFLYS RLTVD KSRWQEGNVFS CS VMHEALHNHYTQ
m_4- KSLSLSLGKMFWVLVVVGGVLACYSLLVTVAFIIFWVRRGR
1B B (KR)_CD3ze RRLLYIFRQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVRF
ta(KR)) SRSADAPAYQQGQNQLYNELNLGRREEYDVLDRRRGRDPE
MGGRPRRRNPQEGLYNELQRDRMAEAYSEIGMRGERRRGR
GHDGLYQGLSTATRDTYDALHMQALPPR
108

CA 03193009 2023-02-24
WO 2022/046935
PCT/US2021/047600
CAR SEQUENCE SEQ
ID
NO:
SP-IL- METDTLLLWVLLLWVPGSTGAGGSDYKDDDDKGGSSPGPV 16
13Ra2/TGF- PPSTALRYLIEELVNITQNQKAPLCNGSMVWSINLTAGMYC
I3.BBz (KR) AALES LINVS GCS AIEKT QRMLS GFCPHKVS AGQFS S LHVRD
CAR; (Murine TKIEVAQFVKDLLLHLKKLFREGRFNGGGGSGGGGSGGGGS
kappa signal GGGGS QVQLV QSGAEVKKPGS SVKV SC KAS GYTFS SNVISW
sequence FLAG VRQAPGQGLEWMGGVIPIVDIANYAQRFKGRVTITADESTS
_SP IL13 TTYMELSSLRSEDTAVYYCALPRAFVLDAMDYWGQGTLVT
mutein_(G45)x4 VSSGGGGSGGGGSGGGGSETVLTQSPGTLSLSPGERATLSCR
_TGF-I3 AS QSLGS SYLAWYQQKPGQAPRLLIYGAS SRAPGIPDRFS GS
scFv_IgG4 GSGTDFTLTISRLEPEDFAVYYCQQYADSPITFGQGTRLEIKE
hinge_CD28tm_4 SKYGPPCPPCPMFWVLVVVGGVLACYSLLVTVAFIIFWVRR
GRRRLLYIFRQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRV
1B B (KR)_CD3ze RFS RS ADAPAYQ QGQNQLYNELNLGRREEYDVLDRRRGRD
ta(KR)) PEMGGRPRRRNPQEGLYNELQRDRMAEAYSEIGMRGERRR
GRGHDGLYQGLSTATRDTYDALHMQALPPR
SP-IL -13Ra2.28 z METDTLLLWVLLLWVPGSTGAGGSDYKDDDDKGGSSPGPV 17
CAR; (Murine PPSTALRYLIEELVNITQNQKAPLCNGSMVWSINLTAGMYC
kappa signal AALES LINVS GCS AIEKT QRMLS GFCPHKVS AGQFS S LHVRD
sequence FLAG TKIEVAQFVKDLLLHLKKLFREGRFNESKYGPPCPPCPAPEF
_SP IL13 EGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFN
mutein_IgG4 WYVDGVEVHNAKTKPREEQFQSTYRVVSVLTVLHQDWLN
(L235E, GKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPS QEE
N297 Q)_CD28t MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL
m_CD28cyto_C D SDGSFFLYS RLTVD KSRWQEGNVFS CS VMHEALHNHYTQ
D3zeta) KSLS LSLGKMFWVLVVVGGVLACYS LLVTVAFIIFWVRS KR
SRGGHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSGGG
RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRG
RDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGER
RRGKGHDGLYQGLSTATKDTYDALHMQALPPR
SP-IL- METDTLLLWVLLLWVPGSTGAGGSDYKDDDDKGGSSPGPV 25
13Ra2/TGF- PPSTALRYLIEELVNITQNQKAPLCNGSMVWSINLTAGMYC
I3.28z CAR; AALES LINVS GCS AIEKT QRMLS GFCPHKVS AGQFS S LHVRD
(Murine kappa TKIEVAQFVKDLLLHLKKLFREGRFNGGGGSGGGGSGGGGS
signal GGGGS QVQLV QSGAEVKKPGS SVKV SC KAS GYTFS SNVISW
sequence FLAG VRQAPGQGLEWMGGVIPIVDIANYAQRFKGRVTITADESTS
_SP IL13 TTYMELSSLRSEDTAVYYCALPRAFVLDAMDYWGQGTLVT
mutein_(G45)x4 VSSGGGGSGGGGSGGGGSETVLTQSPGTLSLSPGERATLSCR
_TGF-I3 AS QSLGS SYLAWYQQKPGQAPRLLIYGAS SRAPGIPDRFS GS
scFv_IgG4 GSGTDFTLTISRLEPEDFAVYYCQQYADSPITFGQGTRLEIKE
hinge_CD28tm_ SKYGPPCPPCPMFWVLVVVGGVLACYSLLVTVAFIIFWVRS
CD28cyto_CD3z KRSRGGHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSG
eta) GGRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKR
RGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMK
GERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
109

CA 03193009 2023-02-24
WO 2022/046935
PCT/US2021/047600
CAR SEQUENCE SEQ
ID
NO:
Murine kappa METDTLLLWVLLLWVPGSTGAGGSDYKDDDDKGGSSPGPV 131
signal PPSTALRYLIEELVNITQNQKAPLCNGSMVWSINLTAGMYC
sequence_FLAG AALES LINVS GCS AIEKT QRMLS GFCPHKVS AGQFS S LHVRD
_SP IL13 TKIEVAQFVKDLLLHLKKLFREGRFNESKYGPPCPPCPAPEF
mutein_IgG4 EGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFN
(L235E,N297Q)_ WYVDGVEVHNAKTKPREEQFQSTYRVVSVLTVLHQDWLN
CD28tm_4- GKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPS QEE
1B B_CD3zeta_T MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL
2A_HA_TGFBR D SDGSFFLYS RLTVD KSRWQEGNVFS CS VMHEALHNHYTQ
2tr(DNR) KSLSLSLGKMFWVLVVVGGVLACYSLLVTVAFIIFWVKRGR
KKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKF
SRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPE
MGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRG
KGHDGLYQGLSTATKDTYDALHMQALPPRLEGGGEGRGSL
LTCGDVEENPGPRMGRGLLRGLWPLHIVLWTRIASTIPPYPY
DVPDYAHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFST
CDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVC
HDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDEC
NDNIIFSEEYNTSNPDLLLVIFQVTGISLLPPLGVAISVIIIFYC
YRVNRQQKLSS
Full IL- METDTLLLWVLLLWVPGSTGAGGSDYKDDDDKGGSLTCL 19
13Ra2.BBz GGFASPGPVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSI
CAR; (Murine NLTAGMYCAALES LINV SGC SAIEKT QRMLS GFCPHKV SAG
kappa signal QFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFNESKYGPP
sequence_FLAG CPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS Q
Full IL13 EDPEVQFNWYVDGVEVHNAKTKPREEQFQSTYRVVSVLTV
mutein_IgG4 LHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVY
(L235E, TLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN
N297 Q)_CD28t YKTTPPVLD S DGSFFLYSRLTVD KSRWQEGNVFS CS VMHEA
m_4- LHNHYTQKSLSLSLGKMFWVLVVVGGVLACYSLLVTVAFII
1B B_CD3zeta) FWVKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEG
GCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLD
KRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIG
MKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
Full-IL- METDTLLLWVLLLWVPGSTGAGGSDYKDDDDKGGSLTCL 21
13Ra2/TGF- GGFASPGPVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSI
I3.BBz CAR; NLTAGMYCAALES LINV SGC SAIEKT QRMLS GFCPHKV SAG
(Murine kappa QFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFNGGGGSG
signal GGGSGGGGSGGGGSQVQLVQSGAEVKKPGSSVKVSCKASG
sequence_FLAG YTFSSNVISWVRQAPGQGLEWMGGVIPIVDIANYAQRFKGR
Full IL13 VTITADESTSTTYMELSSLRSEDTAVYYCALPRAFVLDAMD
mutein_(G45)x4 YWGQGTLVTVSSGGGGSGGGGSGGGGSETVLTQSPGTLSLS
_TGF-I3 PGERATLSCRAS QSLGSSYLAWYQQKPGQAPRLLIYGASSR
scFv_IgG4 APGIPDRFS GS GSGTDFTLTIS RLEPEDFAVYYC QQYAD SPIT
hinge_CD28tm_4 FGQGTRLEIKESKYGPPCPPCPMFWVLVVVGGVLACYSLLV
-1B B_CD3zeta) TVAFIIFWVKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFP
EEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREE
YDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEA
YSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALP
PR
110

CA 03193009 2023-02-24
WO 2022/046935
PCT/US2021/047600
CAR SEQUENCE SEQ
ID
NO:
Murine kappa METDTLLLWVLLLWVPGSTGAGGSDYKDDDDKGGSLTCL 132
signal GGFASPGPVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSI
sequence FLAG NLTAGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAG
Full IL13 QFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFNESKYGPP
mutein_IgG4 CPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQ
(L235E, EDPEVQFNWYVDGVEVHNAKTKPREEQFQSTYRVVSVLTV
N297 Q)_CD28t LHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVY
m_4 -1B B TLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN
(KR)_CD3zeta YKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEA
(KR) LHNHYTQKSLSLSLGKMFWVLVVVGGVLACYSLLVTVAFII
FWVRRGRRRLLYIFRQPFMRPVQTTQEEDGCSCRFPEEEEG
GCELRVRFSRSADAPAYQQGQNQLYNELNLGRREEYDVLD
RRRGRDPEMGGRPRRRNPQEGLYNELQRDRMAEAYSEIGM
RGERRRGRGHDGLYQGLSTATRDTYDALHMQALPPR
Murine kappa METDTLLLWVLLLWVPGSTGAGGSDYKDDDDKGGSLTCL 133
signal GGFASPGPVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSI
sequence FLAG NLTAGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAG
Full IL13 QFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFNGGGGSG
mutein_(G45)x4 GGGSGGGGSGGGGSQVQLVQSGAEVKKPGSSVKVSCKASG
_TGF-13 YTFSSNVISWVRQAPGQGLEWMGGVIPIVDIANYAQRFKGR
scFv_IgG4 VTITADESTSTTYMELSSLRSEDTAVYYCALPRAFVLDAMD
hinge_CD28tm_4 YWGQGTLVTVSSGGGGSGGGGSGGGGSETVLTQSPGTLSLS
-1BB PGERATLSCRAS QSLGS SYLAWYQQKPGQAPRLLIYGAS SR
(KR)_CD3zeta APGIPDRFS GS GSGTDFTLTISRLEPEDFAVYYC QQYAD SPIT
(KR) FGQGTRLEIKESKYGPPCPPCPMFWVLVVVGGVLACYSLLV
TVAFIIFWVRRGRRRLLYIFRQPFMRPVQTTQEEDGCSCRFP
EEEEGGCELRVRFSRSADAPAYQQGQNQLYNELNLGRREE
YDVLDRRRGRDPEMGGRPRRRNPQEGLYNELQRDRMAEA
YSEIGMRGERRRGRGHDGLYQGLSTATRDTYDALHMQALP
PR
Full-IL- METDTLLLWVLLLWVPGSTGAGGSDYKDDDDKGGSLTCL 22
13Ra2.28z CAR; GGFASPGPVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSI
(Murine kappa NLTAGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAG
signal QFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFNESKYGPP
sequence FLAG CPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQ
Full IL13 EDPEVQFNWYVDGVEVHNAKTKPREEQFQSTYRVVSVLTV
mutein_IgG4 LHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVY
(L235E, TLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN
N297 Q)_CD28t YKTTPPVLD SDGSFFLYSRLTVDKSRWQEGNVFS CS VMHEA
m_CD28cyto_C LHNHYTQKSLSLSLGKMFWVLVVVGGVLACYSLLVTVAFII
D3zeta) FWVRSKRSRGGHSDYMNMTPRRPGPTRKHYQPYAPPRDFA
AYRSGGGRVKFSRSADAPAYQQGQNQLYNELNLGRREEYD
VLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYS
EIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
111

CA 03193009 2023-02-24
WO 2022/046935
PCT/US2021/047600
CAR SEQUENCE SEQ
ID
NO:
Full-IL- METDTLLLWVLLLWVPGSTGAGGSDYKDDDDKGGSLTCL 23
13Ra2/TGF- GGFASPGPVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSI
I3.28z CAR; NLTAGMYCAALESLINV SGC SAIEKT QRMLS GFCPHKV SAG
(Murine kappa QFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFNGGGGSG
signal GGGSGGGGSGGGGSQVQLVQSGAEVKKPGSSVKVSCKASG
sequence_FLAG YTFSSNVISWVRQAPGQGLEWMGGVIPIVDIANYAQRFKGR
Full IL13 VTITADESTSTTYMELSSLRSEDTAVYYCALPRAFVLDAMD
mutein_(G45)x4 YWGQGTLVTVSSGGGGSGGGGSGGGGSETVLTQSPGTLSLS
_TGF-I3 PGERATLSCRAS QSLGS SYLAWYQQKPGQAPRLLIYGAS SR
scFv_IgG4 APGIPDRFS GS GSGTDFTLTISRLEPEDFAVYYC QQYAD SPIT
hinge_CD28tm_ FGQGTRLEIKESKYGPPCPPCPMFWVLVVVGGVLACYSLLV
CD28cyto_CD3z TVAFIIFWVRSKRSRGGHSDYMNMTPRRPGPTRKHYQPYAP
eta) PRDFAAYRSGGGRVKFSRSADAPAYQQGQNQLYNELNLGR
REEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKM
AEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM
QALPPR
Murine kappa METDTLLLWVLLLWVPGSTGAGGSDYKDDDDKGGSLTCL 134
signal GGFASPGPVPPSTALRYLIEELVNITQNQKAPLCNGSMVWSI
sequence_FLAG NLTAGMYCAALESLINV SGC SAIEKT QRMLS GFCPHKV SAG
Full IL13 QFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFNESKYGPP
mutein_IgG4 CPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS Q
(L235E,N297Q)_ EDPEVQFNWYVDGVEVHNAKTKPREEQFQSTYRVVSVLTV
CD28tm_4- LHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVY
1B B_CD3zeta_T TLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN
2A_HA_TGFBR YKTTPPVLD SDGSFFLYSRLTVDKSRWQEGNVFS CS VMHEA
2tr(DNR) LHNHYTQKSLSLSLGKMFWVLVVVGGVLACYSLLVTVAFII
FWVKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEG
GCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLD
KRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIG
MKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRLE
GGGEGRGSLLTCGDVEENPGPRMGRGLLRGLWPLHIVLWT
RIASTIPPYPYDVPDYAHVQKSVNNDMIVTDNNGAVKFPQL
CKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKN
DENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETF
FMCS CS SDECNDNIIFSEEYNTSNPDLLLVIFQVTGISLLPPLG
VAISVIIIFYCYRVNRQQKLSS
112

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
CAR SEQUENCE SEQ
ID
NO:
Murine kappa METDTLLLWVLLLWVPGSTGAGGSDYKDDDDKGGSSPGPV 135
signal PPSTALRYLIEELVNITQNQKAPLCNGSMVWSINLTAGMYC
sequence_FLAG AALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQFSSLHVRD
_SP IL13 TKIEVAQFVKDLLLHLKKLFREGRFNESKYGPPCPPCPAPEF
mutein_IgG4 EGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFN
(L235E,N297Q)_ WYVDGVEVHNAKTKPREEQFQSTYRVVSVLTVLHQDWLN
CD28tm_CD28c GKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPS QEE
yto_CD3zeta_T2 MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL
A_HA_TGFBR2t DSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQ
r(DNR) KSLSLSLGKMFWVLVVVGGVLACYSLLVTVAFIIFWVRSKR
SRGGHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSGGG
RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRG
RDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGER
RRGKGHDGLYQGLSTATKDTYDALHMQALPPRLEGGGEGR
GSLLTCGDVEENPGPRMGRGLLRGLWPLHIVLWTRIASTIPP
YPYDVPDYAHVQKSVNNDMIVTDNNGAVKFPQLCKFCDV
RFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLE
TVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSS
DECNDNIIFSEEYNTSNPDLLLVIFQVTGISLLPPLGVAISVIIIF
YCYRVNRQQKLSS
[0249] All of the constructs contain, from N terminal to C terminal of the
protein, the
following components: murine kappa chain signal sequence, binding domains each
separated
by (Gly4 Serl)x4, IgG4 hinge, CD28 transmembrane domain, and CD3t cytoplasmic
domain.
Some CARs contain CD28 cytoplasmic domain between the transmembrane and CD3
domains; others contain 4-1BB cytoplasmic domain instead of CD28 cytoplasmic
domain.
[0250] Constructs 7, 14, and 15 above co-express the single-input IL-13Ra2
CAR with a
dominant-negative TGF-f3 receptor (DNR), which is TGF-f3 receptor chain 2
missing its
cytoplasmic domain. These constructs are built as controls to compare against
the IL-
13Ra2/TGF-f3 bispecific CARs.
[0251] T cells were transduced with a panel of single-input IL-13Ra2 or
bispecific IL-
13Ra2/TGF-f3 CARs, bearing either an SP dipeptide or LTCLGGFASP ("Full")
polypeptide
at the N-terminus of the IL-13 mutein. Each CAR was fused to an N-terminal
FLAG tag to
enable surface detection by antibody staining. On day 7 of culture, transduced
T cells were
stained for surface expression of FLAG-tagged CARs. The relative strength of
CAR expression
for IL-13 muteins with an N-terminal SP versus full N-terminus was construct-
dependent.
Averages of triplicates are shown, with error bars representing 1 standard
deviation. (FIG.
11).
[0252] To evaluate whether CARs signal in response to antigen, CAR-T cells
were cultured
for 21 hours in either media alone, or in the presence of 5 ng/mL recombinant
human TGF-01
113

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
or IL-13Ra2+ PBT106 neurospheres, respectively. T cells were subsequently
stained for
surface expression of CD69 (FIG. 12A), CD25 (FIG. 12B), and FLAG (FIG. 12C,D).
Both
single-input IL-13Ra2 and bispecific IL-13Ra2/TGF-f3 CAR-T cells are strongly
activated by
antigen-expressing PBT106 tumor cells, while only bispecific IL-13Ra2/TGF-f3
CARs are
activated by TGF-f3, as evidenced by upregulation of CD69 and CD25, and
downregulation of
surface FLAG expression (FIG. 12A-D). Moreover, CARs with an N-terminal SP
conferred
greater CD25 upregulation compared to CARs with the full IL-13 mutein N-
terminus,
suggesting that the shorter SP N-terminus of the IL-13 mutein confers greater
functionality
compared to the full N-terminus. Averages of triplicates are shown, with error
bars representing
1 standard deviation.
[0253] To assess anti-tumor function in vitro, CAR-T cells were labeled
with
CellTraceViolet (CTV) dye and co-cultured for 4 days with IL13Ra2+ PBT106
neurospheres
at the indicated E:T ratios. Flow cytometry was performed to quantify viable
tumor-cell count
(FIG. 13A,B), viable T-cell count (FIG. 13C), viable CAR+ T-cell count (FIG.
13D), CTV
dilution among all T cells (FIG. 13E), and CTV dilution among CAR+ T cells
(FIG. 13F). FIG.
13B shows the same data as FIG. 13A, but with the scFv-less CAR condition
removed to enable
clear visualization. CARs bearing an N-terminal SP for the IL-13 mutein
conferred more potent
tumor-cell killing and greater T-cell proliferation (as assessed by CTV
dilution) compared to
CARs bearing the full IL-13 mutein N-terminus. Averages of triplicates are
shown, with error
bars representing 1 standard deviation (FIG. 13).
* * *
[0254] All of the methods disclosed and claimed herein can be made and
executed without
undue experimentation in light of the present disclosure. While the
compositions and methods
of this disclosure have been described in terms of preferred embodiments, it
will be apparent
to those of skill in the art that variations may be applied to the methods and
in the steps or in
the sequence of steps of the method described herein without departing from
the concept, spirit
and scope of the disclosure. More specifically, it will be apparent that
certain agents which are
both chemically and physiologically related may be substituted for the agents
described herein
while the same or similar results would be achieved. All such similar
substitutes and
modifications apparent to those skilled in the art are deemed to be within the
spirit, scope and
concept of the disclosure as defined by the appended claims.
[0255] The references recited in the application, to the extent that they
provide exemplary
procedural or other details supplementary to those set forth herein, are
specifically incorporated
herein by reference.
114

CA 03193009 2023-02-24
WO 2022/046935 PCT/US2021/047600
REFERENCES
[0256] The following references and the publications referred to throughout
the
specification, to the extent that they provide exemplary procedural or other
details
supplementary to those set forth herein, are specifically incorporated herein
by reference.
Chang, Z.L., Lorenzini, M.H., Zah, E., Tran, U., Chen, Y.Y. (2018). Rewiring T-
cell
responses to soluble factors with chimeric antigen receptors. Nature Chemical
Biology,
14(3):317-324.
Hou, A.J., Chang, Z.L., Lorenzini, M.H., Zah, E., and Chen, Y.Y. (2018). TGF-
(3¨
responsive CAR-T cells promote anti-tumor immune function. Bioengineering and
Translational Medicine, 3(2):75-86.
Chang, Z.L., Hou, A.J., and Chen, Y.Y. (2020). Engineering primary T cells
with
chimeric antigen receptors for rewired responses to soluble ligands. Nature
Protocols, Epub
ahead of print.
Debinski, W. and Thompson J.P. (1999). Retargeting interleukin 13 for
radioimmunodetection and radioimmunotherapy of human high-grade gliomas.
Clinical
Cancer Research, 5:3143s-7s.
Kahlon, K.S. et al. (2004). Specific recognition and killing of glioblastoma
multiforme
by interleukin 13-zetakine redirected cytolytic T cells. Cancer Research,
64:9160-6.
Brown C.E. et al. (2015). Bioactivity and safety of IL13Ra2-redirected
chimeric
antigen receptor CD8+ T cells in patients with recurrent glioblastoma.
Clinical Cancer
Research, 21: 4062-72.
Brown, C.E. et al. (2016). Regression of Glioblastoma after Chimeric Antigen
Receptor
T-Cell Therapy. New England Journal of Medicine, 375(26):2561-2596.
115